

Please type a plus sign (+) inside this box → ☐

PTO/SB/05 (4/98)
Approved for use through 09/30/2000. OMB 0651-0032
Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. 1242/19/2

First Inventor or Application Identifier Summar et al.

Title See 1 in Addendum

Express Mail Label No. EJ227696174US

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, DC 20231

1. ☒ * Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)
2. ☒ Specification [Total Pages 177] 1
(preferred arrangement set forth below)
 - Descriptive title of the Invention
 - Cross References to Related Applications
 - Statement Regarding Fed sponsored R & D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings (if filed)
 - Detailed Description
 - Claim(s)
 - Abstract of the Disclosure
3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 12] 1
4. Oath or Declaration [Total Pages] 1
 - a. ☐ Newly executed (original or copy)
 - b. ☐ Copy from a prior application (37 C.F.R. § 1.63(d))
(for continuation/divisional with Box 16 completed)
 - i. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting
inventor(s) named in the prior application,
see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

5. ☐ Microfiche Computer Program (Appendix)
6. Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)
 - a. ☒ Computer Readable Copy
 - b. ☒ Paper Copy (identical to computer copy)
 - c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

7. ☐ Assignment Papers (cover sheet & document(s))
8. ☐ 37 C.F.R. §3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)
9. ☐ English Translation Document (if applicable)
10. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations
11. ☐ Preliminary Amendment
12. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
13. ☐ * Small Entity Statement(s) ☐ Statement filed in prior application
(PTO/SB/09-12) Status still proper and desired
14. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)
15. ☒ Other: See 2 in Addendum

NOTE FOR ITEMS 1 & 13 IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

☐ Continuation ☐ Divisional ☒ Continuation-in-part (CIP) of prior application No: 09/323,472
Prior application information: Examiner Not Assigned Group / Art Unit: 1632

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

17. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☒ Correspondence address below

Name	Arles A. Taylor, Jr. Jenkins & Wilson, P.A.				
Address	Suite 1400 University Tower 3100 Tower Boulevard				
City	Durham	State	NC	Zip Code	27707
Country	USA	Telephone	(919) 493-8000	Fax	(919) 419-0383

Name (Print/Type)	Arles A. Taylor, Jr.	Registration No. (Attorney/Agent)	39,395
Signature	<i>Arles A. Taylor, Jr.</i>	Date	06/01/2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Addendum

1. THERAPEUTIC METHODS RELATING TO CARBAMYL PHOSPHATE SYNTHETASE I POLYMORPHISM
2.
 - Unexecuted Declaration
 - Copy of previously filed Small Entity Statement
 - Copy of previously filed Assignment
 - Sequence Listing in Computer Readable Form
 - Check in the amount of \$390.00


THERAPEUTIC METHODS RELATING TO
CARBAMYL PHOSPHATE SYNTHETASE I POLYMORPHISM

AN APPLICATION FOR
UNITED STATES LETTERS PATENT

By

Marshall L. Summar
Brentwood, Tennessee

Brian Christman
Nashville, Tennessee

-1- "Express Mail" mailing number ES 22769617445
Date of Deposit 6/1/2000
I hereby certify that this paper or fee is being deposited with
the United States Postal Service "Express Mail Post Office
to Addressee" service under 37 C.F.R. 1.10 on the date
indicated above and is addressed to the Commissioner of
Patents and Trademarks, Washington, D.C. 20231
Lynette M. Bailey 

Description

THERAPEUTIC METHODS RELATING TO HUMAN CARBAMYL
PHOSPHATE SYNTHETASE I POLYMORPHISM

Related Application Information

5 This is a continuation-in-part of U.S. Patent Application Serial No.
09/323,472, filed June 1, 1999, the entire contents of which are herein
incorporated by reference.

Grant Statement

10 This work was supported by NIH grants R29-DK46965, NIH HL 55198,
NIH ES 09915 and NIH 1 P30 CA 68485. Thus, the U.S. Government has
certain rights in the invention.

Technical Field

15 The present invention relates to isolated polynucleotide molecules useful
for analyzing carbamyl phosphate synthetase I phenotypes, to peptides
encoded by these molecules, and to the diagnostic and therapeutic uses
thereof relating to a newly identified carbamyl phosphate synthetase I
polymorphism. Among such uses are methods for determining the
susceptibility of a subject to hyperammonemia, decreased production of
20 arginine and to bone marrow transplant toxicity based on an analysis of a

nucleic acid sample isolated from tissue biopsies from the subject.

Table of Abbreviations

	ABG	-	arterial blood gas(es)
	ALI	-	acute lung injury
5	ASO	-	allele-specific oligonucleotide
	ATP	-	adenosine triphosphate
	BCAA	-	branched chain amino acid(s)
	BMT	-	bone marrow transplant
	BSA	-	bovine serum albumin
10	BuCy	-	busulfan, cyclophosphamide
	BUN	-	blood urea nitrogen
	CBVP16	-	cyclophosphamide, bis-chloroethylnitrosourea, etoposide
	cc	-	cubic centimeters
15	CPSI	-	carbaryl phosphate synthetase I
	CTC	-	cyclophosphamide, thiotepa, carboplatin
	CVP16TBI	-	cyclophosphamide, etoposide, total body irradiation
20	ECMO	-	extracorporeal membrane oxygenation
	fl	-	full length
	GSHosc	-	glutathione synthetase

	HAT	-	hypoxanthine, aminopterin, thymidine
	HVOD	-	hepatic veno-occlusive disease
	iNO	-	inhaled nitric oxide
	KDa	-	kilodalton
5	KLH	-	keyhole limpet hemocyanin
	l	-	liter
	LAT	-	ligation activated translation
	LCR	-	ligase chain reaction
	MAS	-	meconium aspiration syndrome
10	NAG	-	n-acetyl glutamate
	NASDA TM	-	nucleic acid sequence-based amplification
	NO or NO _x	-	nitric oxide
	NOS	-	nitric oxide synthetase
15	O/C	-	ornithine/citrulline
	PBSCT	-	peripheral blood stem-cell transplantation
	PPHN	-	persistant pulmonary hypertension in newborns
20	PCR	-	polymerase chain reaction
	RCR	-	repair chain reaction
	RDS	-	respiratory distress syndrome
	REF	-	restriction endonuclease finger- printing

	RT	-	reverse transcriptase
	SSCP	-	single strand conformation polymorphism
	SDA	-	strand displacement activation
5	SNP	-	single nucleotide polymorphism
	TC	-	thiotepa, cyclophosphamide
	TEAA	-	total essential amino acids
	UC	-	urea cycle
	UCF	-	urea cycle function
10	VPA	-	valproic acid

Background Art

The *in vivo* synthetic pathway for arginine commences with ornithine. Ornithine is combined with carbamyl phosphate to produce citrulline, which in turn is combined with aspartate, in the presence of adenosine triphosphate (ATP), to produce argininosuccinate. In the final step, fumarate is split from argininosuccinate, to produce arginine. The degradative pathway for arginine is by the hydrolytic action of arginase, to produce ornithine and urea. These reactions form the urea cycle. The urea cycle serves as the primary pathway for removing waste nitrogen produced by the metabolism of endogenous and exogenous proteins, and is shown schematically in Fig.1.

Disruption of metabolic processes is a frequent side effect of chemotherapy. Indeed, the agents used in high-dose chemotherapy affect a number of cellular processes. Metabolic processes localized in chemo-

sensitive tissues, such as the liver and gastrointestinal tract, face a particularly great risk to disruption.

5 The constant turn-over and processing of nitrogen involves all the tissues in the body, but the first critical steps of the urea cycle are limited to the liver and gut. The high-dose chemotherapy associated with bone marrow transplant (BMT) interferes with liver function and is toxic to the intestine. Idiopathic hyperammonemia, which is suggestive of urea cycle dysfunction, has been reported to be associated with high mortality in patients undergoing bone marrow transplant. Davies et al., *Bone Marrow Transplantation*, 17:1119-1125
10 (1996); Tse et al., *American Journal of Hematology*, 38:140-141 (1991); and Mitchell et al., *American Journal of Medicine*, 85:662-667 (1988).

A common complication of BMT is hepatic veno-occlusive disease (HVOD). HVOD is associated with jaundice, increased liver size and disruption of normal hepatic blood flow. HVOD occurs in approximately 20 to 40% of
15 patients and is associated with severe morbidity and mortality.

Nitric oxide (NO) plays a role in regulating vascular tone and in maintaining patency of hepatic and pulmonary venules following high-dose chemotherapy. Intact urea cycle function is important not only for excretion of ammonia but in maintaining adequate tissue levels of arginine, the precursor
20 of NO.

Carbamyl phosphate synthetase I (CPSI) is the rate limiting enzyme catalyzing the first committed step of ureagenesis via the urea cycle. CPSI is highly tissue specific, with function and production substantially limited to liver and intestines. Genomically encoded, CPSI is produced in the cytoplasm and

transported into the mitochondria where it is cleaved into its mature 160 kDA monomeric form. The enzyme combines ammonia and bicarbonate to form carbamyl with the expenditure of two ATP molecules and using the co-factor N-acetyl-glutamate (NAG).

5 Any genetic predisposition to decreased urea cycle function would lead to hyperammonemia and would likely contribute to the severity of disorders associated with sub-optimal urea cycle function, including BMT-related toxicity. Thus, there is a need in the art for characterization of alleles present in populations suffering from disorders associated with suboptimal urea cycle
10 fuction, undergoing BMT or otherwise facing exposure to environmental or pharmacological hepatotoxins. In view of the role of CPSI in the urea cycle, there is a particular need for characterization of CPSI alleles present in such populations.

Summary of the Invention

15 A method of screening for susceptibility to sub-optimal urea cycle function in a subject is disclosed. The method comprising the steps of: (a) obtaining a nucleic acid sample from the subject; and (b) detecting a polymorphism of a carbamyl phosphate synthase I (CPSI) gene in the nucleic acid sample from the subject, the presence of the polymorphism indicating that
20 the susceptibility of the subject to sub-optimal urea cycle function. In accordance with the present invention, detection of the polymorphism is particularly provided with respect to determining the susceptibility of a subject to bone marrow transplant toxicity.

Preferably, the polymorphism of the carbamyl phosphate synthetase polypeptide comprises a C to A transversion in exon 36 of the CPSI gene, more preferably at nucleotide 4340 of a cDNA that corresponds to the CPSI gene. More preferably, the C to A transversion at nucleotide 4340 of the cDNA that corresponds to the CPSI gene further comprises a change in the triplet code from AAC to ACC, which encodes a CPSI polypeptide having an threonine moiety at amino acid 1405.

The present invention also provides an isolated and purified biologically active CPSI polypeptide. Preferably, a polypeptide of the invention is a recombinant polypeptide. More preferably, a polypeptide of the present invention comprises human CPSI having an asparagine moiety at amino acid 1405.

The present invention also provides an isolated and purified polynucleotide that encodes a biologically active CPSI polypeptide. In a preferred embodiment, a polynucleotide of the present invention comprises a DNA molecule from a human. More preferably, a polynucleotide of the present invention comprises a cDNA that corresponds to the CPSI gene and which includes a C to A transversion at nucleotide 4340. Even more preferably, a polynucleotide of the present invention further comprises a cDNA that corresponds to the CPSI gene that includes a change in the triplet code from ACC to AAC at nucleotide 4340, and encodes a CPSI polypeptide having an asparagine moiety at amino acid 1405.

Kits and reagents, including oligonucleotides, nucleic acid probes and antibodies suitable for use in carrying out the methods of the present invention

and for use in detecting the polypeptides and polynucleotides of the present invention are also disclosed herein. Methods for preparing the polynucleotides and polypeptides of the present invention are also disclosed herein.

5 In a further embodiment, this invention pertains to therapeutic methods based upon a polymorphism of a carbamyl phosphate synthase I (CPSI) gene as described herein. Such therapeutic methods include administration of nitric oxide precursors in the treatment and prophylaxis of disorders mediated or modulated by sub-optimal urea cycle function (e.g. bone marrow transplant toxicity) and gene therapy approaches using an isolated and purified
10 polynucleotide of the present invention.

It is therefore an object of the present invention to provide polynucleotide molecules that can be used in analyzing carbamyl phosphate synthetase I (CPSI) in vertebrate subjects.

15 It is also an object of the present invention to provide for the determination of CPSI phenotype in vertebrate subjects and particularly human subjects, based on information obtained through the analysis of nucleic acids, including genomic DNA and cDNA, derived from tissues from the subject.

It is yet another object of the present invention to provide a ready technique for determining CPSI phenotype.

20 It is still a further object of the present invention to provide polypeptide and polynucleotide molecules for use in generating antibodies that distinguish between the different forms of CPSI which constitute the CPSI polymorphism.

It is yet a further object of the present invention is to provide methods for diagnosing and treating clinical syndromes related to and associated with

the CPSI polymorphism.

Some of the objects of the invention having been stated hereinabove, other objects will become evident as the description proceeds, when taken in connection with the accompanying drawings and examples as best described
5 hereinbelow.

Brief Description of the Drawings

Figure 1 is a schematic of the urea cycle;

Figure 2 is a schematic of the consensus CPSI protein which does not reflect recognized mutations;

10 Figure 3 is a schematic of the consensus CPSI protein depicting several known mutations in the protein and depicting the T1405N polymorphism of the present invention;

Figure 4 is a schematic of recognized post-transcriptional modification of CPSI;

15 Figure 5 is a schematic of the human genomic locus for CPSI;

Figure 6 is a schematic of a cloning strategy for a full length CPSI cDNA;

Figure 7 is a schematic of an alternative cloning strategy for a full length CPSI cDNA;

20 Figure 8 is a graphical depiction of the metabolic activity of the CPSI protein expressed in COS-7 cells;

Figure 9 is a graphical presentation of the size and position of introns in CPSI cDNA;

Figure 10 is a diagram of exon 36 (SEQ ID NO:5) showing the locations

of preferred oligonucleotide primers of the present invention;

Figure 11 presents the amino acid sequence of T1405 CPSI (SEQ ID NO:4) (stop codon translated as "X", 165049 MW, 1.163602e+07 CN), with the initial amino acid methionine considered to be at a -1 position; and

5 Figure 12 presents the amino acid sequence of N1405 CPSI (SEQ ID NO:2) (stop codon translated as "X", 165062 MW, 1.161634E+07 CN), with the initial amino acid methionine considered to be at a -1 position.

Detailed Description of the Invention

10 Disclosed herein is the surprising discovery of a polymorphism of carbamyl phosphate synthetase I (CPSI), the enzyme that catalyzes the rate limiting first step of the urea cycle. Particularly, the polymorphism is characterized by an amino acid substitution, threonine/asparagine at amino acid 1405 (heterozygosity = .44) in CPSI.

15 Also disclosed herein is the surprising observation that a single nucleotide change in the CPSI gene is responsible for the polymorphism of CPSI. Particularly, a C to A transversion with exon 36 of the CPSI gene changes the triplet code from ACC to AAC and leads to the T1405N change in the encoded CPSI polypeptide.

20 In light of these discoveries, manipulation of nucleic acid molecules derived from the tissues of vertebrate subjects can be effected to provide for the analysis of CPSI phenotypes, for the generation of peptides encoded by such nucleic acid molecules, and for diagnostic and therapeutic methods relating to the CPSI polymorphism. Nucleic acid molecules utilized in these

contexts may be amplified, as described below, and generally include RNA, genomic DNA and cDNA derived from RNA.

A. General Considerations

Most of the currently available structural information on CPSI is derived from studies of the rat CPSI enzyme. The rat CPSI enzyme and the human CPSI enzyme each comprise a single polypeptide of 1,500 residues and exhibit about 95% sequence identity. Rat CPSI polypeptide and nucleic acid sequence information is disclosed by Nyunoya, H., et al., *Journal of Biological Chemistry* 260:9346-9356 (1985) and at GenBank accession numbers AH005315, M12335, M12328, M12327, M12326, M12325, M12324, M12323, M12322, M12321, M12320, M12319, M12318 and M11710, herein incorporated by reference. The structural information about rat CPSI is derived from sequence homology and substrate and co-factor binding studies; however, no crystallographic data is available.

Mature CPSI is modular in nature, containing 2 main regions. The first region, residues 39-406, is homologous to the small subunit of the heterodimeric CPS of *Escherichia coli*. Bacterial and yeast CPSI polypeptide and nucleic acid sequence information is disclosed at GenBank accession numbers AB005063, X67573, M27174, P07258, P03965, BAA21088, SYBYCP, SYBYCS, and SYECCS, herein incorporated by reference.

The other region, residues 417-1500 (referred to herein after as the "CPS domain"), is homologous to the large subunit of *E. coli* CPS. Meister, A., *Adv. Enzymol. Relat. Areas Mol. Biol.* 62:315-374 (1989). This subunit is

responsible for carbamyl phosphate synthesis from ammonia and for the binding of the substrates and cofactors. Meister, A., *Adv. Enzymol. Relat. Areas Mol. Biol.* 62:315-374 (1989). The CPS domain arose by gene duplication and tandem fusion in the pro-genome, and, as depicted

5 schematically in Figure 2, is itself composed of two phosphorylation domains and a C-terminal regulatory domain involved in the binding of n-acetylglutamate (NAG). Nyunoya, H., et al., *Journal of Biological Chemistry* 260:9346-9356 (1985).

As depicted schematically in Figure 2, residues 407-416 act as a bridge


10 between the the two major subunits, and residues 1-38 constitute the leader peptide that directs immature CPSI to the mitochondria prior to being removed. Continuing with Figure 2, the small subunit-like region is composed of two approximately equal subdomains. The interaction subdomain, residues 39-212, corresponds to the region which, in the small subunit of the CPS from *E. coli*, is necessary for association with the large subunit. The glutaminase

15 subdomain, residues 213-406, is homologous to several glutamine amidotransferases and to the region of CPSI that when generated free from other components exhibited considerable glutaminase activity, as described by Guillou, F., et al. *Proc Natl Acad Sci* 86:8304-8308 (1989); Nyunoya, H., et al.,

20 *Journal of Biological Chemistry* 260:9346-9356 (1985); and Guy, H. I. et al., *Journal of Biological Chemistry* 270:2190-2197 (1995). Since CPSI has lost the cysteine residue necessary to split glutamine, the function of the glutaminase subdomain is uncertain in this enzyme.

The CPS domain (corresponding to the large subunit in *E. coli*) is

believed to catalyze the synthesis of carbamyl phosphate from ammonia, according to the reaction:



5 As shown schematically in Figures 1 and 2, this reaction comprises three steps: bicarbonate phosphorylation by an ATP molecule that is designated herein as ATP_A, giving carboxyphosphate; carbamate synthesis from carboxyphosphate and ammonia; and carbamate phosphorylation by another ATP molecule (ATP_B), giving carbamyl phosphate, as described by Rubio, V. and Grisolia, S.,
10 *Enzyme* 26:233-239 (1981).

As shown schematically in Fig. 4, the CPS domain appears to have arisen by duplication and tandem fusion of the duplicated component; therefore, its amino and COOH-terminal halves are homologous, as described by Nyunoya, H., et al., *Journal of Biological Chemistry* 260:9346-9356 (1985)).
15 Each homologous half comprises an amino- and a COOH-terminal domain of about 40 and 20 kDa, respectively, of which the domain of 40 kDa of the amino-half is believed to be involved in bicarbonate phosphorylation (bicarbonate phosphorylation domain, residues 417-788) (Fig. 2). The corresponding domain in the COOH-half is involved in carbamate phosphorylation via the carbamate phosphorylation domain, residues 969-1329
20 (Fig. 2), as described by Alonso, E. and Rubio, V., *European Journal of Biochemistry* 229:377-384 (1995)).

These phosphorylation domains are homologous to biotin carboxylase (Toh, H. et al., *European Journal of Biochemistry* 215:687-696 (1993)), an

enzyme of known tri-dimensional structure that phosphorylates bicarbonate as well as DD-ligase and glutathione synthetase (GSHase), two enzymes that catalyze analogous reactions (Artymiuk, P. J. et al., *Nature Struct. Biol.* 3:128-132 (1996)). Thus, information on these enzymes is helpful in interpreting the mutations found in homologous domains in the patients with CPSI deficiency.

Referring again to Fig. 2, of the 20-kDa domains of the large subunit-like region, the function of the domain of the amino-terminal half, residues 789-968, remains to be established. In contrast, the corresponding COOH-terminal domain, residues 1330-1500, is called the allosteric domain, because the activator, n-acetyl-glutamate (NAG) of CPSI and the nucleotide effectors of the *E. coli* enzyme, UMP and IMP, bind in this domain, as described by Rodriguez-Aparicio, L. B. et al., *Biochemistry* 28:3070-3074 (1989) and Cervera, J. et al., *Biochemistry* 35:7247-7255 (1996).

A.1. Enzyme Processing.

Human CPSI mRNA encodes a 165 kDA, 1500 amino acid pre-protein. The amino terminus of this precursor contains 38 residues, including 8 basic residues, and 1 acidic residue with a Pro-Gly sequence 4 residues before the start of the mature enzyme (Nyunoya, H. et al., *Journal of Biological Chemistry* 260:9346-9356 (1985); Lagace, M. et al., *Journal of Biological Chemistry* 262:10415-10418 (1987). This highly conserved signal sequence promotes enzyme entry into the mitochondrial matrix, where it is then removed to produce the 160 kDA mature enzyme.

A.2. Normal Expression of CPSI.

CPSI enzymatic activity is first detected in human fetal liver by 5-10 weeks gestation (Moorman, A. F. et al. *Histochemical Journal* 22:457-468 (1990)). By 20 weeks gestation, the level of CPSI reaches approximately 50% of the normal adult level, where it remains until birth, after which it gradually increases to adult levels by 20 years of age (Raiha, N. C. R. and Suihkonen, *J. Acta Paediatrica Scand* 57:121-127 (1968)). Tissue expression of CPSI is essentially limited to the liver, with trace amounts of activity in the intestine and kidney. When the liver develops its mature acinar structure in adulthood, CPSI is compartmentalized in parenchymal cells around the terminal portal venules (Moorman, A. F. et al. *Histochemical Journal* 22:457-468 (1990)).

In addition to its compartmentalization, several factors are known to be important in the regulation of CPSI activity and expression. For example, low or absent levels of ornithine decrease CPSI activity, presumably due to an inhibitory effect from accumulated carbamyl phosphate (CP) as described by Jackson, M. J. et al., *Annual Review of Genetics* 20:431-464 (1986); and Rubio, V., *Biochemical Society Transactions* 21:198-202 (1993)). Levels of both CPSI mRNA and enzyme increase with a high protein diet, and in response to glucagon and glucocorticoids (Jackson, M. J. et al., *Annual Review of Genetics* 20:431-464 (1986); de Groot, C. J., et al., *Biochemical & Biophysical Research Communications* 124:882-888 (1984)). In normal unstimulated hepatic tissue that has been examined, an abundance of CPSI mRNA has been observed.

B. Screening Techniques

In accordance with the present invention, a method of screening for susceptibility to sub-optimal urea cycle function resulting in decreased ammonia clearance and decreased arginine production in a subject is provided.

5 The method comprises: (a) obtaining a nucleic acid sample from the subject; and (b) detecting a polymorphism of a carbamyl phosphate synthase I (CPSI) gene in the nucleic acid sample from the subject, the presence of the polymorphism indicating that the susceptibility of the subject to sub-optimal urea cycle function resulting in decreased ammonia clearance and decreased
10 arginine production. In accordance with the present invention, detection of the polymorphism is particularly provided with respect to determining the susceptibility of a subject to bone marrow transplant toxicity.

It is further noted that the polymorphism of the present invention may be used to predict toxicity in a number of conditions beyond BMT or valproic acid
15 administration as disclosed herein and in the Examples. The polymorphism is also implicated in the mediation or modulation of disrupted ammonia clearance and arginine production in situations such as adult hepatic cirrhosis, other medication toxicities, newborns with impaired hepatic function, and the like.

As used herein and in the claims, the term "polymorphism" refers to the
20 occurrence of two or more genetically determined alternative sequences or alleles in a population. A polymorphic marker is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%. A polymorphic locus may be as small as one base pair.

Useful nucleic acid molecules according to the present invention include those which will specifically hybridize to CPSI sequences in the region of the C to A transversion at base 4340 and within exon 36 changing the triplet code from ACC to AAC. This transversion leads to the T1405N change in the encoded CPSI polypeptide. Typically these are at least about 20 nucleotides in length and have the nucleotide sequence corresponding to the region of the C to A transversion at base 4340 of the consensus CPSI cDNA sequence (EC6.3.4.16), which changes the triplet code from ACC to AAC. The term "consensus sequence", as used herein, is meant to refer to a nucleic acid or protein sequence for CSPI, the nucleic or amino acids of which are known to occur with high frequency in a population of individuals who carry the gene which codes for a normally functioning protein, or which nucleic acid itself has normal function.

Provided nucleic acid molecules can be labeled according to any technique known in the art, such as with radiolabels, fluorescent labels, enzymatic labels, sequence tags, etc. According to another aspect of the invention, the nucleic acid molecules contain the C to A transversion at base 4340. Such molecules can be used as allele-specific oligonucleotide probes to track a particular mutation, for example, through a family of subjects.

Body samples can be tested to determine whether the CPSI gene contains the C to A transversion at base 4340. Suitable body samples for testing include those comprising DNA, RNA or protein obtained from biopsies, including liver and intestinal tissue biopsies; or from blood, prenatal; or embryonic tissues, for example.

In one embodiment of the invention a pair of isolated oligonucleotide primers are provided: 5'-AGCTGTTTGCCACGGAAGCC-3'(SEQ ID NO:6) and 5'-CCCAGCCTCTCTTCCATCAGAAAGTAAG-3'(SEQ ID NO:7). These primers are derived from CPSI exon 36 (the location of the polymorphism of the present invention) and related intronic sequences (SEQ ID NO:5) and produce a 119 base pair fragment. Other primers derived from CPSI exon 36 (the location of the polymorphism of the present invention) and related intronic sequences (SEQ ID NO:5) are provided in SEQ ID NOs:8-10, in Figure 10, and in Example 2 (SEQ ID NOs:15 and 16).

The oligonucleotide primers are useful in diagnosis of a subject at risk for hyperammonemia such as can result as a BMT complication or toxicity. The primers direct amplification of a target polynucleotide prior to sequencing. These unique CPSI exon 36 oligonucleotide primers were designed and produced based upon identification of the C to A transversion in exon 36.

In another embodiment of the invention isolated allele specific oligonucleotides are provided. Sequences substantially similar thereto are also provided in accordance with the present invention. The allele specific oligonucleotides are useful in diagnosis of a subject at risk for hyperammonemia, such as can result as a BMT complication or toxicity. These unique CPSI exon 36 oligonucleotide primers were designed and produced based upon identification of the C to A transversion in exon 36.

The terms "substantially complementary to" or "substantially the sequence of" refer to sequences which hybridize to the sequences provided (e.g. SEQ ID NOs: 5-10) under stringent conditions and/or sequences having

sufficient homology with any of SEQ ID NOs: 5-10, such that the allele specific oligonucleotides of the invention hybridize to the sequence. The term "isolated" as used herein includes oligonucleotides substantially free of other nucleic acids, proteins, lipids, carbohydrates or other materials with which they may be associated, such association being either in cellular material or in a synthesis medium. A "target polynucleotide" or "target nucleic acid" refers to the nucleic acid sequence of interest e.g., a CPSI-encoding polynucleotide. Other primers which can be used for primer hybridization are readily ascertainable to those of skill in the art based upon the disclosure herein of the CPSI polymorphism.

The primers of the invention embrace oligonucleotides of sufficient length and appropriate sequence so as to provide initiation of polymerization on a significant number of nucleic acids in the polymorphic locus. The CPSI locus is depicted schematically in Fig. 5. Specifically, the term "primer" as used herein refers to a sequence comprising two or more deoxyribonucleotides or ribonucleotides, preferably more than three, and more preferably more than eight and most preferably at least about 20 nucleotides of the CPSI gene wherein the DNA sequence contains the C to A transversion at base 4340 relative to CPSI contained in SEQ ID NO's:1 and 3. The allele including cytosine (C) at base 4340 relative to CPSI is referred to herein as the "CPSIa allele", the "T1405 allele", or the "threonine-encoding allele". The allele including adenosine (A) at base 4340 relative to CPSI is referred to herein as the "CPSIb allele", the "N1405 allele", or the "arginine-encoding allele".

An oligonucleotide that distinguishes between the CPSIa and the CPSIb

alleles of the CPSI gene, wherein said oligonucleotide hybridizes to a portion of said CPSI gene that includes nucleotide 4340 of the cDNA that corresponds to said CPSI gene when said nucleotide 4340 is adenosine, but does not hybridize with said portion of said CPSI gene when said nucleotide 4340 is cytosine is also provided in accordance with the present invention. An oligonucleotide that distinguishes between the CPSIa and the CPSIb alleles of the CPSI gene, wherein said oligonucleotide hybridizes to a portion of said CPSI gene that includes nucleotide 4340 of the cDNA that corresponds to said CPSI gene when said nucleotide 4340 is cytosine, but does not hybridize with said portion of said CPSI gene when said nucleotide 4340 is adenosine is also provided in accordance with the present invention. Such oligonucleotides are preferably between ten and thirty bases in length. Such oligonucleotides may optionally further comprises a detectable label.

Environmental conditions conducive to synthesis include the presence of nucleoside triphosphates and an agent for polymerization, such as DNA polymerase, and a suitable temperature and pH. The primer is preferably single stranded for maximum efficiency in amplification, but may be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent for polymerization. The exact length of primer will depend on many factors, including temperature, buffer, and nucleotide composition. The oligonucleotide primer typically contains 12-20 or more nucleotides, although it may contain fewer nucleotides.

Primers of the invention are designed to be "substantially" complementary to each strand of the genomic locus to be amplified. This means that the primers must be sufficiently complementary to hybridize with their respective strands under conditions which allow the agent for
5 polymerization to perform. In other words, the primers should have sufficient complementarity with the 5' and 3' sequences flanking the transversion to hybridize therewith and permit amplification of the genomic locus.

Oligonucleotide primers of the invention are employed in the amplification method which is an enzymatic chain reaction that produces
10 exponential quantities of polymorphic locus relative to the number of reaction steps involved. Typically, one primer is complementary to the negative (-) strand of the polymorphic locus and the other is complementary to the positive (+) strand. Annealing the primers to denatured nucleic acid followed by extension with an enzyme, such as the large fragment of DNA polymerase I (Klenow) and nucleotides, results in newly synthesized + and - strands
15 containing the target polymorphic locus sequence. Because these newly synthesized sequences are also templates, repeated cycles of denaturing, primer annealing, and extension results in exponential production of the region (i.e., the target polymorphic locus sequence) defined by the primers. The
20 product of the chain reaction is a discrete nucleic acid duplex with termini corresponding to the ends of the specific primers employed.

The oligonucleotide primers of the invention may be prepared using any suitable method, such as conventional phosphotriester and phosphodiester methods or automated embodiments thereof. In one such automated

embodiment, diethylphosphoramidites are used as starting materials and may be synthesized as described by Beaucage et al., *Tetrahedron Letters* 22:1859-1862 (1981). One method for synthesizing oligonucleotides on a modified solid support is described in U.S. Pat. No. 4,458,066.

5 Any nucleic acid specimen, in purified or non-purified form, can be utilized as the starting nucleic acid or acids, providing it contains, or is suspected of containing, a nucleic acid sequence containing the polymorphic locus. Thus, the method may amplify, for example, DNA or RNA, including messenger RNA, wherein DNA or RNA may be single stranded or double
10 stranded. In the event that RNA is to be used as a template, enzymes, and/or conditions optimal for reverse transcribing the template to DNA would be utilized. In addition, a DNA-RNA hybrid which contains one strand of each may be utilized. A mixture of nucleic acids may also be employed, or the nucleic acids produced in a previous amplification reaction herein, using the same or
15 different primers may be so utilized. The specific nucleic acid sequence to be amplified, i.e., the polymorphic locus, may be a fraction of a larger molecule or can be present initially as a discrete molecule, so that the specific sequence constitutes the entire nucleic acid. It is not necessary that the sequence to be amplified be present initially in a pure form; it may be a minor fraction of a
20 complex mixture, such as contained in whole human DNA.

DNA utilized herein may be extracted from a body sample, such as blood, tissue material, preferably liver tissue, and the like by a variety of techniques such as that described by Maniatis et. al. in *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, N.Y., p 280-281 (1982). If the

extracted sample is impure, it may be treated before amplification with an amount of a reagent effective to open the cells, or animal cell membranes of the sample, and to expose and/or separate the strand(s) of the nucleic acid(s). This lysing and nucleic acid denaturing step to expose and separate the strands will allow amplification to occur much more readily.

The deoxyribonucleotide triphosphates dATP, dCTP, dGTP, and dTTP are added to the synthesis mixture, either separately or together with the primers, in adequate amounts and the resulting solution is heated to about 90-100°C from about 1 to 10 minutes, preferably from 1 to 4 minutes. After this heating period, the solution is allowed to cool, which is preferable for the primer hybridization. To the cooled mixture is added an appropriate agent for effecting the primer extension reaction (called herein "agent for polymerization"), and the reaction is allowed to occur under conditions known in the art. The agent for polymerization may also be added together with the other reagents if it is heat stable. This synthesis (or amplification) reaction may occur at room temperature up to a temperature above which the agent for polymerization no longer functions. Thus, for example, if DNA polymerase is used as the agent, the temperature is generally no greater than about 40°C. Most conveniently the reaction occurs at room temperature.

The agent for polymerization may be any compound or system which will function to accomplish the synthesis of primer extension products, including enzymes. Suitable enzymes for this purpose include, for example, *E. coli* DNA polymerase I, Klenow fragment of *E. coli* DNA polymerase, polymerase muteins, reverse transcriptase, other enzymes, including heat-stable enzymes

(i.e., those enzymes which perform primer extension after being subjected to temperatures sufficiently elevated to cause denaturation), such as *Taq* polymerase. Suitable enzyme will facilitate combination of the nucleotides in the proper manner to form the primer extension products which are complementary to each polymorphic locus nucleic acid strand. Generally, the synthesis will be initiated at the 3' end of each primer and proceed in the 5' direction along the template strand, until synthesis terminates, producing molecules of different lengths.

The newly synthesized strand and its complementary nucleic acid strand will form a double-stranded molecule under hybridizing conditions described above and this hybrid is used in subsequent steps of the method. In the next step, the newly synthesized double-stranded molecule is subjected to denaturing conditions using any of the procedures described above to provide single-stranded molecules.

The steps of denaturing, annealing, and extension product synthesis can be repeated as often as needed to amplify the target polymorphic locus nucleic acid sequence to the extent necessary for detection. The amount of the specific nucleic acid sequence produced will accumulate in an exponential fashion. *PCR. A Practical Approach*, ILR Press, Eds. McPherson et al. (1992).

The amplification products may be detected by Southern blot analysis with or without using radioactive probes. In one such method, for example, a small sample of DNA containing a very low level of the nucleic acid sequence of the polymorphic locus is amplified, and analyzed via a Southern blotting technique or similarly, using dot blot analysis. The use of non-radioactive

probes or labels is facilitated by the high level of the amplified signal. Alternatively, probes used to detect the amplified products can be directly or indirectly detectably labeled, for example, with a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a
5 metal chelator or an enzyme. Those of ordinary skill in the art will know of other suitable labels for binding to the probe, or will be able to ascertain such, using routine experimentation.

Sequences amplified by the methods of the invention can be further evaluated, detected, cloned, sequenced, and the like, either in solution or after
10 binding to a solid support, by any method usually applied to the detection of a specific DNA sequence such as dideoxy sequencing, PCR, oligomer restriction (Saiki et al., *Bio/Technology* 3:1008-1012 (1985), allele-specific oligonucleotide (ASO) probe analysis (Conner et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:278 (1983), oligonucleotide ligation assays (OLAs) (Landgren et. al., *Science*
15 241:1007, 1988), and the like. Molecular techniques for DNA analysis have been reviewed (Landgren et. al., *Science* 242:229-237, 1988).

Preferably, the method of amplifying is by PCR, as described herein and in U.S. Pat. Nos. 4,683,195; 4,683,202; and 4,965,188 each of which is hereby incorporated by reference; and as is commonly used by those of ordinary skill
20 in the art. Alternative methods of amplification have been described and can also be employed as long as the CPSI locus amplified by PCR using primers of the invention is similarly amplified by the alternative means. Such alternative amplification systems include but are not limited to self-sustained sequence replication, which begins with a short sequence of RNA of interest and a T7

promoter. Reverse transcriptase copies the RNA into cDNA and degrades the RNA, followed by reverse transcriptase polymerizing a second strand of DNA.

Another nucleic acid amplification technique is nucleic acid sequence-based amplification (NASBATM) which uses reverse transcription and T7 RNA polymerase and incorporates two primers to target its cycling scheme. NASBATM amplification can begin with either DNA or RNA and finish with either, and amplifies to about 10^8 copies within 60 to 90 minutes.

Alternatively, nucleic acid can be amplified by ligation activated transcription (LAT). LAT works from a single-stranded template with a single primer that is partially single-stranded and partially double-stranded. Amplification is initiated by ligating a cDNA to the promoter oligonucleotide and within a few hours, amplification is about 10^8 to about 10^9 fold. The QB replicase system can be utilized by attaching an RNA sequence called MDV-1 to RNA complementary to a DNA sequence of interest. Upon mixing with a sample, the hybrid RNA finds its complement among the specimen's mRNAs and binds, activating the replicase to copy the tag-along sequence of interest.

Another nucleic acid amplification technique, ligase chain reaction (LCR), works by using two differently labeled halves of a sequence of interest which are covalently bonded by ligase in the presence of the contiguous sequence in a sample, forming a new target. The repair chain reaction (RCR) nucleic acid amplification technique uses two complementary and target-specific oligonucleotide probe pairs, thermostable polymerase and ligase, and DNA nucleotides to geometrically amplify targeted sequences. A 2-base gap separates the oligo probe pairs, and the RCR fills and joins the

gap, mimicking normal DNA repair.

Nucleic acid amplification by strand displacement activation (SDA) utilizes a short primer containing a recognition site for *HincII* with short overhang on the 5' end which binds to target DNA. A DNA polymerase fills in the part of the primer opposite the overhang with sulfur-containing adenine analogs. *HincII* is added but only cuts the unmodified DNA strand. A DNA polymerase that lacks 5' exonuclease activity enters at the site of the nick and begins to polymerize, displacing the initial primer strand downstream and building a new one which serves as more primer.

SDA produces greater than about a 10^7 -fold amplification in 2 hours at 37°C. Unlike PCR and LCR, SDA does not require instrumented temperature cycling. Another amplification system useful in the method of the invention is the QB Replicase System. Although PCR is the preferred method of amplification if the invention, these other methods can also be used to amplify the CPSI locus as described in the method of the invention. Thus, the term "amplification technique" as used herein and in the claims is meant to encompass all the foregoing methods.

In another embodiment of the invention a method is provided for diagnosing or identifying a subject having a predisposition or higher susceptibility to (at risk of) hyperammonemia, comprising sequencing a target nucleic acid of a sample from a subject by dideoxy sequencing, preferably following amplification of the target nucleic acid.

In another embodiment of the invention a method is provided for diagnosing a subject having a predisposition or higher susceptibility to (at risk

of) hyperammonemia, comprising contacting a target nucleic acid of a sample from a subject with a reagent that detects the presence of the CPSI polymorphism and detecting the reagent.

Another method comprises contacting a target nucleic acid of a sample
5 from a subject with a reagent that detects the presence of the C to A transversion at base 4340, i.e. within exon 36, and detecting the transversion. A number of hybridization methods are well known to those skilled in the art. Many of them are useful in carrying out the invention.

Hepatic veno-occlusive disease (HVOD) is a common toxicity in bone
10 marrow transplant (BMT). It occurs in approximately 20 to 40% of patients and is associated with severe morbidity and mortality. In accordance with the present invention, the frequency of both CPSI alleles was tested in an HVOD and a non-HVOD group undergoing BMT in an effort to identify evidence of disequilibrium. The results indicated the CPSI polymorphism disclosed herein
15 effects susceptibility to a BMT toxicity. Thus, a method of screening subjects for susceptibility to BMT toxicity, and particularly to HVOD, via detection of the CPSI polymorphism is provided in accordance with the present invention.

The materials for use in the method of the invention are ideally suited for the preparation of a diagnostic kit. Such a kit may comprise a carrier means
20 being compartmentalized to receive in close confinement one or more container means such as vials, tubes, and the like, each of the container means comprising one of the separate elements to be used in the method. For example, one of the container means may comprise means for amplifying CPSI DNA, the means comprising the necessary enzyme(s) and oligonucleotide

primers for amplifying said target DNA from the subject.

The oligonucleotide primers include primers having a sequence selected from the group including, but not limited to: SEQ ID NOs:6-10, or primer sequences substantially complementary or substantially homologous thereto.

5 The target flanking 5' and 3' polynucleotide sequence has substantially the sequence set forth in SEQ ID NO:5, and sequences substantially complementary or homologous thereto. Other oligonucleotide primers for amplifying CPSI will be known or readily ascertainable to those of skill in the art given the disclosure of the present invention presented herein.

10 A kit in accordance with the present invention can further comprise a reagent or reagents for extracting a nucleic acid sample from a biological sample obtained from a subject. Any such reagents as would be readily apparent to one of ordinary skill in the art are contemplated to fall within the scope of the present invention. By way of particular example, a suitable lysis
15 buffer for the tissue along with a suspension of glass beads for capturing the nucleic acid sample and an elution buffer for eluting the nucleic acid sample off of the glass beads comprise reagents for extracting a nucleic acid sample from a biological sample obtained from a subject.

Other examples include commercially available, such as the GENOMIC
20 ISOLATION KIT A.S.A.P.TM (Boehringer Mannheim, Indianapolis, Ind.), Genomic DNA Isolation System (GIBCO BRL, Gaithersburg, Md.), ELU-QUIKTM DNA Purification Kit (Schleicher & Schuell, Keene, N.H.), DNA Extraction Kit (Stratagene, La Jolla, Calif.), TURBOGENTM Isolation Kit (Invitrogen, San Diego, Calif.), and the like. Use of these kits according to the manufacturer's

instructions is generally acceptable for purification of DNA prior to practicing the methods of the present invention.

C. Definitions Affecting CPSI-Encoding Polynucleotide and CPSI Polypeptides Encoded by Same

5 In accordance with the present invention, purified and isolated CPSI-encoding polynucleotides and CPSI polypeptides encoded by same are provided. A particularly provided CPSI-encoding polynucleotide comprises a CPSI encoding polynucleotide which includes a C to A transversion at base 4340, i.e. within exon 36, of the CPSI gene which changes the triplet code from
10 ACC to AAC and leads to the T1405N change in the encoded CPSI polypeptide. The encoded CPSI polypeptide comprising the T1405N change is also particularly provided. Thus, allelic variant polynucleotides and polypeptides encoded by same are provided in accordance with the present invention. Further, a biologically active CPSI polypeptide is also provided in
15 accordance with the present invention, as is a CPSI-encoding polynucleotide encoding such a CPSI polypeptide. Exemplary biological activities include the biological activity of mediating the first step of the urea cycle and the biological activity of cross-reacting with an anti-CPSI antibody.

The provided CPSI-encoding polynucleotides and polypeptides have
20 broad utility given the biological significance of the urea cycle, as is known in the art. By way of example, the CPSI-encoding polynucleotides and polypeptides are useful in the preparation of screening assays and assay kits that are used to detect the presence of the proteins and nucleic acids of this

invention in biological samples. Additionally, it is well known that isolated and purified polypeptides have utility as feed additives for livestock and polynucleotides encoding the polypeptides are thus useful in producing the polypeptides.

5 Preferably, the provided CPSI polynucleotides and polypeptides are isolated from vertebrate and invertebrate sources. Thus, homologs of CPSI, including, but not limited to, mammalian, yeast and bacterial homologs are provided in accordance with the present invention. Preferred mammalian homologs of CPSI members include, but are not limited to, rat and human
10 homologs.

The terms "CPSI gene product", "CPSI protein" and "CPSI polypeptide" refer to proteins having amino acid sequences which are substantially identical to the native amino acid sequences in CPSI and which are biologically active in that they are capable of mediating the synthesis of carbamyl phosphate in
15 the urea cycle, or cross-reacting with anti-CPSI antibodies raised against a CPSI polypeptide.

The terms "CPSI gene product", "CPSI protein" and "CPSI polypeptide" also include analogs of CPSI molecules which exhibit at least some biological activity in common with native CPSI gene products. Furthermore, those skilled
20 in the art of mutagenesis will appreciate that other analogs, as yet undisclosed or undiscovered, may be used to construct CPSI analogs. There is no need for an "CPSI gene product", "CPSI protein" or "CPSI polypeptide" to comprise all, or substantially all of the amino acid sequence of a native CPSI gene product. Shorter or longer sequences are anticipated to be of use in the

invention. Thus, the term "CPSI gene product" also includes fusion or recombinant CPSI polypeptides and proteins. Methods of preparing such proteins are described herein.

5 The terms "CPSI-encoding polynucleotide", "CPSI gene", "CPSI gene sequence" and "CPSI gene segment" refer to any DNA sequence that is substantially identical to a polynucleotide sequence encoding a CPSI gene product, CPSI protein or CPSI polypeptide as defined above. The terms also refer to RNA, or antisense sequences, compatible with such DNA sequences. A "CPSI-encoding polynucleotide", "CPSI gene", "CPSI gene sequence" and
10 "CPSI gene segment" may also comprise any combination of associated control sequences.

The term "substantially identical", when used to define either a CPSI gene product or CPSI amino acid sequence, or a CPSI gene or CPSI nucleic acid sequence, means that a particular sequence, for example, a mutant sequence, varies from the sequence of a natural CPSI by one or more
15 deletions, substitutions, or additions, the net effect of which is to retain at least some of biological activity of CPSI. Alternatively, DNA analog sequences are "substantially identical" to specific DNA sequences disclosed herein if: (a) the DNA analog sequence is derived from coding regions of the natural CPSI gene;
20 or (b) the DNA analog sequence is capable of hybridization of DNA sequences of (a) under moderately stringent conditions and which encode biologically active CPSI gene product; or (c) the DNA sequences are degenerative as a result of the genetic code to the DNA analog sequences defined in (a) and/or (b). Substantially identical analog proteins will be greater than about 60%

identical to the corresponding sequence of the native protein. Sequences having lesser degrees of similarity but comparable biological activity are considered to be equivalents. In determining nucleic acid sequences, all subject nucleic acid sequences capable of encoding substantially similar amino acid sequences are considered to be substantially similar to a reference nucleic acid sequence, regardless of differences in codon sequences.

C.1. Percent Similarity

Percent similarity may be determined, for example, by comparing sequence information using the GAP computer program, available from the University of Wisconsin Geneticist Computer Group. The GAP program utilizes the alignment method of Needleman et al., *J. Mol. Biol.* 48:443 (1970), as revised by Smith et al., *Adv. Appl. Math.* 2:482 (1981). Briefly, the GAP program defines similarity as the number of aligned symbols (i.e. nucleotides or amino acids) which are similar, divided by the total number of symbols in the shorter of the two sequences. The preferred default parameters for the GAP program include: (1) a unitary comparison matrix (containing a value of 1 for identities and 0 for non-identities) of nucleotides and the weighted comparison matrix of Gribskov et al., *Nucl. Acids. Res.* 14:6745 (1986), as described by Schwartz et al., eds., *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, pp. 357-358 (1979); (2) a penalty of 3.0 for each gap and an additional 0.01 penalty for each symbol and each gap; and (3) no penalty for end gaps. Other comparison techniques are described in the Examples.

The term "homology" describes a mathematically based comparison of sequence similarities which is used to identify genes or proteins with similar functions or motifs. Accordingly, the term "homology" is synonymous with the term "similarity" and "percent similarity" as defined above. Thus, the phrases

5 "substantial homology" or "substantial similarity" have similar meanings.

C.2. Nucleic Acid Sequences

In certain embodiments, the invention concerns the use of CPSI genes and gene products that include within their respective sequences a sequence which is essentially that of a CPSI gene, or the corresponding protein. The

10 term "a sequence essentially as that of a CPSI gene", means that the sequence substantially corresponds to a portion of a CPSI polypeptide or CPSI encoding polynucleotide and has relatively few bases or amino acids (whether DNA or protein) which are not identical to those of a CPSI protein or CPSI gene, (or a biologically functional equivalent of, when referring to proteins).

15 The term "biologically functional equivalent" is well understood in the art and is further defined in detail herein. Accordingly, sequences which have between about 70% and about 80%; or more preferably, between about 81% and about 90%; or even more preferably, between about 91% and about 99%; of amino acids which are identical or functionally equivalent to the amino acids of a CPSI

20 protein or CPSI gene, will be sequences which are "essentially the same".

CPSI gene products and CPSI genes which have functionally equivalent codons are also covered by the invention. The term "functionally equivalent codon" is used herein to refer to codons that encode the same amino acid,

such as the six codons for arginine or serine, and also to refer to codons that encode biologically equivalent amino acids (see Table 1).

TABLE 1

Table of the Genetic Code

5	Amino Acids			Codons
	Alanine	Ala	A	GCA GCC GCG GCU
	Cysteine	Cys	C	UGC UGU
	Aspartic Acid	Asp	D	GAC GAU
	Glumatic acid	Glu	E	GAA GAG
10	Phenylalanine	Phe	F	UUC UUU
	Glycine	Gly	G	GGA GGC GGG GGU
	Histidine	His	H	CAC CAU
	Isoleucine	Ile	I	AUA AUC AUU
	Lysine	Lys	K	AAA AAG
15	Leucine	Leu	L	UUA UUG CUA CUC CUG CUU
	Methionine	Met	M	AUG
	Asparagine	Asn	N	AAC AAU
	Proline	Pro	P	CCA CCC CCG CCU
	Glutamine	Gln	Q	CAA CAG
20	Arginine	Arg	R	AGA AGG CGA CGC CGG CGU
	Serine	Ser	S	ACG AGU UCA UCC UCG UCU
	Threonine	Thr	T	ACA ACC ACG ACU
	Valine	Val	V	GUA GUC GUG GUU
	Tryptophan	Trp	W	UGG
25	Tyrosine	Tyr	Y	UAC UAU

It will also be understood that amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned. The addition of terminal sequences particularly applies to nucleic acid sequences which may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, i.e., introns, which

are known to occur within genes.

5 The present invention also encompasses the use of DNA segments which are complementary, or essentially complementary, to the sequences set forth in the specification. Nucleic acid sequences which are “complementary” are those which are base-pairing according to the standard Watson-Crick complementarity rules. As used herein, the term “complementary sequences” means nucleic acid sequences which are substantially complementary, as may be assessed by the same nucleotide comparison set forth above, or as defined as being capable of hybridizing to the nucleic acid segment in question under relatively stringent conditions such as those described herein. A particular example of a contemplated complementary nucleic acid segment is an antisense oligonucleotide.

15 Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, or organic solvents, in addition to the base composition, length of the complementary strands, and the number of nucleotide base mismatches between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. Stringent temperature conditions will generally include temperatures in excess of 30°C, typically in excess of 37°C, and preferably in excess of 45°C. Stringent salt conditions will ordinarily be less than 1,000 mM, typically less than 500 mM, and preferably less than 200 mM. However, the combination of parameters is much more important than the measure of any single parameter. (See e.g., Wetmur & Davidson, *J. Mol. Biol.* 31:349-370 (1968)).

Probe sequences may also hybridize specifically to duplex DNA under

certain conditions to form triplex or other higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well known in the art.

As used herein, the term "DNA segment" refers to a DNA molecule which has been isolated free of total genomic DNA of a particular species. Furthermore, a DNA segment encoding a CPSI polypeptide refers to a DNA segment which contains CPSI coding sequences, yet is isolated away from, or purified free from, total genomic DNA of a source species, such as *Homo sapiens*. Included within the term "DNA segment" are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phages, viruses, and the like.

Similarly, a DNA segment comprising an isolated or purified CPSI gene refers to a DNA segment including CPSI coding sequences isolated substantially away from other naturally occurring genes or protein encoding sequences. In this respect, the term "gene" is used for simplicity to refer to a functional protein, polypeptide or peptide encoding unit. As will be understood by those in the art, this functional term includes both genomic sequences and cDNA sequences. "Isolated substantially away from other coding sequences" means that the gene of interest, in this case, the CPSI gene, forms the significant part of the coding region of the DNA segment, and that the DNA segment does not contain large portions of naturally-occurring coding DNA, such as large chromosomal fragments or other functional genes or cDNA coding regions. Of course, this refers to the DNA segment as originally isolated, and does not exclude genes or coding regions later added to the

segment by the hand of man.

In particular embodiments, the invention concerns isolated DNA segments and recombinant vectors incorporating DNA sequences which encode a CPSI polypeptide that includes within its amino acid sequence an amino acid sequence of any of SEQ ID NOs:2, 4, 12 and 14. In other particular embodiments, the invention concerns isolated DNA segments and recombinant vectors incorporating DNA sequences which encode a protein that includes within its amino acid sequence the amino acid sequence of a CPSI polypeptide corresponding to human tissues.

It will also be understood that this invention is not limited to the particular nucleic acid and amino acid sequences of SEQ ID NO's:1-4 and 11-14. Recombinant vectors and isolated DNA segments may therefore variously include the CPSI polypeptide-encoding region itself, include coding regions bearing selected alterations or modifications in the basic coding region, or include encoded larger polypeptides which nevertheless include CPSI polypeptide-encoding regions or may encode biologically functional equivalent proteins or peptides which have variant amino acid sequences.

In certain embodiments, the invention concerns isolated DNA segments and recombinant vectors which encode a protein or peptide that includes within its amino acid sequence an amino acid sequence essentially as set forth in any of SEQ ID NOs:2, 4, 12 and 14. Naturally, where the DNA segment or vector encodes a full length CPSI gene product, the most preferred nucleic acid sequence is that which is essentially as set forth in any of SEQ ID NOs: 1, 3, 11 and 13 and which encode a protein that exhibits activity in the urea cycle,

as may be determined by, for example, colorimetric assays to detect production of carbonyl phosphate from ammonia, as disclosed herein in Example 3.

5 The term "a sequence essentially as set forth in any of SEQ ID NO:2, 4, 12 and 14" means that the sequence substantially corresponds to a portion an amino acid sequence either of SEQ ID NOs:2, 4, 12 and 14 and has relatively few amino acids which are not identical to, or a biologically functional equivalent of, the amino acids of an amino acid sequence of any of SEQ ID NOs:2, 4, 12 and 14. The term "biologically functional equivalent" is well understood in the art and is further defined in detail herein. Accordingly, 10 sequences, which have between about 70% and about 80%; or more preferably, between about 81% and about 90%; or even more preferably, between about 91% and about 99%; of amino acids which are identical or functionally equivalent to the amino acids in any of SEQ ID NOs: 2, 4, 12 and 14, will be sequences which "a sequence essentially as set forth in SEQ ID 15 NOs:2, 4, 12 and 14".

In particular embodiments, the invention concerns gene therapy methods that use isolated DNA segments and recombinant vectors incorporating DNA sequences which encode a protein that includes within its amino acid sequence an amino acid sequence of any of SEQ ID NOs:2, 4, 12 20 and 14, SEQ ID NOs:2, 4, 12 and 14 including sequences which are derived from human tissue. In other particular embodiments, the invention concerns isolated DNA sequences and recombinant DNA vectors incorporating DNA sequences which encode a protein that includes within its amino acid sequence the amino acid sequence of the CPSI protein from human hepatic tissue.

In certain other embodiments, the invention concerns isolated DNA segments and recombinant vectors that include within their sequence a nucleic acid sequence essentially as set forth in any of SEQ ID NO:1, 3, 11 and 13. The term "a sequence essentially as set forth in any of SEQ ID NO:1, 3, 11 and 13" is used in the same sense as described above and means that the nucleic acid sequence substantially corresponds to a portion of any of SEQ ID NOs:1, 3, 11 and 13, respectively, and has relatively few codons which are not identical, or functionally equivalent, to the codons of any of SEQ ID NOs:1, 3, 11 and 13, respectively. Again, DNA segments which encode gene products exhibiting activity in the urea cycle, cross-reactivity with an anti-CPSI antibody, or other biological activity of the CPSI gene product will be most preferred. The term "functionally equivalent codon" is used herein to refer to codons that encode the same amino acid, such as the six codons for arginine or serine, and also to refer to codons that encode biologically equivalent amino acids (see Table 1).

The nucleic acid segments of the present invention, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, enhancers, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, nucleic acid fragments may be prepared which include a short stretch

complementary to a nucleic acid sequence set for in any of SEQ ID NOs:1, 3, 11 and 13 respectively, such as about 10 nucleotides, and which are up to 10,000 or 5,000 base pairs in length, with segments of 3,000 being preferred in certain cases. DNA segments with total lengths of about 1,000, 500, 200, 100 and about 50 base pairs in length are also contemplated to be useful.

The DNA segments of the present invention encompass biologically functional equivalent CPSI proteins and peptides. Such sequences may rise as a consequence of codon redundancy and functional equivalency which are known to occur naturally within nucleic acid sequences and the proteins thus encoded. Alternatively, functionally equivalent proteins or peptides may be created via the application of recombinant DNA technology, in which changes in the protein structure may be engineered, based on considerations of the properties of the amino acids being exchanged, e.g. substitution of Ile and Leu at amino acids 4 and 5 is SEQ ID NOs:11-14. Changes designed by man may be introduced through the application of site-directed mutagenesis techniques, e.g., to introduce improvements to the antigenicity of the protein or to test CPSI mutants in order to examine activity in the urea cycle, or other activity at the molecular level.

If desired, one may also prepare fusion proteins and peptides, e.g., where the CPSI coding region is aligned within the same expression unit with other proteins or peptides having desired functions, such as for purification or immunodetection purposes (e.g., proteins which may be purified by affinity chromatography and enzyme label coding regions, respectively).

Recombinant vectors form important further aspects of the present

invention. Particularly useful vectors are contemplated to be those vectors in which the coding portion of the DNA segment is positioned under the control of a promoter. The promoter may be in the form of the promoter which is naturally associated with the CPSI gene, e.g., in mammalian tissues, as may
5 be obtained by isolating the 5' non-coding sequences located upstream of the coding segment or exon, for example, using recombinant cloning and/or PCR technology, in connection with the compositions disclosed herein.

In other embodiments, it is contemplated that certain advantages will be gained by positioning the coding DNA segment under the control of a
10 recombinant, or heterologous, promoter. As used herein, a recombinant or heterologous promoter is intended to refer to a promoter that is not normally associated with a CPSI gene in its natural environment. Such promoters may include promoters isolated from bacterial, viral, eukaryotic, or mammalian cells. Naturally, it will be important to employ a promoter that effectively directs the
15 expression of the DNA segment in the cell type chosen for expression. The use of promoter and cell type combinations for protein expression is generally known to those of skill in the art of molecular biology, for example, see Sambrook et al., 1989, incorporated herein by reference. The promoters employed may be constitutive, or inducible, and can be used under the
20 appropriate conditions to direct high level expression of the introduced DNA segment, such as is advantageous in the large-scale production of recombinant proteins or peptides. Appropriate promoter systems provided for use in high-level expression include, but are not limited to, the vaccina virus promoter and the baculovirus promoter.

In an alternative embodiment, the present invention provides an expression vector comprising a polynucleotide that encodes a CPSI polypeptide having activity in the urea cycle, cross-reacting with an anti-CPSI antibody, or other biological activity in accordance with the present invention.

5 Also preferably, an expression vector of the present invention comprises a polynucleotide that encodes a human CPSI gene product. More preferably, an expression vector of the present invention comprises a polynucleotide that encodes a polypeptide comprising an amino acid residue sequence of any of SEQ ID NOs:2, 4, 12 and 14. More preferably, an expression vector of the present invention comprises a polynucleotide comprising the nucleotide base sequence of any of SEQ ID NO:1, 3, 11 and 13.

10 Even more preferably, an expression vector of the invention comprises a polynucleotide operatively linked to an enhancer-promoter. More preferably still, an expression vector of the invention comprises a polynucleotide operatively linked to a prokaryotic promoter. Alternatively, an expression vector of the present invention comprises a polynucleotide operatively linked to an enhancer-promoter that is a eukaryotic promoter, and the expression vector further comprises a polyadenylation signal that is positioned 3' of the carboxy-terminal amino acid and within a transcriptional unit of the encoded polypeptide.

20 In yet another embodiment, the present invention provides a recombinant host cell transfected with a polynucleotide that encodes a CPSI polypeptide having activity in the modulation of the urea cycle, cross-reactivity with an anti-CPSI antibody, or other biological activity in accordance with the

present invention. SEQ ID NO's: 1-4 and 11-14 set forth nucleotide and amino acid sequences from an exemplary vertebrate, human. Also provided by the present invention are homologous or biologically equivalent polynucleotides and CPSI polypeptides found in other vertebrates, including rat. Also provided

5 by the present invention are homologous or biologically equivalent polynucleotides and CPSI polypeptides found in invertebrates, including bacteria and yeast.

Preferably, a recombinant host cell of the present invention is transfected with the polynucleotide that encodes human CPSI polypeptide.

10 More preferably, a recombinant host cell of the present invention is transfected with the polynucleotide sequence of any of SEQ ID NOs:1, 3, 11 and 13. Even more preferably, a host cell of the invention is a eukaryotic host cell. Still more preferably, a recombinant host cell of the present invention is a vertebrate cell. Preferably, a recombinant host cell of the invention is a mammalian cell.

15 In another aspect, a recombinant host cell of the present invention is a prokaryotic host cell. Preferably, a recombinant host cell of the invention is a bacterial cell, preferably a strain of *Escherichia coli*. More preferably, a recombinant host cell comprises a polynucleotide under the transcriptional control of regulatory signals functional in the recombinant host cell, wherein the

20 regulatory signals appropriately control expression of the CPSI polypeptide in a manner to enable all necessary transcriptional and post-transcriptional modification.

In yet another embodiment, the present invention provides a method of preparing a CPSI polypeptide comprising transfecting a cell with polynucleotide

that encodes a CPSI polypeptide having activity in the urea cycle, cross-reacting with an anti-CPSI antibody, or other biological activity in accordance with the present invention, to produce a transformed host cell; and maintaining the transformed host cell under biological conditions sufficient for expression

5 of the polypeptide. More preferably, the transformed host cell is a eukaryotic cell. More preferably still, the eukaryotic cell is a vertebrate cell. Alternatively, the host cell is a prokaryotic cell. More preferably, the prokaryotic cell is a bacterial cell of *Escherichia coli*. Even more preferably, a polynucleotide transfected into the transformed cell comprises a nucleotide base sequence of

10 any of SEQ ID NOs:1, 3, 11 and 13. SEQ ID NO's:1-4 and 11-14 set forth nucleotide and amino acid sequences for an exemplary vertebrate, human. Also provided by the present invention are homologues or biologically equivalent CPSI polynucleotides and polypeptides found in other vertebrates, particularly warm blooded vertebrates, and more particularly rat. Also

15 provided by the present invention are homologous or biologically equivalent polynucleotides and CPSI polypeptides found in invertebrates, including bacteria and yeast.

As mentioned above, in connection with expression embodiments to prepare recombinant CPSI proteins and peptides, it is contemplated that longer

20 DNA segments will most often be used, with DNA segments encoding the entire CPSI protein, functional domains or cleavage products thereof, being most preferred. However, it will be appreciated that the use of shorter DNA segments to direct the expression of CPSI peptides or epitopic core regions, such as may be used to generate anti-CPSI antibodies, also falls within the

scope of the invention.

DNA segments which encode peptide antigens from about 15 to about 50 amino acids in length, or more preferably, from about 15 to about 30 amino acids in length are contemplated to be particularly useful. DNA segments
5 encoding peptides will generally have a minimum coding length in the order of about 45 to about 150, or to about 90 nucleotides. DNA segments encoding full length proteins may have a minimum coding length on the order of about 4,500 to about 4,600 nucleotides for a protein in accordance with any of SEQ ID NOs: 2, 4, 12 and 14.

10 Naturally, the present invention also encompasses DNA segments which are complementary, or essentially complementary, to the sequences set forth in any of SEQ ID NO's: 1, 3, 11 and 13. The terms "complementary" and "essentially complementary" are defined above. Excepting intronic or flanking regions, details of which are disclosed graphically in Fig. 9, and allowing for the
15 degeneracy of the genetic code, sequences which have between about 70% and about 80%; or more preferably, between about 81% and about 90%; or even more preferably, between about 91% and about 99%; of nucleotides which are identical or functionally equivalent (i.e. encoding the same amino acid) of nucleotides in any of SEQ ID NOs:1, 3, 11 and 13 will be sequences
20 which are "a sequence essentially as set forth in any of SEQ ID NOs:1, 3, 11 and 13". Sequences which are essentially the same as those set forth in any of SEQ ID NOs:1, 3, 11 and 13 may also be functionally defined as sequences which are capable of hybridizing to a nucleic acid segment containing the complement in any of SEQ ID NOs:1, 3, 11 and 13 under relatively stringent

conditions. Suitable relatively stringent hybridization conditions are described herein and will be well known to those of skill in the art.

C.2. Biologically Functional Equivalents

As mentioned above, modification and changes may be made in the
5 structure of the CPSI proteins and peptides described herein and still obtain a
molecule having like or otherwise desirable characteristics. For example,
certain amino acids may be substituted for other amino acids in a protein
structure without appreciable loss of interactive capacity with structures such
as, for example, in the nucleus of a cell. Since it is the interactive capacity and
10 nature of a protein that defines that protein's biological functional activity,
certain amino acid sequence substitutions can be made in a protein sequence
(or, of course, its underlying DNA coding sequence) and nevertheless obtain
a protein with like or even countervailing properties (e.g., antagonistic v.
agonistic). It is thus contemplated by applicants that various changes may be
15 made in the sequence of the CPSI proteins and peptides (or underlying DNA)
without appreciable loss of their biological utility or activity.

It is also well understood by the skilled artisan that, inherent in the
definition of a biologically functional equivalent protein or peptide, is the
concept that there is a limit to the number of changes that may be made within
20 a defined portion of the molecule and still result in a molecule with an
acceptable level of equivalent biological activity. Biologically functional
equivalent peptides are thus defined herein as those peptides in which certain,
not most or all, of the amino acids may be substituted. Of course, a plurality

of distinct proteins/peptides with different substitutions may easily be made and used in accordance with the invention.

It is also well understood that where certain residues are shown to be particularly important to the biological or structural properties of a protein or peptide, e.g., residues in active sites, such residues may not generally be exchanged. This is the case in the present invention, where if any changes, for example, in the phosphorylation domains of a CPSI polypeptide, could result in a loss of an aspect of the utility of the resulting peptide for the present invention.

Amino acid substitutions, such as those which might be employed in modifying the CPSI proteins and peptides described herein, are generally based on the relative similarity of the amino acid side-chain substituents, for example, their hydrophobicity, hydrophilicity, charge, size, and the like. An analysis of the size, shape and type of the amino acid side-chain substituents reveals that arginine, lysine and histidine are all positively charged residues; that alanine, glycine and serine are all a similar size; and that phenylalanine, tryptophan and tyrosine all have a generally similar shape. Therefore, based upon these considerations, arginine, lysine and histidine; alanine, glycine and serine; and phenylalanine, tryptophan and tyrosine; are defined herein as biologically functional equivalents.

In making such changes, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a hydropathic index on the basis of their hydrophobicity and charge characteristics, these are: isoleucine (+ 4.5); valine (+ 4.2); leucine (+ 3.8); phenylalanine (+ 2.8); cysteine/cystine

(+ 2.5); methionine (+ 1.9); alanine (+ 1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

5 The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte & Doolittle, *J. Mol. Biol.* 157:105-132 (1982), incorporated herein by reference). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar
10 biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within ± 2 of the original value is preferred, those which are within ± 1 of the original value are particularly preferred, and those within ± 0.5 of the original value are even more particularly preferred.

15 It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Pat. No. 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e. with a
20 biological property of the protein. It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent protein.

As detailed in U.S. Pat. No. 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+ 3.0); lysine (+

3.0); aspartate (+ 3.0 \pm 1); glutamate (+ 3.0 \pm 1); serine (+ 0.3); asparagine (+ 0.2); glutamine (+ 0.2); glycine (0); threonine (-0.4); proline (-0.5 \pm 1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4) .

5 In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within ± 2 of the original value is preferred, those which are within ± 1 of the original value are particularly preferred, and those within ± 0.5 of the original value are even more particularly preferred.

10 While discussion has focused on functionally equivalent polypeptides arising from amino acid changes, it will be appreciated that these changes may be effected by alteration of the encoding DNA, taking into consideration also that the genetic code is degenerate and that two or more codons may code for the same amino acid.

15 C.3. Sequence Modification Techniques

Modifications to the CPSI proteins and peptides described herein may be carried out using techniques such as site directed mutagenesis. Site-specific mutagenesis is a technique useful in the preparation of individual peptides, or biologically functional equivalent proteins or peptides, through
20 specific mutagenesis of the underlying DNA. The technique further provides a ready ability to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA. Site-specific mutagenesis

allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both
5 sides of the deletion junction being traversed. Typically, a primer of about 17 to 30 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered.

In general, the technique of site-specific mutagenesis is well known in the art as exemplified by publications (e.g., Adelman et al., 1983). As will be
10 appreciated, the technique typically employs a phage vector which exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage (Messing et al., 1981). These phage are readily commercially available and their use is generally well known to those skilled in the art. Double stranded plasmids are
15 also routinely employed in site directed mutagenesis which eliminates the step of transferring the gene of interest from a plasmid to a phage.

In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector or melting apart the two strands of a double stranded vector which includes within its sequence a DNA
20 sequence which encodes, for example, a human CPSI polypeptide. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically, for example by the method of Crea et al. (1978). This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, in order

to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing the mutated sequence arrangement.

The preparation of sequence variants of the selected gene using site-directed mutagenesis is provided as a means of producing potentially useful CPSI polypeptide or other species having activity in the urea cycle and is not meant to be limiting as there are other ways in which sequence variants of these peptides may be obtained. For example, recombinant vectors encoding the desired genes may be treated with mutagenic agents to obtain sequence variants (see, e.g., a method described by Eichenlaub, 1979) for the mutagenesis of plasmid DNA using hydroxylamine.

C.4. Other Structural Equivalents

In addition to the CPSI peptidyl compounds described herein, the inventors also contemplate that other sterically similar compounds may be formulated to mimic the key portions of the peptide structure. Such compounds may be used in the same manner as the peptides of the invention and hence are also functional equivalents. The generation of a structural functional equivalent may be achieved by the techniques of modeling and chemical design known to those of skill in the art. It will be understood that all such sterically similar constructs fall within the scope of the present invention.

D. Introduction of Gene Products

Where the gene itself is employed to introduce the gene products, a convenient method of introduction will be through the use of a recombinant vector which incorporates the desired gene, together with its associated control sequences. The preparation of recombinant vectors is well known to those of skill in the art and described in many references, such as, for example, Sambrook et al. (1989), specifically incorporated herein by reference.

In vectors, it is understood that the DNA coding sequences to be expressed, in this case those encoding the CPSI gene products, are positioned adjacent to and under the control of a promoter. It is understood in the art that to bring a coding sequence under the control of such a promoter, one generally positions the 5' end of the transcription initiation site of the transcriptional reading frame of the gene product to be expressed between about 1 and about 50 nucleotides "downstream" of (i.e., 3' of) the chosen promoter. One may also desire to incorporate into the transcriptional unit of the vector an appropriate polyadenylation site (e.g., 5'-AATAAA-3'), if one was not contained within the original inserted DNA. Typically, these poly A addition sites are placed about 30 to 2000 nucleotides "downstream" of the coding sequence at a position prior to transcription termination.

While use of the control sequences of the specific gene (i.e., a CPSI promoter for a CPSI gene) will be preferred, there is no reason why other control sequences could not be employed, so long as they are compatible with the genotype of the cell being treated. Thus, one may mention other useful promoters by way of example, including, e.g., an SV40 early promoter, a long

terminal repeat promoter from retrovirus, an actin promoter, a heat shock promoter, a metallothionein promoter, and the like.

As is known in the art, a promoter is a region of a DNA molecule typically within about 100 nucleotide pairs in front of (upstream of) the point at which transcription begins (i.e., a transcription start site). That region typically contains several types of DNA sequence elements that are located in similar relative positions in different genes. As used herein, the term "promoter" includes what is referred to in the art as an upstream promoter region, a promoter region or a promoter of a generalized eukaryotic RNA Polymerase II transcription unit.

Another type of discrete transcription regulatory sequence element is an enhancer. An enhancer provides specificity of time, location and expression level for a particular encoding region (e.g., gene). A major function of an enhancer is to increase the level of transcription of a coding sequence in a cell that contains one or more transcription factors that bind to that enhancer. Unlike a promoter, an enhancer can function when located at variable distances from transcription start sites so long as a promoter is present.

As used herein, the phrase "enhancer-promoter" means a composite unit that contains both enhancer and promoter elements. An enhancer-promoter is operatively linked to a coding sequence that encodes at least one gene product. As used herein, the phrase "operatively linked" means that an enhancer-promoter is connected to a coding sequence in such a way that the transcription of that coding sequence is controlled and regulated by that enhancer-promoter. Means for operatively linking an enhancer-promoter

to a coding sequence are well known in the art. As is also well known in the art, the precise orientation and location relative to a coding sequence whose transcription is controlled, is dependent *inter alia* upon the specific nature of the enhancer-promoter. Thus, a TATA box minimal promoter is typically located
5 from about 25 to about 30 base pairs upstream of a transcription initiation site and an upstream promoter element is typically located from about 100 to about 200 base pairs upstream of a transcription initiation site. In contrast, an enhancer can be located downstream from the initiation site and can be at a considerable distance from that site.

10 An enhancer-promoter used in a vector construct of the present invention can be any enhancer-promoter that drives expression in a cell to be transfected. By employing an enhancer-promoter with well-known properties, the level and pattern of gene product expression can be optimized.

For introduction of, for example, the human CPSI gene including allelic variations thereof, it is proposed that one will desire to preferably employ a
15 vector construct that will deliver the desired gene to the affected cells. This will, of course, generally require that the construct be delivered to the targeted cells, for example, mammalian hepatic cells. It is proposed that this may be achieved most preferably by introduction of the desired gene through the use of a viral
20 vector to carry the CPSI sequence to efficiently infect the cells. These vectors will preferably be an adenoviral, a retroviral, a vaccinia viral vector or adeno-associated virus. These vectors are preferred because they have been successfully used to deliver desired sequences to cells and tend to have a high infection efficiency. Suitable vector-CPSI gene constructs are adapted for

administration as pharmaceutical compositions, as described herein below.

Commonly used viral promoters for expression vectors are derived from polyoma, cytomegalovirus, Adenovirus 2, and Simian Virus 40 (SV40). The early and late promoters of SV40 virus are particularly useful because both are
5 obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication. Smaller or larger SV40 fragments may also be used, provided there is included the approximately 250 bp sequence extending from the *Hind* III site toward the *Bgl* I site located in the viral origin of replication. Further, it is also possible, and often desirable, to utilize promoter or control
10 sequences normally associated with the desired gene sequence, provided such control sequences are compatible with the host cell systems.

The origin of replication may be provided either by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (e.g., Polyoma, Adeno, VSV, BPV) source, or may be provided by
15 the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.

Where a CPSI gene itself is employed it will be most convenient to simply use a wild type CPSI gene directly. The CPSI gene can thus comprise the threonine encoding allele such that amino acid 1405 of the encoded
20 polypeptide comprises threonine. Alternatively, the CPSI gene comprises the arginine encoding allele such that amino acid 1405 of the encoded polypeptide comprises arginine. Additionally, it is envisioned that certain regions of a CPSI gene can be employed exclusively without employing an entire wild type CPSI gene or an entire allelic variant thereof. It is proposed that it will ultimately be

preferable to employ the smallest region needed to modulate the urea cycle so that one is not introducing unnecessary DNA into cells which receive a CPSI gene construct. Techniques well known to those of skill in the art, such as the use of restriction enzymes, will allow for the generation of small regions of an exemplary CPSI gene. The ability of these regions to modulate the urea cycle can easily be determined by the assays reported in the Examples. In general, techniques for assessing the modulation of the urea cycle are known in the art.

D.1. Transgenic Animals

It is also provided within the scope of the present invention to prepare a transgenic non-human animal which expresses a CPSI gene of the present invention or in which expression of a CPSI gene is "knocked-out". Provided transgenic non-human animals express either the T1405 form of CPSI or the N1405 form of CPSI. A preferred transgenic animal is a mouse.

Techniques for the preparation of transgenic animals are known in the art. Exemplary techniques are described in U.S. Patent No. 5,489,742 (transgenic rats); U.S. Patent Nos. 4,736,866, 5,550,316, 5,614,396, 5,625,125 and 5,648,061 (transgenic mice); U.S. Patent No. 5,573,933 (transgenic pigs); U.S. Patent No. 5,162,215 (transgenic avian species) and U.S. Patent No. 5,741,957 (transgenic bovine species), the entire contents of each of which are herein incorporated by reference.

With respect to an exemplary method for the preparation of a transgenic mouse, cloned recombinant or synthetic DNA sequences or DNA segments encoding a CPSI gene product are injected into fertilized mouse eggs. The

injected eggs are implanted in pseudo pregnant females and are grown to term to provide transgenic mice whose cells express a CPSI gene product. Preferably, the injected sequences are constructed having promoter sequences connected so as to express the desired protein in hepatic cells of the transgenic mouse.

D.2. Gene Therapy

CPSI genes can be used for gene therapy in accordance with the present invention. Exemplary gene therapy methods, including liposomal transfection of nucleic acids into host cells, are described in U.S. Patent Nos. 5,279,833; 5,286,634; 5,399,346; 5,646,008; 5,651,964; 5,641,484; and 5,643,567, the contents of each of which are herein incorporated by reference.

Briefly, CPSI gene therapy directed toward modulation of the urea cycle in a target cell is described. Target cells include but are not limited to hepatic cells and intestinal cells. In one embodiment, a therapeutic method of the present invention provides a method for modulating of the urea cycle in a cell comprising the steps of: (a) delivering to the cell an effective amount of a DNA molecule comprising a polynucleotide that encodes a CPSI polypeptide that modulates the urea cycle; and (b) maintaining the cell under conditions sufficient for expression of said polypeptide.

Delivery is preferably accomplished by injecting the DNA molecule into the cell. Where the cell is in a subject delivering is preferably administering the DNA molecule into the circulatory system of the subject. In a preferred embodiment, administering comprises the steps of: (a) providing a vehicle that

contains the DNA molecule; and (b) administering the vehicle to the subject.

A vehicle is preferably a cell transformed or transfected with the DNA molecule or a transfected cell derived from such a transformed or transfected cell. An exemplary and preferred transformed or transfected cell is a hepatic cell. Means for transforming or transfecting a cell with a DNA molecule of the present invention are set forth above.

Alternatively, the vehicle is a virus or an antibody that specifically infects or immunoreacts with an antigen of the tumor. Retroviruses used to deliver the constructs to the host target tissues generally are viruses in which the 3'-LTR (linear transfer region) has been inactivated. That is, these are enhancerless 3'-LTR's, often referred to as SIN (self-inactivating viruses) because after productive infection into the host cell, the 3'-LTR is transferred to the 5'-end and both viral LTR's are inactive with respect to transcriptional activity. A use of these viruses well known to those skilled in the art is to clone genes for which the regulatory elements of the cloned gene are inserted in the space between the two LTR's. An advantage of a viral infection system is that it allows for a very high level of infection into the appropriate recipient cell.

Antibodies have been used to target and deliver DNA molecules. An N-terminal modified poly-L-lysine (NPLL)-antibody conjugate readily forms a complex with plasmid DNA. A complex of monoclonal antibodies against a cell surface thrombomodulin conjugated with NPLL was used to target a foreign plasmid DNA to an antigen-expressing mouse lung endothelial cell line and mouse lung. Those targeted endothelial cells expressed the product encoded by that foreign DNA.

It is also envisioned that this embodiment of the present invention can be practiced using alternative viral or phage vectors, including retroviral vectors and vaccinia viruses whose genome has been manipulated in alternative ways so as to render the virus non-pathogenic. Methods for creating such a viral mutation are set forth in detail in U.S. Patent No. 4,769,331, incorporated herein by reference.

By way of specific example, a human CPSI-encoding polynucleotide or a CPSI-encoding polynucleotide homolog from another warm-blooded vertebrate or a CPSI-encoding homolog from an invertebrate source, such as bacteria or yeast is introduced into isolated hepatic cells or other relevant cells. The re-injection of the transgene-carrying cells into the liver or other relevant tissues provides a treatment for susceptibility to hyperammonemia or other relevant diseases in human and animals.

E. Supplementation Therapy

In addition to its role in nitrogen clearance, the urea cycle is the body's intrinsic source of arginine which acts as a precursor of nitric oxide (NO), a potent vasodilator. Methods of treating suboptimal urea cycle function are provided in accordance with the present invention, including treatment by administration of nitric oxide precursors such as citrulline. Typically, the suboptimal urea cycle function is associated with the polymorphism disclosed herein. The sub-optimal urea cycle function can further comprise hyperammonemia or decreased arginine production.

The subject to be treated can be suffering from a disorder associated

with sub-optimal urea cycle function. Such disorders include but are not limited to disorders that involve impaired or damaged liver and/or gut tissue. Representative disorders include but are not limited to hepatitis (including hepatitis A, B and C), sclerosis, pulmonary hypertension, bone marrow transplant toxicity in a subject undergoing bone marrow transplant and combinations thereof.

The subject to be treated can also exposed or about to be exposed to an environmental stimulus associated with sub-optimal urea cycle function. Such environmental stimuli include but are not limited to stimuli that involve impairment or damage to liver and/or gut tissue. Representative environmental stimulus include but are not limited to chemotherapy or other pharmaceutical therapy, cardiac surgery, increased oxidative stress, bone marrow transplant, and combinations thereof.

Thus, a method of treating or preventing a disorder related to sub-optimal urea cycle function in a subject is provided in accordance with the present invention. The method comprises administering to the subject a therapeutically effective amount of a nitric oxide precursor, whereby treatment or prevention of the disorder is accomplished. The nitric oxide precursor can include but is not limited to citrulline, arginine and combinations thereof. The nitric oxide precursor is administered in a dose ranging from about 0.01 mg to about 1,000 mg, preferably in a dose ranging from about 0.5 mg to about 500 mg, and more preferably in a dose ranging from about 1.0 mg to about 250 mg.

Optionally, the supplementation therapy method of the present invention further comprises the step of initially detecting a polymorphism of a carbamyl

phosphate synthase I (CPSI) gene in the subject. The polymorphism of the carbamyl phosphate synthetase polypeptide preferably comprises a C to A transversion within CPSI exon 36, more preferably comprises a C to A transversion at nucleotide 4340 of a cDNA that corresponds to the CPSI gene, and ever more preferably, the C to A transversion at nucleotide 4340 of the cDNA that corresponds to the CPSI gene further comprises a change in the triplet code from AAC to ACC, which encodes a CPSI polypeptide having an threonine moiety at amino acid 1405.

A significant decrease in urea cycle intermediates (citrulline, arginine) was observed in subjects undergoing BMT associated with the T1405N CPSI polymorphism disclosed herein. In accordance with the present invention, a method for the treatment or prophylaxis of BMT toxicity, such as HVOD, comprising administering a therapeutically effective amount of a NO precursor, such as citrulline and/or arginine, to a subject in need thereof is also provided in accordance with the present invention. Preferably, the T1405N CPSI polymorphism disclosed herein is present in the subject. More preferably, a therapeutically effective amount of citrulline is administered to the subject.

In accordance with the present invention, a method of reducing toxicity and/or the occurrence of HVOD in a subject undergoing BMT is thus provided. This method comprises administering the BMT subject an effective amount of arginine and/or citrulline, with citrulline being preferred, to bolster arginine and NO synthesis in the subject. The bolstering of arginine and NO synthesis in the subject will reduce and/or substantially prevent the occurrence of HVOD associated with BMT. Citrulline is a preferred supplementation agent given that

it is more readily converted to NO. Additionally and preferably, subjects having the CPSI polymorphism of the present invention are contemplated to be preferred candidates for supplementation in accordance with this method.

5 The subject treated in the present invention in its many embodiments is desirably a human subject, although it is to be understood that the principles of the invention indicate that the invention is effective with respect to all vertebrate species, including warm-blooded vertebrates such as mammals and birds, which are intended to be included in the term "subject". In this context, a mammal is understood to include any mammalian species in which treatment
10 of hyperammonemia, BMT toxicity and other diseases associated with impaired urea cycle function is desirable, particularly agricultural and domestic mammalian species.

Thus, contemplated is the treatment of mammals such as humans, as well as those mammals of importance due to being endangered (such as
15 Siberian tigers), of economical importance (animals raised on farms for consumption by humans) and/or social importance (animals kept as pets or in zoos) to humans, for instance, carnivores other than humans (such as cats and dogs), swine (pigs, hogs, and wild boars), ruminants (such as cattle, oxen, sheep, giraffes, deer, goats, bison, and camels), and horses. Also
20 contemplated is the treatment of birds, including the treatment of those kinds of birds that are endangered, kept in zoos, as well as fowl, and more particularly domesticated fowl, i.e., poultry, such as turkeys, chickens, ducks, geese, guinea fowl, and the like, as they are also of economical importance to humans. Thus, contemplated is the treatment of livestock, including, but not

limited to, domesticated swine (pigs and hogs), ruminants, horses, poultry, and the like.

The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for administration to humans may contain from 0.5 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. For example, in a human adult, the doses per person per administration are generally between 1 mg and 500 mg up to several times per day. Thus, dosage unit forms will generally contain between from about 1 mg to about 500 mg of an active ingredient, typically 25 mg, 50 mg, 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, 600 mg, 800 mg, or 1000 mg.

It will be understood, however, that the specific dose level for any particular subject will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

F. Pharmaceutical Compositions

In a preferred embodiment, the present invention provides pharmaceutical compositions comprising a polypeptide or polynucleotide of the present invention and a physiologically acceptable carrier. More preferably, a pharmaceutical composition comprises a polynucleotide that encodes a

biologically active CPSI polypeptide. Alternatively, provided pharmaceutical compositions comprise citrulline or arginine in dosages as described above.

5 A composition of the present invention is typically administered orally or parenterally in dosage unit formulations containing standard, well-known nontoxic physiologically acceptable carriers, adjuvants, and vehicles as desired. The term "parenteral" as used herein includes intravenous, intra-muscular, intra-arterial injection, or infusion techniques.

10 Injectable preparations, for example sterile injectable aqueous or oleaginous suspensions, are formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.

15 Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

20 Preferred carriers include neutral saline solutions buffered with phosphate, lactate, Tris, and the like. Of course, in the case of a pharmaceutical composition provided for use in gene therapy, one purifies the vector sufficiently to render it essentially free of undesirable contaminants, such as defective interfering adenovirus particles or endotoxins and other pyrogens

such that it does not cause any untoward reactions in the individual receiving the vector construct. A preferred means of purifying the vector involves the use of buoyant density gradients, such as cesium chloride gradient centrifugation.

5 A transfected cell can also serve as a carrier. By way of example, a liver cell can be removed from an organism, transfected with a polynucleotide of the present invention using methods set forth above and then the transfected cell returned to the organism (e.g. injected intra-vascularly).

G. Generation of Antibodies

10 In still another embodiment, the present invention provides an antibody immunoreactive with a polypeptide or polynucleotide of the present invention. Preferably, an antibody of the invention is a monoclonal antibody. Means for preparing and characterizing antibodies are well known in the art (See, e.g., *Antibodies A Laboratory Manual*, E. Howell and D. Lane, Cold Spring Harbor Laboratory, 1988). More preferred antibodies distinguish between the different
15 forms of CPSI which comprise the CPSI polymorphism.

Briefly, a polyclonal antibody is prepared by immunizing an animal with an immunogen comprising a polypeptide or polynucleotide of the present invention, and collecting antisera from that immunized animal. A wide range of animal species can be used for the production of antisera. Typically an
20 animal used for production of anti-antisera is a rabbit, a mouse, a rat, a hamster or a guinea pig. Because of the relatively large blood volume of rabbits, a rabbit is a preferred choice for production of polyclonal antibodies.

As is well known in the art, a given polypeptide or polynucleotide may

vary in its immunogenicity. It is often necessary therefore to couple the immunogen (e.g., a polypeptide or polynucleotide) of the present invention) with a carrier. Exemplary and preferred carriers are keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). Other albumins such as

5 ovalbumin, mouse serum albumin or rabbit serum albumin can also be used as carriers.

Means for conjugating a polypeptide or a polynucleotide to a carrier protein are well known in the art and include glutaraldehyde, m-maleimidobencoyl-N-hydroxysuccinimide ester, carbodiimide and

10 bis-biazotized benzidine.

As is also well known in the art, immunogenicity to a particular immunogen can be enhanced by the use of non-specific stimulators of the immune response known as adjuvants. Exemplary and preferred adjuvants include complete Freund's adjuvant, incomplete Freund's adjuvants and

15 aluminum hydroxide adjuvant.

The amount of immunogen used of the production of polyclonal antibodies varies, *inter alia*, upon the nature of the immunogen as well as the animal used for immunization. A variety of routes can be used to administer the immunogen, e.g. subcutaneous, intramuscular, intradermal, intravenous

20 and intraperitoneal. The production of polyclonal antibodies is monitored by sampling blood of the immunized animal at various points following immunization. When a desired level of immunogenicity is obtained, the immunized animal can be bled and the serum isolated and stored.

In another aspect, the present invention provides a method of producing

an antibody immunoreactive with a CPSI polypeptide, the method comprising the steps of (a) transfecting recombinant host cells with a polynucleotide that encodes that polypeptide; (b) culturing the host cells under conditions sufficient for expression of the polypeptide; (c) recovering the polypeptide; and (d) preparing antibodies to the polypeptide. Preferably, the CPSI polypeptide is capable of mediating the first step of the urea cycle, cross-reacting with anti-CPSI antibody, or other biological activity in accordance with the present invention. Even more preferably, the present invention provides antibodies prepared according to the method described above.

A monoclonal antibody of the present invention can be readily prepared through use of well-known techniques such as those exemplified in U.S. Patent No 4,196,265, herein incorporated by reference. Typically, a technique involves first immunizing a suitable animal with a selected antigen (e.g., a polypeptide or polynucleotide of the present invention) in a manner sufficient to provide an immune response. Rodents such as mice and rats are preferred animals. Spleen cells from the immunized animal are then fused with cells of an immortal myeloma cell. Where the immunized animal is a mouse, a preferred myeloma cell is a murine NS-1 myeloma cell.

The fused spleen/myeloma cells are cultured in a selective medium to select fused spleen/myeloma cells from the parental cells. Fused cells are separated from the mixture of non-fused parental cells, for example, by the addition of agents that block the *de novo* synthesis of nucleotides in the tissue culture media. Exemplary and preferred agents are aminopterin, methotrexate, and azaserine. Aminopterin and methotrexate block *de novo* synthesis of both

purines and pyrimidines, whereas azaserine blocks only purine synthesis. Where aminopterin or methotrexate is used, the media is supplemented with hypoxanthine and thymidine as a source of nucleotides. Where azaserine is used, the media is supplemented with hypoxanthine.

5 This culturing provides a population of hybridomas from which specific hybridomas are selected. Typically, selection of hybridomas is performed by culturing the cells by single-clone dilution in microtiter plates, followed by testing the individual clonal supernatants for reactivity with an antigen-polypeptides. The selected clones can then be propagated indefinitely
10 to provide the monoclonal antibody.

 By way of specific example, to produce an antibody of the present invention, mice are injected intraperitoneally with between about 1-200 µg of an antigen comprising a polypeptide of the present invention. B lymphocyte cells are stimulated to grow by injecting the antigen in association with an
15 adjuvant such as complete Freund's adjuvant (a non-specific stimulator of the immune response containing killed *Mycobacterium tuberculosis*). At some time (e.g., at least two weeks) after the first injection, mice are boosted by injection with a second dose of the antigen mixed with incomplete Freund's adjuvant.

 A few weeks after the second injection, mice are tail bled and the sera
20 titered by immunoprecipitation against radiolabeled antigen. Preferably, the process of boosting and titering is repeated until a suitable titer is achieved. The spleen of the mouse with the highest titer is removed and the spleen lymphocytes are obtained by homogenizing the spleen with a syringe. Typically, a spleen from an immunized mouse contains approximately 5×10^7 to

2×10^8 lymphocytes.

5 Mutant lymphocyte cells known as myeloma cells are obtained from laboratory animals in which such cells have been induced to grow by a variety of well-known methods. Myeloma cells lack the salvage pathway of nucleotide biosynthesis. Because myeloma cells are tumor cells, they can be propagated indefinitely in tissue culture, and are thus denominated immortal. Numerous cultured cell lines of myeloma cells from mice and rats, such as murine NS-1 myeloma cells, have been established.

10 Myeloma cells are combined under conditions appropriate to foster fusion with the normal antibody-producing cells from the spleen of the mouse or rat injected with the antigen/polypeptide of the present invention. Fusion conditions include, for example, the presence of polyethylene glycol. The resulting fused cells are hybridoma cells. Like myeloma cells, hybridoma cells grow indefinitely in culture.

15 Hybridoma cells are separated from unfused myeloma cells by culturing in a selection medium such as HAT media (hypoxanthine, aminopterin, thymidine). Unfused myeloma cells lack the enzymes necessary to synthesize nucleotides from the salvage pathway because they are killed in the presence of aminopterin, methotrexate, or azaserine. Unfused lymphocytes also do not
20 continue to grow in tissue culture. Thus, only cells that have successfully fused (hybridoma cells) can grow in the selection media.

Each of the surviving hybridoma cells produces a single antibody. These cells are then screened for the production of the specific antibody immunoreactive with an antigen/polypeptide of the present invention. Single

cell hybridomas are isolated by limiting dilutions of the hybridomas. The hybridomas are serially diluted many times and, after the dilutions are allowed to grow, the supernatant is tested for the presence of the monoclonal antibody. The clones producing that antibody are then cultured in large amounts to produce an antibody of the present invention in convenient quantity.

By use of a monoclonal antibody of the present invention, specific polypeptides and polynucleotide of the invention can be recognized as antigens, and thus identified. Once identified, those polypeptides and polynucleotide can be isolated and purified by techniques such as antibody-affinity chromatography. In antibody-affinity chromatography, a monoclonal antibody is bound to a solid substrate and exposed to a solution containing the desired antigen. The antigen is removed from the solution through an immunospecific reaction with the bound antibody. The polypeptide or polynucleotide is then easily removed from the substrate and purified.

H. Detecting a Polynucleotide or a Polypeptide of the Present Invention

Alternatively, the present invention provides a method of detecting a polypeptide of the present invention, wherein the method comprises immunoreacting the polypeptides with antibodies prepared according to the methods described above to form antibody-polypeptide conjugates, and detecting the conjugates.

In yet another embodiment, the present invention provides a method of detecting messenger RNA transcripts that encode a polypeptide of the present invention, wherein the method comprises hybridizing the messenger RNA

transcripts with polynucleotide sequences that encode the polypeptide to form duplexes; and detecting the duplex. Alternatively, the present invention provides a method of detecting DNA molecules that encode a polypeptide of the present invention, wherein the method comprises hybridizing DNA
5 molecules with a polynucleotide that encodes that polypeptide to form duplexes; and detecting the duplexes.

The detection and screening assays disclosed herein can be used as a prognosis tool. Human CPSI-encoding polynucleotides as well as their protein products can be readily used in clinical setting as a prognostic indicator
10 for screening for susceptibility to hyperammonemia and to other heritable CPSI-related diseases in humans.

The detection and screening assays disclosed herein can be also used as a part of a diagnostic method. Human CPSI-encoding polynucleotides as well as their protein products can be readily used in clinical setting to diagnose
15 susceptibility to hyperammonemia and to other heritable CPSI-related diseases in humans.

H.1. Screening Assays for a Polypeptide of the Present Invention

The present invention provides a method of screening a biological sample for the presence of a CPSI polypeptide. Preferably, the CPSI
20 polypeptide possesses activity in the urea cycle, cross-reactivity with an anti-CPSI antibody, or other biological activity in accordance with the present invention. A biological sample to be screened can be a biological fluid such as extracellular or intracellular fluid or a cell or tissue extract or homogenate. A

biological sample can also be an isolated cell (e.g., in culture) or a collection of cells such as in a tissue sample or histology sample. A tissue sample can be suspended in a liquid medium or fixed onto a solid support such as a microscope slide. Hepatic tissues comprise particularly contemplated tissues.

5 Preferably, antibodies which distinguish between the N1405 CPSI polypeptide and the T1405 CPSI polypeptide are provided. Such antibodies may compare polyclonal antibodies but are preferably monoclonal antibodies prepared as described hereinabove.

10 In accordance with a screening assay method, a biological sample is exposed to an antibody immunoreactive with the polypeptide whose presence is being assayed. Typically, exposure is accomplished by forming an admixture in a liquid medium that contains both the antibody and the candidate polypeptide. Either the antibody or the sample with the polypeptide can be affixed to a solid support (e.g., a column or a microtiter plate).

15 The biological sample is exposed to the antibody under biological reaction conditions and for a period of time sufficient for antibody-polypeptide conjugate formation. Biological reaction conditions include ionic composition and concentration, temperature, pH and the like.

20 Ionic composition and concentration can range from that of distilled water to a 2 molal solution of NaCl. Preferably, osmolality is from about 100 mosmols/l to about 400 mosmols/l and, more preferably from about 200 mosmols/l to about 300 mosmols/l. Temperature preferably is from about 4°C. to about 100°C., more preferably from about 15°C. to about 50°C. and, even more preferably from about 25°C to about 40°C. pH is preferably from about

a value of 4.0 to a value of about 9.0, more preferably from about a value of 6.5 to a value of about 8.5 and, even more preferably from about a value of 7.0 to a value of about 7.5. The only limit on biological reaction conditions is that the conditions selected allow for antibody-polypeptide conjugate formation and that the conditions do not adversely affect either the antibody or the polypeptide.

Exposure time will vary *inter alia* with the biological conditions used, the concentration of antibody and polypeptide and the nature of the sample (e.g., fluid or tissue sample). Means for determining exposure time are well known to one of ordinary skill in the art. Typically, where the sample is fluid and the concentration of polypeptide in that sample is about 10^{-10} M, exposure time is from about 10 minutes to about 200 minutes.

The presence of polypeptide in the sample is detected by detecting the formation and presence of antibody-polypeptide conjugates. Means for detecting such antibody-antigen (e.g., receptor polypeptide) conjugates or complexes are well known in the art and include such procedures as centrifugation, affinity chromatography and the like, binding of a secondary antibody to the antibody-candidate receptor complex.

In one embodiment, detection is accomplished by detecting an indicator affixed to the antibody. Exemplary and well known such indicators include radioactive labels (e.g., ^{32}P , ^{125}I , ^{14}C), a second antibody or an enzyme such as horse radish peroxidase. Means for affixing indicators to antibodies are well known in the art. Commercial kits are available.

H.2. Screening Assay for Anti-Polypeptide Antibody

In another aspect, the present invention provides a method of screening

a biological sample for the presence of antibodies immunoreactive with a CPSI polypeptide. Preferably the CPSI polypeptide has activity in the urea cycle, cross-reactivity with an anti-CPSI antibody, or other biological activity in accordance with the present invention. In accordance with such a method, a
5 biological sample is exposed to a CPSI polypeptide under biological conditions and for a period of time sufficient for antibody-polypeptide conjugate formation and the formed conjugates are detected.

H.3. Screening Assay for Polynucleotide That Encodes a CPSI Polypeptide of the Present Invention

10 A nucleic acid molecule and, particularly a probe molecule, can be used for hybridizing as an oligonucleotide probe to a nucleic acid source suspected of encoding a CPSI polypeptide of the present invention. Optimally, the CPSI polypeptide has activity in the urea cycle, cross-reactivity with an anti-CPSI antibody, or other biological activity in accordance with the present invention.

15 The probing is usually accomplished by hybridizing the oligonucleotide to a DNA source suspected of possessing a CPSI gene. In some cases, the probes constitute only a single probe, and in others, the probes constitute a collection of probes based on a certain amino acid sequence or sequences of the polypeptide and account in their diversity for the redundancy inherent in the
20 genetic code.

A suitable source of DNA for probing in this manner is capable of expressing a polypeptide of the present invention and can be a genomic library of a cell line of interest. Alternatively, a source of DNA can include total DNA

from the cell line of interest. Once the hybridization method of the invention has identified a candidate DNA segment, one confirms that a positive clone has been obtained by further hybridization, restriction enzyme mapping, sequencing and/or expression and testing.

5 Alternatively, such DNA molecules can be used in a number of techniques including their use as: (1) diagnostic tools to detect normal and abnormal DNA sequences in DNA derived from subject's cells, such as a CPSI polymorphism described herein; (2) means for detecting and isolating other members of the polypeptide family and related polypeptides from a DNA library
10 potentially containing such sequences; (3) primers for hybridizing to related sequences for the purpose of amplifying those sequences; (4) primers for altering native CPSI DNA sequences; as well as other techniques which rely on the similarity of the DNA sequences to those of the DNA segments herein disclosed.

15 As set forth above, in certain aspects, DNA sequence information provided by the invention allows for the preparation of relatively short DNA (or RNA) sequences (e.g., probes) that specifically hybridize to encoding sequences of a selected CPSI gene. In these aspects, nucleic acid probes of an appropriate length are prepared based on a consideration of the encoding
20 sequence for a polypeptide of this invention. The ability of such nucleic acid probes to specifically hybridize to other encoding sequences lend them particular utility in a variety of embodiments. Most importantly, the probes can be used in a variety of assays for detecting the presence of complementary sequences in a given sample. However, other uses are envisioned, including

the use of the sequence information for the preparation of mutant species primers, or primers for use in preparing other genetic constructions.

To provide certain of the advantages in accordance with the invention, a preferred nucleic acid sequence employed for hybridization studies or assays includes probe sequences that are complementary to at least a 14 to 40 or so long nucleotide stretch of a nucleic acid sequence of the present invention, such as a sequence shown in any of SEQ ID NOs:1, 3, 11 and 13. A size of at least 14 nucleotides in length helps to ensure that the fragment is of sufficient length to form a duplex molecule that is both stable and selective. Molecules having complementary sequences over stretches greater than 14 bases in length are generally preferred, though, to increase stability and selectivity of the hybrid, and thereby improve the quality and degree of specific hybrid molecules obtained. One will generally prefer to design nucleic acid molecules having gene-complementary stretches of 14 to 20 nucleotides, or even longer where desired. Such fragments can be readily prepared by, for example, directly synthesizing the fragment by chemical means, by application of nucleic acid reproduction technology, such as the PCR technology of U.S. Pat. No. 4,683,202, herein incorporated by reference, or by introducing selected sequences into recombinant vectors for recombinant production.

Accordingly, a nucleotide sequence of the present invention can be used for its ability to selectively form duplex molecules with complementary stretches of the gene. Depending on the application envisioned, one employs varying conditions of hybridization to achieve varying degrees of selectivity of the probe toward the target sequence. For applications requiring a high degree of

selectivity, one typically employs relatively stringent conditions to form the hybrids. For example, one selects relatively low salt and/or high temperature conditions, such as provided by 0.02M-0.15M salt at temperatures of about 50°C to about 70°C including particularly temperatures of about 55°C, about 60°C and about 65°C. Such conditions are particularly selective, and tolerate little, if any, mismatch between the probe and the template or target strand.

Of course, for some applications, for example, where one desires to prepare mutants employing a mutant primer strand hybridized to an underlying template or where one seeks to isolate polypeptide coding sequences from related species, functional equivalents, or the like, less stringent hybridization conditions are typically needed to allow formation of the heteroduplex. Under such circumstances, one employs conditions such as 0.15M-0.9M salt, at temperatures ranging from about 20°C to about 55°C, including particularly temperatures of about 25°C, about 37°C, about 45°C, and about 50°C. Cross-hybridizing species can thereby be readily identified as positively hybridizing signals with respect to control hybridizations. In any case, it is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide, which serves to destabilize the hybrid duplex in the same manner as increased temperature. Thus, hybridization conditions can be readily manipulated, and thus will generally be a method of choice depending on the desired results.

In certain embodiments, it is advantageous to employ a nucleic acid sequence of the present invention in combination with an appropriate means, such as a label, for determining hybridization. A wide variety of appropriate

indicator means are known in the art, including radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of giving a detectable signal. In preferred embodiments, one likely employs an enzyme tag such a urease, alkaline phosphatase or peroxidase, instead of radioactive or other environmentally undesirable reagents. In the case of enzyme tags, calorimetric indicator substrates are known which can be employed to provide a means visible to the human eye or spectrophotometrically, to identify specific hybridization with complementary nucleic acid-containing samples.

In general, it is envisioned that the hybridization probes described herein are useful both as reagents in solution hybridization as well as in embodiments employing a solid phase. In embodiments involving a solid phase, the sample containing test DNA (or RNA) is adsorbed or otherwise affixed to a selected matrix or surface. This fixed, single-stranded nucleic acid is then subjected to specific hybridization with selected probes under desired conditions. The selected conditions depend *inter alia* on the particular circumstances based on the particular criteria required (depending, for example, on the G+ C contents, type of target nucleic acid, source of nucleic acid, size of hybridization probe, etc.). Following washing of the hybridized surface so as to remove nonspecifically bound probe molecules, specific hybridization is detected, or even quantified, by means of the label.

H.4. Assay Kits

In another aspect, the present invention provides a diagnostic assay kit for detecting the presence of a polypeptide of the present invention in biological

samples, where the kit comprises a first container containing a first antibody capable of immunoreacting with the polypeptide, with the first antibody present in an amount sufficient to perform at least one assay. Preferably, the assay kits of the invention further comprise a second container containing a second antibody that immunoreacts with the first antibody. More preferably, the antibodies used in the assay kits of the present invention are monoclonal antibodies. Even more preferably, the first antibody is affixed to a solid support. More preferably still, the first and second antibodies comprise an indicator, and, preferably, the indicator is a radioactive label or an enzyme.

10 The present invention also provides a diagnostic kit for screening agents. Such a kit can contain a polypeptide of the present invention. The kit can contain reagents for detecting an interaction between an agent and a receptor of the present invention. The provided reagent can be radiolabeled. The kit can contain a known radiolabelled agent capable of binding or
15 interacting with a receptor of the present invention.

 In an alternative aspect, the present invention provides diagnostic assay kits for detecting the presence, in biological samples, of a polynucleotide that encodes a polypeptide of the present invention, the kits comprising a first container that contains a second polynucleotide identical or complementary to
20 a segment of at least 10 contiguous nucleotide bases of, as a preferred example, in any of SEQ ID NOs:1, 3, 11 and 13.

 In another embodiment, the present invention provides diagnostic assay kits for detecting the presence, in a biological sample, of antibodies immunoreactive with a polypeptide of the present invention, the kits comprising

a first container containing a CPSI polypeptide, that immunoreacts with the antibodies, with the polypeptide present in an amount sufficient to perform at least one assay. Preferably, the CPSI polypeptide has activity in the urea cycle, cross-reactivity on an anti-CPSI antibody, or other biological activity in accordance with the present invention. The reagents of the kit can be provided as a liquid solution, attached to a solid support or as a dried powder. Preferably, when the reagent is provided in a liquid solution, the liquid solution is an aqueous solution. Preferably, when the reagent provided is attached to a solid support, the solid support can be chromatograph media or a microscope slide. When the reagent provided is a dry powder, the powder can be reconstituted by the addition of a suitable solvent. The solvent can be provided.

EXAMPLES

The following Examples have been included to illustrate preferred modes of the invention. Certain aspects of the following Examples are described in terms of techniques or procedures found or contemplated by the present inventors to work well in the practice of the invention. These Examples are exemplified through the use of standard laboratory practices of the inventors. In light of the present disclosure and the general level of skill in the art, those of skill will appreciate that the following Examples are intended to be exemplary only in that numerous changes, modification, and alterations can be employed without departing from the spirit and scope of the invention.

Materials and Methods Used in Examples 1-3

The following materials and methods are employed in each of Examples 1-3. Additional materials and methods are also described in each Example.

Clinical/Patient Recruitment: More than 200 patients undergoing BMT at Vanderbilt University Medical Center, Nashville, Tennessee, have been enrolled in the BMT-Lung Injury Following Engraftment (LIFE) Study aimed at understanding mechanisms of acute lung injury and multiple organ failure after transplant. Consent was sought from consecutive patients undergoing BMT or PBSCT for treatment of malignancy. Definitions of organ failure (including HVOD) and reversal were prospectively defined and data was collected concurrently during hospitalization. Plasma, cell pellets, and urine were collected at study enrollment (before receiving chemotherapy) and on the day of transplantation (before marrow infusion) after completing ablative chemoradiotherapy.

Amino Acid Analysis— Blood and urine were immediately centrifuged after collection. All samples were kept on ice, then stored at -70°C until analyzed. Under these storage conditions, glutamine, cysteine and homocysteine are known to decrease, so these were not used in the analysis. Plasma amino acids were measured in the Vanderbilt Diagnostic Laboratories, Vanderbilt University, Nashville, Tennessee. Briefly, a protein free extract of plasma was prepared by protein precipitation with sulfosalicylic acid and filtration through a 0.45 μ m ACRODISC™ 4 filter (Gelman Sciences, Ann Arbor, Michigan). Amino acids were separated by cation exchange chromatography using a four-component pH- and ionic strength-graded lithium citrate buffer

system on a Beckmann 7300 amino acid analyzer (Beckmann, Palo Alto, California). Post column derivatization of amino acids with ninhydrin allowed detection of primary amine amino acids at 570 nm, and secondary amines at 440 nm. Quantification was achieved by instrument calibration with standard reference materials (Sigma, St. Louis, Missouri).

Statistics. Plasma amino acid values were expressed as mean \pm SEM. Comparisons between baseline and post-chemotherapy amino acid values were made using Student's t-Test. Allelic frequency was compared between patients with and without HVOD using Chi square analysis.

Patients. Patients were identified from those enrolled in the BMT Lift Study at Vanderbilt University. DNA was isolated from pre-transplant blood or spun urine samples. HVOD status was determined using the Baltimore criteria:

- Bilirubin > 2.0 mg/dl
- Hepatomegaly
- 2% sudden weight gain

Genotyping. DNA was isolated using a QIAmp™ blood kit (Qiagen). The T1405N polymorphism changes the DNA sequence as follows:

CCT-GCC-ACC-CCA-GTG Normal

CCT-GCC-AAC-CCA-GTG Change

The C to A transversion replaces the pyrimidine C with the purine A which destroys a *Msp*I site. The use of a primer from within the 35th intron of CPSI and an exotic primer from exon 36 of the CPSI gene reliably PCR amplifies a 387 bp fragment encompassing the region containing the change. This combination gives a robust amplification. PCR Ready-to-Go™ beads are

also used in amplification (Pharmacia).

5 The polymorphism was detected using a non-denaturing gel to take advantage of the secondary structures created by the C to A transversion. This change creates enough secondary structure to prevent reliable digestion by restriction enzymes (*Msp* I) to detect the polymorphism. This change also interferes with direct sequence analysis unless ITP is substituted for GTP in the reaction. Non-denaturing gels take advantage of the secondary structures created by this change. Fifteen (15) individuals were compared by this method and sequence analysis.

10 To detect the DNA fragments in the gel, a silver staining technique was adapted. This inexpensive rapid method allowed visualization of bands shortly after electrophoresis.

Statistical Analysis. A sufficient sample size was obtained to perform Chi Square analysis on the results. The Hardy-Weinburg equation was used to calculate the expected frequencies for the genotypes ($p^2 + 2pq + q^2$). P values were obtained from a standard Chi Square table using 2 degrees of freedom.

Example 1

Alleles of CPSI Exonic Polymorphism (T1405N) Are Not in Hardy-

Weinburg Equilibrium with the Presence or Absence of HVOD

20 In accordance with the present invention, a common polymorphism near the 3' end of the CPSI mRNA (about .44 heterozygosity) has been identified. Sequence analysis of this change revealed a C to A transversion at base 4340

changing the triplet code from ACC to AAC. This results in a substitution of asparagine for threonine at amino acid 1405 (referred to herein as "T1405N"). The threonine is within the allosteric domain, preceding the signature sequence PV(A/S)WP(T/S)(A/Q)E, a sequence that is important in the binding of the cofactor n-acetyl-glutamate (NAG).

In all known CPSIs activated by NAG, a threonine residue is among the two residues that precede the signature sequence. (Rubio, *Biochemical Society Transactions* 21:198-202 (1998)). On the basis of structure-function studies, hydrogen bond formation with the carbonyl oxygen of the acetamido group of NAG is felt to play a role in the binding of this activator. (Stapleton et al., *Biochemistry* 35:14352-14361 (1996); Javid-Majd et al., *Biochemistry* 35:14362-14369 (1996)). The substitution of the threonine side chain by asparagine is envisioned to alter the hydrogen bond formation with NAG and results in a qualitative change in CPSI enzymatic function and in sensitivity to the available pool of NAG. Although applicants do not wish to be bound by any particular theory of operation, it is speculated that based on the precedent of the effects of other xenobiotics, that limited availability of NAG after escalated dose chemotherapy is one of the mechanisms promoting urea cycle dysfunction.

126 individuals were genotyped from the BMT Life Study group. 30 individuals manifested evidence of HVOD in this group (24%). 70 patients were genotyped from blood samples and 56 from urine cell pellets. Samples from 15 patients were reamplified via PCR and sequenced to confirm the consistency of the results.

Tables 2 and 3 show the results of genotype analysis for the T1405N polymorphism between HVOD+ and HVOD- patients. The C allele, also referred to herein as the CPSIa allele or the threonine encoding allele, has a frequency of .62 in the examined population and the A allele, also referred to herein as the CPSIb allele or the asparagine encoding allele, has a frequency of 0.38. The Chi Square value for the table is 4.3 (P=0.1) indicating that the polymorphism is probably not in Hardy-Weinburg equilibrium with the presence of HVOD. Thus, these results provide evidence for disequilibrium in the distribution of the T1405N alleles in BMT patients with HVOD, indicating that the polymorphism can be used to identify subjects who are susceptible to BMT toxicity.

Table 2

Genotype	HVOD+	HVOD-
CC	13 (expected 11.4)	32 (expected 36.5)
AC	16 (expected 14.1)	50 (expected 45.1)
AA	1 (expected 4.5)	14 (expected 14.4)

Table 3

Total alleles:	Expected Frequencies:
A: 96	AA: 0.15
C: 62	AC: 0.47
	CC: 0.38

Additional data gathered from a study of approximately 200 patients provided additional statistical evidence supporting the use of the polymorphism

in detection of susceptibility to sub-optimal urea cycle function. This data was subjected to the statistical methods described above.

Bone marrow transplant toxicity results in significant morbidity and mortality. HVOD is associated with a poor prognosis in BMT patients. This study was undertaken to assess an association between the CPSI enzyme and the occurrence of HVOD. The T1405N polymorphism affects CPSI function. Its wide distribution in the population suggests that both forms provide adequate urea cycle function under normal conditions. The addition of metabolic stressors (such as high-dose chemotherapy) serves to lower CPSI efficiency below an effective threshold. Analysis of the data thus suggests that HVOD is more likely to occur in patients with the threonine encoding allele than those with the asparagine. The threonine encoding allele is shared by the rodent form of CPSI.

Example 2

Biochemical and Genetic Alterations in Carbamyl Phosphate Synthetase I in Patients with Post-Bone Marrow Transplant Complications

Bone marrow transplantation (BMT) and peripheral blood stem cell transplants (PBSCT) are increasingly being used as primary therapy for selected malignancies. Use of stem cell support for hematopoietic reconstitution allows for substantial escalation in the dose of chemotherapy in an attempt to eradicate potentially lethal cancers. With improvements in prophylaxis for infection and prevention of disabling graft-versus-host disease,

chemotherapy-induced organ dysfunction remains a significant barrier to more widespread use of this treatment.

Hepatic venocclusive disease (HVOD), a clinical syndrome of hyperbilirubinemia (serum bilirubin > 2.0 mg/dL), hepatomegaly, and fluid retention early after BMT, is a major dose-limiting toxicity after BMT, afflicting up to 54% of patients . Many patients developing HVOD after BMT will also meet the criteria for acute lung injury (ALI) . Nearly half of patients with severe HVOD require mechanical ventilation, with an attendant mortality in excess of 90% . Such data underscore the large impact on mortality of sequential organ dysfunction, even in a young patient population, and reinforce the clinically important association of poor prognosis after acute lung injury in patients with hepatic dysfunction. The mechanisms responsible for this organ interaction remain incompletely understood.

In this Example, whether conditioning chemotherapy administered prior to BMT might affect early enzymes in the UC and secondarily predispose patients for hepatic dysfunction and multiple organ failure was analyzed. The plasma amino acid analyses supported the notions of both impaired UC function and decreased production of nitric oxide (NO_x). In light of these findings, patients were screened for the exonic single nucleotide polymorphism (SNP) in CPS-I disclosed herein. It was found that homozygosity for the SNP was associated with a decreased incidence of HVOD and enhanced early survival after BMT, consistent with a significant pharmacogenetic interaction.

Methods

Clinical/Patient Recruitment: Over the last three years 200 patients undergoing BMT at Vanderbilt University Medical Center have been sequentially enrolled in the Bone Marrow Transplant-Lung Injury Following Engraftment (BMT-LIFE) Study, a coordinated clinical-biochemical exploratory investigation aimed at understanding mechanisms of acute lung injury and multiple organ failure after transplant. Definitions of organ failure and reversal were prospectively defined and data was collected concurrently during hospitalization and until 60 days after BMT. Exclusion criteria included active viral and prior escalated dose therapy with hematopoietic stem cell support (either PBSCT or BMT).

Hepatic venocclusive disease (HVD) was identified in patients with bilirubin > 2 mg/dL before 21 days after transplant with either weight gain > 5% of baseline or new onset of tender hepatomegaly. Acute lung injury (ALI) was defined as bilateral infiltrates on chest roentgenogram for three consecutive dates with a ratio of partial pressure of oxygen in arterial blood to the fraction of inspired oxygen concentration ($\text{PaO}_2 / \text{FiO}_2$) of less than 300 in the absence of clinical cardiac dysfunction. Patients alive 60 days after transplant were defined as survivors. Plasma, circulating cell pellets, and urine were collected at study enrollment (before receiving chemotherapy) and on the day of BMT, several days after completing high dose chemotherapy but before marrow infusion. Samples were aliquotted, and immediately placed on ice prior to storage at -80°C before analysis.

Amino Acid Analysis. Amino acid analysis was performed on

cryopreserved plasma samples from days -8 and 0 (pre-treatment and day of transplantation) in 60 patients. Patient samples were initially randomly selected for pilot studies; subsequently analyzed samples were specifically enriched to include extra patients with the SNP AA genotype of CPS-I (see below) and additional patients with the post-BMT complications of HVOD and ALI. A protein free extract of plasma was prepared by protein precipitation with sulfosalicylic acid and filtration through a 0.45 µm Acrodisc 4 (Gelman Sciences, Ann Arbor, Michigan).

Amino acids were separated by cation exchange chromatography using a four-component pH- and ionic strength-graded lithium citrate buffer system on a Beckmann 7300 amino acid analyzer (Beckmann, Palo Alto, California). Post column derivatization of amino acids with ninhydrin allowed detection of primary amine amino acids at 570 nm, and secondary amines at 440 nm. Quantitation was achieved by instrument calibration with standard reference materials (Sigma, St. Louis, Missouri). Citrulline, arginine, and ornithine were examined as measurable indices of flux of intermediates through the urea cycle.

Measurement of plasma nitric oxide metabolites (NO_x). Plasma NO_x was measured in a subgroup of patients using modified Griess reagents after samples were deproteinated and incubated with cadmium beads to convert nitrate to nitrite.

Detection of T1405N polymorphism. Oligonucleotide primers from within the 36th exon (CGGAAGCCACATCAGACTGG (SEQ ID NO:15) and intron (GGAGAGTGAACTTGACAATCATC (SEQ ID NO:16)) of CPS1 and the

polymerase chain reaction (PCR) to reliably amplify a 251 bp fragment encompassing the region containing the change from genomic DNA obtained from buffy coat preparations or urinary sediment. This combination of primers gave reproducible amplification using PCR Ready-to-Go beads (Pharmacia) and PCR cycle conditions as follows: 35 cycles of 1 minute anneal at 55°C, 1 minute extension at 72°C, and 1 minute denaturation at 94°C.

After formamide treatment, samples were subjected to electrophoresis for 4 hours at 4°C in a non-denaturing MDE™ gel (FMC, Rockland, Maine), then stained with silver nitrate to detect DNA fragments. Confirmatory genotyping of 17 individuals using both non-denaturing gel electrophoresis and direct sequence analysis yielded identical results. Patients were classified as having homozygous SNP genotypes of CC or AA, or as being heterozygous (AC). For comparison, using identical methods, a cohort of 100 patients with Alzheimer's disease was analyzed to assess the distribution of CPSI SNP genotypes.

Statistical Analysis. Plasma amino acid levels before and after chemotherapy, and levels between groups of patients, were compared using Student's T-test or Wilcoxon's Rank Sum Test (if the data were not normally distributed). Distribution of genotypes of CPSI was compared across groups by calculating allelic frequency for the entire group and searching for evidence of Hardy-Weinberg disequilibrium in specifically selected subgroups using P^2 analysis. Sensitivity, specificity, predictive values, and relative risk assessments were generated from two-by-two contingency tables constructed using specific amino acid values in groups of patients divided by presence and

absence of specific clinical outcomes (e.g. HVOD, ALI, and death).

RESULTS

Two hundred patients were enrolled in the BMT-LIFE Study. 52% underwent autologous transplant (mean age 46 ± 1 years); 48% received allogeneic grafts (mean age 40 ± 1 years). Of the patients undergoing allogeneic transplants, 24% received grafts from HLA-matched unrelated donors. Nearly two-thirds of the patients in the autologous group were women, reflecting the increased prevalence of breast cancer in this population. The indications for transplant were diverse, but 79% of the patients were transplanted for breast cancer, leukemia, or non-Hodgkin's lymphoma. The different preparative regimens used prior to BMT included CTC (cyclophosphamide, thiotepa, carboplatin), BuCy (busulfan, cyclophosphamide), CVP16TBI (cyclophosphamide, etoposide, total body irradiation), CBVP16 (cyclophosphamide, bis-chloroethylnitrosourea, etoposide) and TC (thiotepa, cyclophosphamide).

Both morbidity and mortality are not uncommon after BMT. While the overall 60 day mortality in the study was 14%, it was 20% in patients receiving allografts. Complications of acute lung injury (ALI) and hepatic venocclusive disease (HVOD) each occurred in 19% of the patients. These complications were more than twice as common in patients receiving allografts. In the group of patients developing HVOD, 62% (24/38) also met criteria for ALI during hospitalization. Only 38% (14/38) of the cases of ALI occurred in patients who never met criteria for HVOD.

A subset (60/200) of the patients, specifically enriched during sample selection with extra patients with CPS-I AA SNP genotype and additional patients with post-transplant complications, had plasma amino acid determinations before administration of chemotherapy and on the day of transplant. Comparison of levels of selected amino acids that participate in the UC (citrulline, ornithine, and arginine) before and after chemotherapy revealed significant differences. Citrulline levels fell in virtually all patients with a mean group decrease from $23.4 \pm 1.3 \mu\text{M}$ to $9.1 \pm 0.7 \mu\text{M}$ ($P < 0.05$). Arginine levels rose by approximately 35% ($P < 0.05$), and ornithine levels rose by 21% ($P < 0.05$).

The ratio of ornithine/citrulline (O/C ratio), an index of flux through the early steps of the UC (i.e. lower values indicate better cycle flow), increased from 3.9 ± 0.7 at study enrollment to 11.8 ± 1.8 after induction chemotherapy ($P < 0.05$). Shifts also occurred in amino acids that are not part of the UC. Levels of glycine and alanine, two aliphatic amino acids, fell significantly by 11% and 19%, respectively, in a pattern not consistent with decreased flux of intermediates through the cycle simply due to decreased protein intake (acute or chronic). Phenylalanine and methionine levels rose by 43% and 23%, respectively, suggesting subclinical hepatic dysfunction.

Baseline plasma levels of citrulline and the O/C ratios had prognostic importance. Sixty day survivors of BMT had higher baseline levels of citrulline than did nonsurvivors (24.4 ± 1.3 vs $17.7 \pm 2.9 \mu\text{M}$, respectively; $P < 0.05$). The relative risk for death before 60 days after BMT was 2.92 for patients with an enrollment citrulline level less than 20. The negative predictive value for death

of a plasma citrulline level greater than 20 μM was 90%. O/C ratios at enrollment were significantly lower in patients never developing either HVOD (2.8 ± 0.2) or ALI (2.9 ± 0.2) when compared to patients who subsequently developed these complications (5.8 ± 1.9 and 6.5 ± 2.7 , respectively; $P < 0.05$).

- 5 Comparison of O/C ratios between 60 day survivors and nonsurvivors of BMT at study enrollment showed a trend toward lower values in survivors (3.3 ± 0.2 vs. 6.9 ± 3.9 ; $P = 0.06$). The negative predictive value for death within 60 days after BMT associated with a baseline O/C ratio less than 2.5 was 92%.

- 10 Several urea cycle amino acid intermediate levels after preparative therapy, on the day of BMT, also had significance. Plasma arginine levels were higher in survivors ($114.5 \pm 5.9 \mu\text{M}$) when compared to nonsurvivors ($92.3 \pm 10.4 \mu\text{M}$) ($P < 0.05$). O/C ratios were significantly higher, suggesting more impaired UCF, in patients who later developed ALI when compared to those never developing severe lung dysfunction (18.4 ± 5.9 vs 9.5 ± 0.7 ; $P < 0.05$).
- 15 Although the negative predictive value for development of ALI of a post-chemotherapy O/C ratio less than ten was high (86%), the relative risk for mortality associated with this threshold was only 1.44. There was a trend toward higher O/C ratios in patients on the day of BMT in patients who subsequently developed HVOD ($P = 0.09$).

- 20 Levels of nitric oxide metabolites (NO_x) in plasma were measured in 62 patients. Plasma NO_x levels fell 20% after induction therapy, from $40 \pm 2 \mu\text{M}$ at study enrollment to $32 \pm 2 \mu\text{M}$ on the day of BMT ($P < 0.05$). The median NO_x value on the day of BMT in 20 patients developing either HVOD or ALI was 28 μM ; for patients without such complications the plasma NO_x was 35 μM .

No clear differences between plasma NO_x was observed when patients with different CPSI SNP genotypes were compared.

To assess whether certain patients might have a genetic predisposition to develop morbid complications following induction therapy and BMT, all patients in the study were genotyped for a CPSI SNP. Of 200 patients, data was analyzed from 196 patients (i.e. 2 clinical exclusions; 2 unsuccessful PCR amplifications) to determine if the CPS-I C4340A SNP was in Hardy-Weinberg equilibrium with the development of HVOD. The distribution of CPSI SNP genotypes in patients undergoing BMT was identical to that of the control group (100 patients with Alzheimer's disease): 44% CC (wild type), 45% AC (heterozygous), and 11% AA (homozygous for the transversion). The attack rate of HVOD in those with the CC or AC genotype were 18% and 24%, respectively. There were no cases of HVOD in patients with the AA genotype.

Finding that this allelic distribution was not in Hardy-Weinburg equilibrium with the development of HVOD ($P^2 = 5.06$, $P < 0.05$) suggests that the SNP AA genotype alters susceptibility to hepatic toxicity following induction chemotherapy. There were also trends toward differences in mortality 60 days after BMT between the SNP genotypes. Nonsurvivors constituted 15% and 20% of the AC and CC genotype groups, respectively. Interestingly, all of the patients with the AA genotype survived 60 days after BMT ($P^2 = 3.36$; $P = 0.06$). Of note, almost all of the P^2 score came from the AA/survivor cell. There were no significant differences between patients with different SNP C4340A genotypes in the attack rate of ALI (16%, 15%, and 25% in the AA, AC, and CC groups, respectively). While ALI was associated with significant mortality in

patients with either the AC or CC genotypes (71% and 66%, respectively), all patients with the AA genotype who developed ALI eventually had resolution of both bilateral pulmonary infiltrates on CXR and impaired gas exchange and survived 60 days after BMT.

5

Discussion

The data presented in this Example reflect a close association between HVOD and ALI in patients after BMT, with nearly two-thirds of patients with HVOD meeting criteria for ALI. In this study, 68% (26/38) of patients developing ALI required mechanical ventilation. Rubenfeld and Crawford have reported a meaningful survival, defined as extubation followed by discharge from the hospital with thirty day survival, of only 6% in patients requiring mechanical ventilation after BMT. See Rubenfeld, G. D. and Crawford, S. W., *Annals of Internal Medicine* (1996) 125:625-33.

10

15

20

HVOD remains the major dose limiting toxicity of escalated dose chemotherapy. It is clinically characterized by fluid retention, jaundice, ascites, and painful hepatic enlargement occurring within 3 weeks of BMT. Autopsy studies of those non-surviving patients fulfilling these clinical criteria provide histological confirmation in >80% of cases and are consistent with the idea that enhanced local thrombosis might be an initiating event in the pathogenesis of HVOD.

The significant fall in citrulline levels and rise in plasma ornithine levels from patients undergoing BMT suggests a significant disturbance in flux of carbon intermediates through the hepatic UC in patients after induction

chemotherapy. Analysis of the patterns of other amino acids argues that this effect is not simply due to decreased protein intake. In contrast to the patterns seen in patients with starvation, where levels of glycine and branched chain amino acids (BCAA) are usually significantly elevated, we observed a fall in glycine and no significant change in the BCAAs. Furthermore, starvation tends to increase activity of CPSI in liver and should not lead to increases in plasma ornithine.

The pretreatment ability of patients undergoing BMT to maintain flow of intermediates through the UC had particular prognostic importance. Sixty day nonsurvivors after BMT and those patients developing HVD or ALI had significantly lower levels of citrulline and higher O/C ratios compared to patients who did not develop these complications. Of interest was the observation that nonsurvivors of BMT had lower plasma arginine values after induction therapy when compared to surviving patients. In light of the clustering of cells containing early UC enzymes about the terminal hepatic venules, local concentrations of both arginine and nitric oxide (NO) might be much higher and might play an important role in maintaining patency of these vessels and regulating regional hepatic blood flow. The studies showing a significant reduction in plasma NO_x levels after induction chemotherapy support the idea that NO production is altered during BMT.

The apparent discrepancy between apparently normal plasma levels of arginine on the day of transplant and markedly reduced plasma NO_x underscores the complex *in vivo* kinetics of arginine and citrulline flux across different organ beds. Stable isotope studies of whole body arginine

homeostasis have indicated that only about 15% of plasma arginine turnover is associated with urea formation, and that only 1.2% of plasma arginine turnover is associated with NO formation. Furthermore, *in vitro* studies have documented substantial channeling of urea cycle intermediates, from citrulline to arginine, that is not influenced by exogenous provision of substrate . The ability of an individual patient to maintain urea cycle function and hepatic NO production during the stresses of induction chemotherapy can, in part, influence their resistance to complications after BMT.

Since there is no gender disparity in the occurrence of HVOD, we concentrated on potential pharmacogenetic issues related to CPSI, an autosomally encoded gene, rather than on the X-linked ornithine transcarbamylase gene. While characterizing the molecular changes underlying the causes of neonatal and late-onset CPSI deficiency, a common SNP near the 3' end of the CPSI mRNA (0.44 heterozygosity) was identified. This C4340A transversion encodes a predicted substitution of asparagine (AAC) for threonine (ACC) at amino acid 1405 (T1405N). This threonine is within the allosteric domain, preceding the sequence PV(A/S)WP(T/S)(A/Q)E important in the binding of a cofactor, n-acetyl-glutamate (NAG), that increases enzyme activity. Although applicants do not wish to be bound by any particular theory of operation, it is speculated that based on the precedent of the effects of other xenobiotics, that limited availability of NAG after escalated dose chemotherapy is one of the mechanisms promoting urea cycle dysfunction. Nonetheless, it appears that the presence of the CPS-I SNP AA genotype is associated with protection against the development of HVOD, resolution of ALI

if it occurs, and improved 60 day survival after BMT. Thus, the data suggest that alteration in UC function plays a role in modifying liver-lung interaction during sepsis and acute lung injury.

In summary, this Example documents significant impairment in hepatic UC function in patients who receive escalated dose chemotherapy prior to BMT. Patients with more severe derangement in cycle function are more likely to develop morbid complications after BMT. Additionally, a significant association between a CPS-I C4340A SNP and both post-BMT complications and short-term survival has been found. Such data are useful in assessment of risk for patients undergoing BMT and provide a rationale for therapeutic attempts to support UC function during high-dose chemotherapy.

Example 3

Arginine/Citrulline Supplementation Therapy

The added decrease in urea cycle products (arginine and citrulline) and increase in precursors (ammonia, glutamine, etc.) resulting from the polymorphism contribute to BMT associated toxicity. As part of the BMT Life Study, citrulline and arginine levels were measured in 10 patients undergoing BMT.

High-dose chemotherapy used in BMT disrupts normal functions of urea cycle enzymes and contributes to either the occurrence of or toxicity associated with HVOD. To further evaluate this information, an analysis of stored plasma from ten patients undergoing BMT before treatment and after completion of induction chemotherapy was performed. Amino acid profiles were determined

from all samples. Particular attention was paid to the urea cycle intermediates citrulline, arginine, and ornithine. As shown in Table 4, a marked decrease in citrulline levels of all patients from a pre-treatment baseline mean of 24 ± 3 $\mu\text{mol/L}$ to a post-treatment mean of 8 ± 1 $\mu\text{mol/L}$ ($P < 0.001$). Plasma arginine levels fell from a mean of 91 ± 6 $\mu\text{mol/L}$ to 70 ± 6 $\mu\text{mol/L}$ ($P < 0.05$), despite the use of arginine-containing parenteral nutrition in several patients:

Table 4

Amino Acid	Pre Chemo.	Post Chemo.	P Value
citrulline	24 ± 3 μM	8 ± 1 μM	<0.001
arginine	91 ± 6 μM	70 ± 6 μM	0.03

The fall in citrulline and arginine was similar in patients who did and did not receive total parenteral nutrition and was the same in males and females. The decreases in citrulline suggest that there is a decrease in flow through the first steps of the urea cycle (Figure 1).

Thus, in accordance with the present invention, a method of reducing toxicity and/or the occurrence of HVOD in a patient undergoing BMT is provided. This method comprises administering the BMT patient arginine and/or citrulline, with citrulline being preferred, in an amount effective to bolster arginine and NO synthesis in the patient. The bolstering of arginine and NO synthesis in the patient reduces and/or substantially prevents the occurrence of HVOD associated with BMT. Citrulline is a preferred supplementation agent given that it is more readily converted to NO.

Example 4

Construction of a Functional Full-Length CPSI Expression Clone

After attempting a number of strategies, a human CPSI cDNA expression clone containing the entire coding region was constructed. Figures 6 and 7 present schematic diagrams illustrating the method used to construct the expression clone. This clone has been completely sequenced and does not contain any changes from the consensus CPSI sequence which has been characterized in the art.

The ability of the clone to make CPSI protein was tested in COS-7 cells. COS-7 cells were chosen for their lack of native CPSI activity or production. A western blot analysis of the COS-7 cells transfected with the flCPSI-PCDNA3.1 construct was prepared. HepG2 cell extracts were used as a control as these liver-derived cells have retained CPSI activity. Untransfected COS-7 cells were used as a negative control. Unlike the untransfected COS-7 cells, the HepG2 and COS-7-flCPSI cells demonstrated the expected 160 kDa band using a rabbit anti-rat CPSI antibody. Additionally, a colorimetric assay was performed to detect the production of carbamyl phosphate from ammonia. As shown graphically in Fig. 8, the transected cells demonstrated activity similar to HepG2 cells while untransfected COS-7 cells did not.

Site-directed mutagenesis has been performed on the T1405 containing CPSI insert and a copy with the N1405 polymorphic codon has been created. The N1405 polymorphic codon was sequenced for its entire length and no other changes were detected. The QuikChange™ (Stratagene) system, which takes advantage of the methylation introduced into DNA by host bacteria, was

used to prepare this construct.

These constructs are used to provide a steady supply of recombinant CPSI protein as encoded by both alleles, (T1405, N1405) using COS cells and the respective CPSI/PC DNA 3.1 constructs as an expression system.

5 Enzymatically active CPSI has been produced using this system, as shown by the graph in Fig. 8.

A component of these experiments is to determine the *in vitro* effect of the T1405N polymorphism on CPSI function. As discussed in Examples 1 and 2, this change affects the sensitivity of the enzyme to NAG concentrations.

10 Screening of 20 individuals for the C to A change showed a heterozygosity rate of 50% with 25% of the group homozygous AA. This suggests that a significant portion of the general population has a potential qualitative abnormality in CPSI function. This abnormality, while silent under normal conditions, is unmasked by stressful conditions and toxins such as high-dose chemotherapy or valproic acid administration.

15

Comparison of the protein products is then done in stages. The first stage examines the physical characteristics of the expressed mRNA and protein. Using the flCPSI insert as a probe, Northern blots of message prepared from the expressing COS-7 cell lines are probed. Positive controls

20 include HepG2 and human liver message. Negative controls were COS-7 cells transfected with empty cassette pcDNA3.1. The expressed flCPSI derived message is somewhat smaller than the native CPSI (4.9 kb vs. 5.7 kb) since the clone does not contain the 1 kb 3' untranslated region.

Using the same controls, Western blot analysis of cell lysates by SDS-

PAGE are performed. Comassie blue staining is used to examine total protein production. For specific CPSI detection, a polyclonal rabbit anti-rat CPSI antibody is used. This antibody detects the expressed CPSI from COS-7 cells as well as the control samples. Finally, changes in the protein's structure are determined by examining the mobility pattern by 2-D electrophoresis, a useful tool to detect conformational changes. Any large changes in confirmation likely explain the alteration in CPSI function for that mutation.

The next stage involves measuring the functional characteristics of the expressed enzymes. A sensitive colorimetric assay has been modified for this purpose (Pierson, D. L., *J. Biochem. Biophys. Methods*, 3:31-37 (1980)). The modified assay allows 4-5 analyses from 20-50 mg of tissue or cells. The tissue is first homogenized in 0.75M KCl. Small molecules, including ATP and NAG, are removed through a SEPHADEX™ G25 column (Boehringer). The reaction mix contains ammonium bicarbonate, ATP, magnesium DTT, n-acetylglutamate (NAG), and triethanolamine. The concentration of any reagent can be varied, and experiments on HepG2 cells show decreased activity with both low and high concentrations of NAG (0.50 mM). Absence of NAG in preliminary COS-7 cell expression experiments yields no measurable enzyme activity.

Since CPSI is an allosteric enzyme, it does not follow Michaelis-Menton kinetics under varying NAG concentrations; however, when the amount of NAG is fixed, the production of carbamyl phosphate is steady. As shown in Fig. 8, carbamyl phosphate production is measured by the addition of hydroxylamine to the solution after incubation at 37°C for varying time periods (0, 5, 10, 20,

25, 30 minutes). This step, carried out at 95°C, also serves to inactivate the enzyme and prevent further production of carbamyl phosphate. The hydroxylamine converts the carbamyl phosphate to hydroxyurea which is subsequently treated with a sulfuric/acetic acid solution with butanedione to
5 derive a compound with peak absorption at 458 nm. The reaction is then spun at 12,000 X g for 15 minutes to remove precipitated protein. Next, the 458 nm absorbance is measured for each reaction. Activity typically begins to decrease after 20-30 minutes of reaction.

A number of expressing cell pellets are pooled for analysis. To ensure
10 that activity measurements are based on consistent amounts of enzyme, expressed CPSI is quantified by Western blot analysis of the pooled sample using a CPSI antibody such as the rabbit anti-rat CPSI described hereinabove. Basal activity is first determined using fixed amounts of substrate and cofactor and a time course analysis. Varying amounts of ammonia bicarbonate, ATP,
15 and NAG are then used to determine the binding efficiency for these elements. These elements are varied from 0 to 10-fold the normal amount. Enzyme activity is also measured after heat treatment of the homogenate. Protein labeling (pulse-chase) experiments are performed to determine the stability of the protein over time.

20 Stable CPSI protein expression is obtained using the methods described above. The establishment of stable transfected cell lines allows the production of sufficient quantities of both varieties of CPSI to carry out these studies. In activity studies, changes in activity for the N1405 as compared to the T1405 type of CPSI are noted. A change in the enzyme activity under varying

concentrations of NAG is also noted. These results support the role of this polymorphism of the present invention in predicting susceptibility to sub-optimal urea cycle function and hyperammonemia and decreased arginine production associated therewith.

5

Example 5

Relationship of the T1405N Polymorphism and

Urea Cycle Intermediates to the Ammonia Elevation

Seen in Patients on Valproic Acid Therapy

10

Valproic acid (VPA) is a commonly used seizure medication, particularly for the treatment of absence seizures or as an adjunct therapy of other seizure disorders. Toxicity from VPA treatment is a complex and multi-variant process and probably reflects several metabolic disruptions. Hyperammonemia and hepatic micro-vesicular steatosis and necrosis are the most commonly reported serious medical complications.

15

Although the development of toxic hyperammonemia involves only a small number of patients, it carries a significant morbidity and mortality, and several deaths have been attributed to this complication. The development of asymptomatic hyperammonemia (plasma ammonia level greater than 60 $\mu\text{mol/L}$) occurs within one hour of VPA administration, and is, however, relatively common.

20

Mechanisms of VPA-induced Hyperammonemia. The mechanisms by which VPA causes hyperammonemia has been the subject of some debate, and a number of different theories currently have support in the art. A renal

model proposed that the changed in glutamine metabolism resulted in an increased ammonia load to the liver, while most other theories concentrate on different aspects of urea cycle function. See, for example, Warter et al., *Revue Neurologique*, 139:753-757 (1983). Since the urea cycle is the major mechanism for the removal of ammonia in humans, it is thought that hyperammonemia arises in some way from the inhibitory interactions of VPA and/or its metabolites with urea cycle function and capacity.

Evidence for urea cycle dysfunction in VPA therapy comes from a number of experimental and clinical observations aside from elevations in plasma ammonia described above. For example, Marrini et al. measured a reduction in both baseline and stimulated CPSI activity in non-nephrectomized animals following an amino acid and VPA load (Marrini et al., *Neurology* 38:365-371 (1988)). Marrini et al. also observed that nephrectomized rats injected with an amino acid load and VPA also developed hyperammonemia. Another group, Castro-Gago et al., measured serum amino acids in 22 epileptic children treated with VPA, and found reduction in aspartic acid and ornithine, implicating a decrease in urea cycle efficiency rather than an increase in precursors (Castro-Gago et al., *Childs Neurons System* 6:434-436 (1990)).

Significance of Carbamyl Phosphate Synthase I. Mechanisms of VPA-induced urea cycle deficits typically revolve around mitochondrial carbamyl phosphate synthetase I (CPSI). A patient with severe toxicity following VPA overdose was found to have 50% normal CPSI activity (Bourrier et al., *Prese Medicales* 17:2063-2066 (1988)). Applicants have observed several mild CPSI deficient patients who deteriorated when given valproic acid with ready reversal

after discontinuation.

Role of NAG. N-acetylglutamate (NAG) is a required allosteric cofactor for CPSI. NAGA is synthesized from glutamate and acetyl CoA in mitochondria, with a cellular distribution that mirrors that of CPSI (Shigesada et al., *Journal of Biological Chemistry* 246: 5588-5595 (1971)). It is synthesized from glutamate (from amino acid catabolism) and acetyl CoA. There are several ways in which an alteration of NAG availability is envisaged to reduce the activity of CPSI. Genetic deficiencies in NAG synthetase have been observed, and this enzyme is known to be inhibited competitively by alternate substrates such as propionyl CoA or succinate (Bachmann et al., *New England Journal of Medicine* 304:543 (1981); Kamoun et al., *Lancet* 48 (1987); Coude et al., *J. Clin. Invest.* 64:1544-1551 (1979); Rabier et al., *Biochem. And Biophys. Research Comm.* 91:456-460 (1979); Rabier et al., *Biochimie* 68:639-647 (1986)). It has been shown experimentally that CPSI is inhibited in a competitive manner by the presence of increased amounts of propionyl CoA, and that VPA therapy causes an increase in blood propionate concentration (Coulter et al., *Lancet* 1 (8181): 1310-1311 (1980); Gruskay et al., *Ped. Res.* 15:475 (1981); Schmidt, R. D., *Clin. Chim. Acta.* 74:39-42 (1977)). VPA exposure has also been shown to decrease NAG concentrations in intact hepatocytes, by decreasing concentrations of both acetyl CoA and glutamine (Coude et al., *Biochem. J.* 216:233-236 (1983)). The decrease in glutamine concentration is attributed to inhibition of both pyruvate dehydrogenase and pyruvate carboxylase.

Alternatively, it has been suggested that depletion of mitochondrial

acetyl CoA occurs because CoA is diverted on VPA therapy for the manufacture of valproyl CoA (Becker et al., *Archives of Biochemistry & Biophysics* 223:381-392 (1983)). It is well known that VPA also disrupts fatty acid β -oxidation, with resultant diminution of acetyl CoA (Eadie et al., *Med. Toxicol.* 3:85-106 (1998)). All these mechanisms could lead to a shortage in NAG since it is synthesized from acetyl CoA. Given the effects of VPA on NAG availability it follows that any change in the binding properties of CPSI for NAG would affect its activity.

Thus, this Example sets forth experimentation for determining correlation between the presence or absence of the polymorphism of the present invention in the CPSI gene with susceptibility to hyperammonemia using VPA as a model agent for the production of hyperammonemia. Initially, genomic DNA is isolated from patients who are beginning valproic acid therapy for genotyping for the T1405N polymorphism in accordance with the methods described herein, such as PCR amplification and use of non-denaturing gels. After genotyping these patients, pre- and post-treatment amino acid and ammonia determination is performed for these patients. Particularly, DNA is isolated from whole blood using the QIAmp™ (Qiagen) kit described in Example I.

Next, plasma total VPA concentration is determined by an enzyme-mediated immunoassay technique (EMIT™ Syva-Behring, San Jose, California on a Syva 30R™ analyzer). This technique utilizes competitive binding for VPA antibody binding sites between VPA in the patient plasma and that complexed with the enzyme G6PDH. Release of the VPA enzyme complex from the antibody reactivates the enzyme, and its activity is assessed by the rate of

formation of NADH upon addition of the substrate. NADH production is monitored via spectroscopy at 340 nanometers (nm). Free (non-protein bound) VPA is isolated from plasma using a centrifugal micro partition filter device with a 3000 Dalton cut-off (CENTRIFREE™, Aimcon, Beverley, Massachusetts).

5 The VPA concentration in the plasma ultra filtrate is measured as described for total VPA.

Data collected from VPA patients is analyzed for correlations between genotype and phenotype. Additionally, free and conjugated VPA fractionation are compared to evaluate effects on NAG production and availability. The
10 latter comparison is prepared given that there are known effects of VPA on NAG availability. For example, VPA exposure has been shown to decrease NAG concentrations in intact hepatocytes by decreasing concentrations of both acetyl CoA and glutamine. See Coude et al., *Biochem. J.*, 216:233-236 (1983). Thus, this comparison reflects that changes in the binding properties of CPSI
15 for NAG affect the activity of CPSI.

Example 6

Detection of Additional Polymorphisms in CPSI

Using the techniques developed for mutation analysis of CPSI message,
10 non-CPSI deficient, unrelated patients are screened for additional polymorphisms in the coding region. This is done using "illegitimate" transcripts
20 from lymphoblastoid and fibroblast cell lines. Polymorphisms with a widespread effect on the population should be evident in this size sample. As used herein and in the claims, the term "polymorphism" refers to the

occurrence of two or more genetically determined alternative sequences or alleles in a population. A polymorphic marker is the locus at which divergence occurs. Preferred markers have at least two alleles, each occurring at frequency of greater than 1%. A polymorphic locus may be as small as one
5 base pair. Provided polymorphic markers thus include restriction fragment length polymorphisms, variable number of tandem repeats (VNTR's), hypervariable regions, minisatellites, dinucleotide repeats and tetranucleotide repeats.

A number of "mutation" detection techniques have been carried out, all
10 of which are based on detectable changes in the mobility of non-denatured single-stranded DNA, as described by Summar, M., *J. Inherited Metabolic Disease* 21:30-39 (1998). Examples of CPSI mutations identified by these techniques are disclosed in Fig. 3. Due to the large size of the CPSI message (about 5,700 bases) a method to screen a large amount of DNA in a few
15 reactions is preferred. Restriction endonuclease fingerprinting (REF) provides for the screening large DNA fragments, up to about 2,000 bp, with excellent sensitivity.

Reverse transcriptase reactions (RT) are carried out using 1 μ g of total RNA and either an oligo-dT primer or an antisense primer from the midpoint of
20 the CPSI message. Using the RT product as template, PCR reactions are performed with 4 different primer sets creating 4 overlapping fragments spanning the 4,600 base coding region. Control PCR reactions are run with each set of experiments, to ensure that contaminating template is not amplified. Genomic DNA is not preferred for this study due to the size of the gene

(80,000+ bp), the number of introns (36), and that sequencing of the intron exon boundaries for CPSI has not been completed. However, intronic locations are characterized graphically in Fig. 9.

The 4 overlapping RT/PCR products described above are used for mutation screening. Careful analysis of the restriction maps leads to the selection of three restriction enzymes for each fragment which cleave them into pieces ranging from 100-250 bp. Fragments of this size are ideal for single strand conformation polymorphism (SSCP) analysis. The enzymes are selected such that each fragment can be evenly evaluated across its length.

Prior to digestion, the PCR products are purified by gel electrophoresis and isolation from the agarose slices. After 3 hours, the digested fragments are ethanol precipitated. These fragments are separated in a 6% non-denaturing polyacrylamide gel at 4°C running at a constant 35 watts. These conditions maximize the detection of conformational changes in the single stranded fragments, as described by Liu, Q. and Sommer, S. S., *Biotechniques* 18(3):470-477 (1995). DNA detection is done by silver staining and the gels are scored for mobility shifts. Based on the location of any shifted fragment, direct sequence analysis of the RT/PCR product is performed using a cycle-sequencing protocol. To eliminate the possibility of a mutation resulting from *Taq* polymerase errors, a fresh RT product is amplified and sequenced in each case. The entire 4,600 bases of coding message is rapidly screened in this fashion. Any regions containing unclear areas are sequenced, looking for changes in the expected sequence.

The restriction digestion products of each RT/PCR fragment are

isolated. These individual fragments are then run against the combined digestion in a non-denaturing gel as described above. By characterizing the fragment pattern in this way, the portions of the CPSI message involved in any observed mobility shifts are readily identified.

5 Polymorphisms detected in these experiments are genotyped against the Centre d'Etude Polymorphisme Humain (CEPH) parents panel to establish frequency. All changes are examined for their effect on codon use and those resulting in mis-sense mutations are examined using the CPSI characterization data disclosed herein.

10 The techniques described in Example 3 are used to express site-directed mutants containing these changes. Using this system the *in vitro* effects of the changes on CPSI production and activity are observed.

15 A T344A polymorphism was detected in CPSI. Oligonucleotide primers were used from the 10th exon (U1119:tactgctcagaatcatggc - SEQ ID NO:17) and intron (LI10+37: tcatacacaactgaacagg - SEQ ID NO:18) to amplify a 91 bp fragment containing the change. PCR cycle conditions were: 35 cycles of 1 minute anneal at 59°C, 1 minute extension at 72°C, and 1 minute denaturation at 94°C. Patients were classified as having either homozygous SNP genotypes of AA or TT, or as being heterozygous (AT). The adult population distribution of this polymorphism is 35% AA, 44% AT, and 21% TT.

20 A 118-CTT polymorphism was also detected in CPSI. Oligonucleotide primers were used from the 5' untranslated region (U5'-74: ggtaagagaaggaggagctg - SEQ ID NO:19) and intron (L175: aaccagtcttcagtgtcctca - SEQ ID NO:20) to amplify a 249 bp fragment

containing the change. PCR cycle conditions were: 35 cycles of 1 minute anneal at 59°C, 1 minute extension at 72°C, and 1 minute denaturation at 94°C. Patients were classified as having either a homozygous genotype with the 118 trinucleotide insertion or deletion, or as being heterozygous. The adult population distribution of this polymorphism is 34% CTT-, 43% heterozygous, and 23% CTT+.

Example 7

Biochemical and Genetic Alterations in Carbamyl Phosphate Synthetase I in Neonatal Patients with With Persistent Pulmonary Hypertension

This Example investigates the role of the limitation of endogenous NO production in the pathogenesis of persistent pulmonary hypertension (PPHN) in the sick term neonate. Endogenous NO is the product of the urea cycle intermediate arginine. Production of arginine depends on the rate-determining enzyme of the urea cycle, carbamyl phosphate synthetase (CPSI). Newborns possess less than half the normal urea cycle function making them particularly susceptible to minor changes in enzyme form and function. A common exonic polymorphism (T1405N) in CPSI has been observed which affects flow through the first step of the urea cycle.

In this Example, it was tested whether newborns who developed PPHN would have lower NO precursors (arginine and citrulline) than matched controls. Whether PPHN patients have predominantly the CC (threonine/threonine) or AC (asparagine/threonine) CPSI genotypes which are

associated with lower function than AA (asparagine/asparagine) CPSI genotype was also analyzed.

Methods. Forty-seven neonates >2kg, >35weeks, and <72 hours old who were admitted to the Vanderbilt Neonatal Intensive Care Unit with (n=22) and without (n=25) echocardiographically-documented pulmonary hypertension were enrolled. Clinically important measures of the severity of respiratory distress were recorded. Ammonia levels and plasma amino acid profiles were obtained. Genotypes were determined by running PCR-amplified DNA on nondenaturing MDE™ gels.

Results. Patients who developed PPHN had an average arginine of 21.5 $\mu\text{mol/l}$ while those who did not averaged 38.3 $\mu\text{mol/l}$ ($p=0.0004$). The citrulline averages were 6.1 $\mu\text{mol/l}$ and 10.3 $\mu\text{mol/l}$ respectively ($p=0.02$). The levels of arginine and citrulline were inversely correlated with the severity of hypoxemia as measured by oxygenation index, days of mechanical ventilation, and days requiring supplemental O_2 . Genotype analysis of PPHN patients for T1405N showed 5CCs, 17ACs, and 0AAs, whereas the controls had 7CCs, 16ACs, and 2AAs (Chi-square $p=0.005$ using the expected population allele frequency). Infants with the CC genotype had lower arginine and citrulline means (21.5 $\mu\text{mol/l}$ and 5.8 $\mu\text{mol/l}$) than infants with the AA genotype (31.5 $\mu\text{mol/l}$ and 13.5 $\mu\text{mol/l}$) consistent with a functional difference between the two forms of the enzyme.

Conclusions. This Example shows that the development of PPHN in sick newborns is associated with inadequate availability of the urea cycle intermediates arginine and citrulline. The T1405N polymorphism in the CPSI

DNA leads to diminished enzyme function and subsequent lower levels of NO precursors.

Discussion. Carbamyl phosphate synthetase (CPS I) catalyzes the rate-determining step in the urea cycle thereby determining tissue levels of the urea cycle intermediates including arginine and citrulline. As disclosed herein, a widely distributed C to A exonic polymorphism in the CPS I gene changes a conserved threonine to an asparagine at position 1405 near the critical N-acetyl glutamate binding domain. Data has shown that the asparagine-containing version of CPSI displays more efficient kinetics in enzyme function studies.

The T1405N allele exhibits 50% heterozygosity and appears to be a silent variant in normal healthy adults. However, consequences of the qualitative change can be unmasked by stressful conditions. As disclosed in Examples 1-3, adults exposed to high-dose chemotherapy in preparation for bone marrow transplantation that the threonine-containing enzyme produces inadequate levels of arginine and citrulline and is associated with an increased incidence of hepatic veno-occlusive disease, acute lung injury, and death. As nitric oxide (NO) is generated in endothelial cells from L-arginine by nitric oxide synthetase (NOS), decreased levels of urea cycle intermediates could predispose to disturbances in vascular tone by limiting endogenous NO production.

In the prospective cohort study of this Example, the possibility that a similar process could be involved in the pathogenesis of persistent pulmonary hypertension of the newborn (PPHN) was investigated. Endogenously produced NO functions in regulation of pulmonary vascular resistance and in

the transition from fetal to neonatal circulation. Lipsitz, E. C., et al. *J Pediatr Surg* (1996) 31:137-140; Abman, S.H., et al. *Am J Physiol* (1990) 259:H1921-H1927. Between 20 weeks gestation and term birth, CPSI production and function are less than 50% of adult levels. This physiologic deficiency could unmask the effect of the T1405N gene mutation particularly if coupled with other neonatal stresses affecting hepatic function; for instance, asphyxia or sepsis.

Patients eligible for this study included appropriately grown neonates ≥ 35 weeks gestation and ≥ 2 kg birthweight who were admitted to the Vanderbilt University Medical Center neo-natal intensive care unit (NICU) between July 1, 1999 and February 29, 2000 for symptoms of respiratory distress. Infants with multiple congenital anomalies, known genetic syndromes, and anatomic causes of pulmonary hypertension (congenital diaphragmatic hernia, Potter's syndrome, asphyxiating thoracic dystrophy, etc.) were excluded. Parental consent was obtained for all enrollees. Fifty-one neonates had 3 cc of blood drawn in the first 72 hours of life for plasma amino acid profiles, ammonia and BUN levels, nitric oxide metabolite determination, and CPS1 genotyping. Blood was drawn prior to blood transfusion, enteral or parenteral protein intake, inhaled nitric oxide administration, or ECMO cannulation.

Data collected on the enrollees included (1) baseline characteristics (birthweight, gestational age, sex, race, Apgar scores, primary diagnosis, any pulmonary complications, and the postnatal age at the time blood was drawn) and (2) measures of respiratory support (FiO₂, MAP, iNO, ECMO) and clinical

response (ABGs, duration of mechanical ventilation and supplemental O₂, survival.) Maximum oxygenation index [$OI = FiO_2 \times MAP / PaO_2$] was used as a measure of the severity of respiratory distress. Predominant primary diagnoses included (1) birth asphyxia: 5-minute Apgar score <5 with a mixed acidosis on first ABG or cord blood gas plus evidence of neurologic dysfunction and other end-organ injury, (2) respiratory distress syndrome (RDS): clinical symptoms of respiratory distress with ground-glass lung fields and air bronchograms on chest X-ray plus combined hypercarbia/hypoxia on ABG (Note: given the gestational age of these neonates, infants with this picture could have had either surfactant-deficiency or congenital pneumonia; however, in no case was a positive tracheal aspirate culture obtained), and (3) meconium aspiration syndrome (MAS): history of meconium-staining at delivery plus clinical symptoms of respiratory distress, hypoxemia, and coarse infiltrates chest X-ray.

Infants were defined as having pulmonary hypertension (PPHN) if they developed significant hypoxemia ($PaO_2 < 100$ on 100% O₂ > 6 hours) with normal intracardiac anatomy and echocardiographic evidence of elevated pulmonary artery pressure. The latter was defined as (1) right-to-left or bidirectional ductal or foramen ovale flow or (2) elevated (>35 mmHg) pulmonary artery pressure based on Doppler estimate of the tricuspid regurgitation jet as read by a blinded third party.

Amino acid analysis was performed on fresh plasma samples in 47 patients. A protein free extract of plasma was prepared by protein precipitation with sulfosalicylic acid and filtration through a 0.45 um Acrodisc 4 (Gelman

Sciences, Ann Arbor, Michigan). Amino acids were separated by cation exchange chromatography using a four-component pH- and ionic strength-graded lithium citrate buffer system on a Beckmann 7300 amino acid analyzer (Beckmann, Palo Alto, California). Post column derivatization of amino acids with ninhydrin allowed detection of primary amine amino acids at 570 nm, and secondary amines at 440 nm. Quantitation was achieved by instrument calibration with standard reference materials (Sigma, St. Louis, Missouri). Citrulline and arginine were detected as measurable indices of flux of intermediates through the urea cycle.

Measurement of plasma nitric oxide metabolites (NO_x). Plasma NO_x was measured in a subgroup of patients using modified Griess reagents after samples were deproteinated and incubated with cadmium beads to convert nitrate to nitrite.

SNP Detection. Oligonucleotide primers from within the 36th exon (U4295 - SEQ ID NO:15) and intron (LI36 - SEQ ID NO:16) of CPS1 and the polymerase chain reaction (PCR) to reliably amplify a 251 bp fragment encompassing the region containing the change from genomic DNA obtained from whole blood preparations. This combination of primers gave reproducible amplification using Taq polymerase (Promega) and PCR cycle conditions as follows: 35 cycles of 1 minute anneal at 67°C, 1 minute extension at 72°C, and 1 minute denaturation at 94°C. After formamide treatment, samples were subjected to electrophoresis for 5 hours at 4°C in a non-denaturing MDE™ gel (FMC, Rockland, Maine), then stained with silver nitrate to detect DNA fragments. Patients were classified as having homozygous SNP genotypes of

CC or AA, or as being heterozygous (AC). Genotyping using nondenaturing gel electrophoresis and direct sequence analysis yielded identical results as those disclosed above. Thus, the adult population distribution of the T1405N polymorphism was determined to be: 45% CC, 44% AC, and 11% AA.

5 An identical technique to that described above was used to detect the T344A polymorphism. Oligonucleotide primers were used from the 10th exon (U1119:tactgctcagaatcatggc - SEQ ID NO:17) and intron (LI10+37:tcatacacaactgaacagg - SEQ ID NO:18) to amplify a 91 bp fragment containing the change. PCR cycle conditions were: 35 cycles of 1 minute anneal at 59°C, 10 1 minute extension at 72°C, and 1 minute denaturation at 94°C. Patients were classified as having either homozygous SNP genotypes of AA or TT, or as being heterozygous (AT). The adult population distribution of this polymorphism is 35% AA, 44% AT, and 21% TT.

 An identical technique to that described above was used to detect the 15 118-CTT polymorphism. Oligonucleotide primers were used from the 5' untranslated region (U5'-74: ggtaagagaaggaggagctg - SEQ ID NO:19) and intron (L175: aaccagtcttcagtgtctca - SEQ ID NO:20) to amplify a 249 bp fragment containing the change. PCR cycle conditions were: 35 cycles of 1 minute anneal at 59°C, 1 minute extension at 72°C, and 1 minute denaturation 20 at 94°C. Patients were classified as having either a homozygous genotype with the 118 trinucleotide insertion or deletion, or as being heterozygous. The adult population distribution of this polymorphism is 34% CTT-, 43% heterozygous, and 23% CTT+.

Ammonia and plasma amino acid levels were compared between groups

of patients using Student's T-test. Distributions of genotypes of CPSI were compared across groups by calculating allelic frequency for the entire group and searching for evidence of Hardy-Weinberg disequilibrium in specifically selected subgroups using Chi-square analysis. Of the 51 neonates originally enrolled, 25 developed PPHN while 26 did not. There were no statistically significant differences in the baseline characteristics of the two groups including birthweight, gestational age, race, or the postnatal age in hours of the infants at enrollment. There was, however, a slight predominance of males in the control group.

The distribution of primary diagnoses was evenly distributed. In the PPHN group, 5 infants had birth asphyxia, 9 infants had RDS, 5 infants had meconium aspiration syndrome, and 6 infants had other diagnoses, including 4 infants with primary PPHN. In the control group, 4 infants had birth asphyxia, 8 infants had RDS, 3 infants had MAS, and 11 infants had other diagnoses. The other diagnoses included supraventricular tachycardia, anemia, birth trauma, and viral sepsis. No infant in the study had a positive bacterial blood culture.

As expected, infants who had PPHN complicate their primary pathology did develop more severe illness than the controls by some clinical criteria. Eight of the infants with PPHN required treatment with inhaled NO (iNO), 2 required ECMO, and 2 died (one infant with asphyxia and multiorgan-system failure on iNO; another infant with alveolar capillary dysplasia was withdrawn from ECMO.) Obviously, none of the controls were treated with iNO or ECMO; and there was no mortality in the control group.

Three infants in the PPHN group were excluded from analysis. The infant found to have alveolar capillary dysplasia on lung biopsy was considered to have an anatomical etiology for pulmonary hypertension. Another infant was mistakenly enrolled with a congenital diaphragmatic hernia, and the third was enrolled at 119 hours of age after TPN had been initiated. One infant in the control group was excluded from analysis after karyotype analysis revealed the etiology of his hypotonia to be Prader-Willi syndrome.

The infants who developed PPHN had significantly lower serum arginine and citrulline levels on amino acid analysis. The mean arginine level in PPHN cases was 21.5 ± 9.2 $\mu\text{mol/l}$ whereas the mean arginine of the control group was 38.3 ± 18.4 $\mu\text{mol/l}$ ($p = 0.0004$). The mean citrulline in PPHN cases was 6.1 ± 3.6 $\mu\text{mol/l}$ compared to 10.3 ± 7 $\mu\text{mol/l}$ in the control group ($p = 0.02$). There were no significant differences in the levels of other amino acids between the two groups, including glutamine, glycine, alanine, lysine, valine, ornithine, and leucine. The level of total essential amino acids (TEAA) was slightly lower in the PPHN cases, about 537 $\mu\text{mol/l}$ versus about 654 $\mu\text{mol/l}$, but this difference was not statistically significant ($p = 0.08$). by birthweight, gestational age, or number of hours of postnatal life. The level of TEAA was found to be significantly higher in the four infants whose blood was drawn prior to six hours of age (about 1021.5 $\mu\text{mol/l}$ vs. about 542 $\mu\text{mol/l}$, $p = 0.0026$). This difference is presumed to reflect the recent cessation of parenteral protein influx in these infants from the placental circulation.

No differences in arginine and citrulline levels were found when the primary diagnosis categories of asphyxia, RDS, MAS, and "other" were

separately analyzed. In each group, infants with pulmonary hypertension tended to have lower values, but the results were not statistically significant given the small numbers of infants in each group. For example, asphyxiated infants with PPHN had a mean arginine of about 18.5 $\mu\text{mol/l}$ compared to about 52.7 $\mu\text{mol/l}$ in asphyxiated controls ($p = 0.06$) and a mean citrulline of about 6.8 $\mu\text{mol/l}$ compared to about 14.3 $\mu\text{mol/l}$ ($p = 0.04$).

There was an inverse relationship between the levels of serum arginine and citrulline and the severity of hypoxemia. Arginine and citrulline values fell progressively as oxygenation index increased, days of mechanical ventilation increased, and days requiring supplemental oxygen increased birthweight, gestational age, or number of hours of postnatal life. The NH_3 levels in infants with PPHN tended to be slightly higher than in controls ($54 \pm 18.1 \mu\text{mol/l}$ vs. $45.6 \pm 12 \mu\text{mol/l}$) but these values were not statistically significant ($p = 0.08$). On CPS1 T1405N genotype analysis, of the 22 infants who developed PPHN, 5 were CC and 17 were AC. There were no AAs in the PPHN cases. In the 25 controls, there were 7 CCs, 16 ACs, and 2 AAs. These distributions of genotypes were then compared by calculating the expected allelic frequency for the entire group revealing evidence of Hardy-Weinberg disequilibrium in the PPHN group. On Chi-square analysis these two groups are significantly different from each other with a $p\text{-value} = 0.005$. Of the two infants with the AA genotype, one infant had RDS while the other suffered from birth asphyxia. Neither infant ever achieved an $\text{OI} \geq 15$; both spent < 1 week on the ventilator and < 10 days on oxygen.

Infants with the CC genotype had mean arginine levels of 21.9 ± 7

umol/l and citrulline levels of 5.8 ± 1.8 umol/l while infants with the AA genotype had a mean arginine level of 31.5 ± 3.5 umol/l and a mean citrulline level of 13.5 ± 6.4 umol/l. Again, given the small number of AAs, this data has difficulty reaching statistical significance with p-values of 0.1 and 0.006, respectively.

5

REFERENCES

The references listed below as well as all references cited in the specification are incorporated herein by reference to the extent that they supplement, explain, provide a background for or teach methodology, techniques and/or compositions employed herein.

- 10 Abman, S. H., et al., *Am J Physiol* (1990) 259:H1921-H1927.
- Adelman et al., *DNA* 2:183 (1983).
- Alonso, E. and Rubio, V., *European Journal of Biochemistry* 229:377-384 (1995).
- Artymiuk, P. J. et al., *Nature Struct. Biol.* 3:128-132 (1996).
- 15 Bachmann et al., *New England Journal of Medicine* 304:543 (1981).
- Batshaw ML, Brusilow SW. *Annals of Neurology* 1982; 11:319-21.
- Bearman SI, *Journal of Clinical Oncology* 1993; 11:1729-36.
- Beaucage et al., *Tetrahedron Letters* 22:1859-1862 (1981).
- Beaumier L, *Biomedical & Environmental Sciences* 1996; 9:296-315.
- 20 Becker et al., *Archives of Biochemistry & Biophysics* 223:381-392 (1983).
- Bernard GR, Artigas A, Brigham KL, et al. *Intensive Care Medicine* 1994; 20:225-32.
- Blau N, Duran, M., and Blaskovics, M.E. *Physician's Guide to the Laboratory*

Diagnosis of Metabolic Diseases London: Chapman&Hall Medical, 1996.

Bourrier et al., *Prese Medica* 17:2063-2066 (1988).

Castillo, L., et al., *Pediatr Res* (1995) 38:17-24.

Castillo L, et al., *Journal of Biological Chemistry* 1989; 264:4038-44.

5 Castro-Gago et al., *Child Neuro Systems* 6:434-436 (1990).

Cervera, J. et al., *Biochemistry* 35:7247-7255 (1996).

Cohen PP. *Current Topics in Cellular Regulation* 1981; 18:1-19.

Coude et al., *Biochem. J.* 216:233-236 (1983).

Coude et al., *J. Clin. Invest.* 64: 1544-1551 (1979).

10 Coulter et al., *Lancet* 1 (8181): 1310-1311 (1980).

Crea et al., *Proc. Natl. Acad. Sci. USA* 75:5765 (1978).

Davies et al., *Bone Marrow Transplantation* 17:1119-1125 (1996).

de Groot, C. J., et al., *Biochemical & Biophysical Research Communications*
124:882-888 (1984).

15 Eadie et al., *Med. Toxicol.* 3:85-106 (1998).

Eichenlaub et al., *J. Bacteriol.* 138:559-566 (1979).

Faber-Langendoen K, et al. *Bone Marrow Transplantation* (1993) 12:12501-7.

Gribskov et al., *Nucl. Acids. Res.* 14:6745 (1986).

Gruskay et al., *Ped. Res.* 15:475 (1981).

20 Guillou, F., et al. *Proc Natl Acad Sci* 86:8304-8308 (1989).

Guy, H. I. et al., *Journal of Biological Chemistry* 270:2190-2197 (1995).

Hauser ER, et al., *New England Journal of Medicine* 1990; 322:1641-5.

Hebert PC, *Chest* 1993; 104:230-5.

Howell et al., *Antibodies A Laboratory Manual* Cold Spring Harbor Laboratory,

(1988).

Jackson, M. J. et al., *Annual Review of Genetics* 20:431-464 (1986).

Jackson MJ, *Annual Review of Genetics* 1986; 20:431-64.

Javid-Majd et al., *Biochemistry* 35:14362-14369 (1996).

5 Jones RJ, et al. *Transplantation* 1987; 44:778-83.

Kamoun et al., *Lancet* 48 (1987).

Kinsella, J. P., et al., *Lancet* (1992) 340:819-820.

Kyte & Doolittle, *J. Mol. Biol.* 157:105-132 (1982).

Lagace, M. et al., *Journal of Biological Chemistry* 262:10415-10418 (1987).

10 Lipsitz, E. C. , et al., *J Pediatr Surg* (1996) 31:137-140.

Liu, Q. and Sommer, S. S., *Biotechniques* 18(3):470-477 (1995).

Maniatis et. al. in *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor, N.Y., p 280-281 (1982).

Marrini et al., *Neurology* 38:365-371(1988).

15 Marshall JC, et al., *Critical Care Medicine* (1995) 23:1638-52.

Matuschak, G. M., *Clinics in Chest Medicine* (1996) 17:83-98.

Matuschak, G. M. and Rinaldo, J. E., *Chest* (1988) 94:400-6.

Matuschak et al., *American Review of Respiratory Disease* 1990; 141:1296-306.

20 McCaffrey, M. J., et al., *Biol Neonate* (1995) 67:240-243.

McDonald, G. B., et al., *Annals of Internal Medicine* 1993; 118:255-67.

Meister, A., *Adv. Enzymol. Relat. Areas Mol. Biol.* 62:315-374 (1989).

Messing et al., *Third Cleveland Symposium on Macro Molecular and Recombinant DNA* Ed. Walton, A., (Elsevier, Amsterdam) (1981).

Mitchell RB, Wagner JE, Karp JE, et al. *American Journal of Medicine* 1988; 85:662-7.

Mitchell et al., *Amer. J. Med.* 85:662-667 (1988).

Moncada S, Higgs A. *New England Journal of Medicine* 1993; 329:2002-12.

5 Moorman, A. F. et al. *Histochemical Journal* 22:457-468 (1990).

Needleman et al., *J. Mol. Biol.* 48:443 (1970).

Nuzum, C. T. and Snodgrass, P. J., *Science* 1971; 172:1042-3.

Nyunoya, H., et al., *Journal of Biological Chemistry* 260:9346-9356 (1985).

Palmer RMJ, et al., *Biochem Biophys Res Commun* (1988) 153:1251-1256.

10 *PCR. A Practical Approach*, ILR Press, Eds. McPherson, et al. (1992).

Pierson, D.L., *J. Biochem. Biophys. Methods* 3:31-37 (1980).

Price, K. J., et al., *American Journal of Respiratory & Critical Care Medicine* 1998; 158:876-84.

Rabier et al., *Biochem. & Biophys. Research Comm.* 91:456-460 (1979).

15 Rabier et al., *Biochimie* 68:639-647 (1986).

Raiha, N. C. R. and Suihkonen, J. *Acta Paediatrica Scand* 57:121-127 (1968).

Richardson, P. and Bearman, S. I., *Leukemia & Lymphoma* (1998) 31:267-77.

Rinaldo JE, et al., *American Journal of Respiratory Cell & Molecular Biology* 1994; 11:625-30.

20 Roberts, J. D., et al., *Lancet* (1992) 340:818-819.

Rodriguez-Aparicio, L. B. et al., *Biochemistry* 28:3070-3074 (1989).

Rubenfeld GD, Crawford SW. *Annals of Internal Medicine* 1996; 125:625-33.

Rubio, V., (Review) *Biochemical Society Transactions* 21:198-202 (1993).

Rubio, V. and Grisolia, S., *Enzyme* 26:233-239 (1981).

Saiki et al., *Bio/Technology* 3:1008-1012 (1985).

Sambrook et al., *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Press, Cold Spring Harbor, N.Y.) (1989).

Schmidt, R. D., *Clin. Chim. Acta.* 74:39-42 (1977).

5 Schwartz et al., eds., *Atlas of Protein Sequence and Structure*, National Biomedical Research Foundation, pp. 357-358 (1979).

Shulman HM, et al., *Hepatology* 1994; 19:1171-81.

Smith et al., *Adv. Appl. Math.* 2:482 (1981).

Stapleton et al., *Biochemistry* 35:14352-14361 (1996).

10 Summar ML. *Journal of Inherited Metabolic Disease* 1998; 21 Suppl 1:30-9.

Summar, M., *J. Inherited Metabolic Disease* 21:30-39 (1998).

Summar ML, et al., *Cytogenetics & Cell Genetics* 1995; 71:266-7.

Takiguchi MaM, M., *Biochem J.* (1995) 312:649-659.

Toh, H. et al., *European Journal of Biochemistry* 215:687-696 (1993).

15 Tse et al., *American Journal of Hematology* 38:140-141 (1991).

U.S. Patent No. 5,399,346

U.S. Patent No. 5,162,215

U.S. Patent No. 5,279,833

U.S. Patent No. 5,643,567

20 U.S. Patent No. 4,683,202

U.S. Patent No. 4,683,195

U.S. Patent No. 5,286,634

U.S. Patent No. 5,646,008

U.S. Patent No. 4,196,265

U.S. Patent No. 5,489,742

U.S. Patent No. 5,550,316

U.S. Patent No. 5,573,933

U.S. Patent No. 5,614,396

5 U.S. Patent No. 5,625,125

U.S. Patent No. 5,641,484

U.S. Patent No. 5,648,061

U.S. Patent No. 5,651,964

U.S. Patent No. 4,965,188

10 U.S. Patent No. 4,769,331

U.S. Patent No. 5,741,957

U.S. Patent No. 4,458,066

U.S. Patent No. 4,554,101

U.S. Patent No. 4,736,866

15 van den Hoff, M. J. et al, *Journal of Molecular Evolution* 41:813-832 (1995).

Vosatka RJ, et al., *Biol Neonate* (1994) 66:65-70.

Warter et al., *Revue Neurologique* 139:753-757 (1983).

Wingard JR, et al. *Bone Marrow Transplantation* 1989; 4:685-9.

Zamora, S. A., et al., *Crit Care Med* (1998) 26: 1271-1276.

SEQUENCE LISTING

<110> Summar, Marshall L.

Christman, Brian

<120> THERAPEUTIC METHODS RELATING TO

5 CARBAMYL PHOSPHATE SYNTHETASE I POLYMORPHISM

<130> Attorney Docket No. 1242-19-2 CIP

<140>

<141>

<150> 09/323,472

10 <151> 1999-06-01

<160> 20

<170> PatentIn Ver. 2.0

<210> 1

<211> 5761

15 <212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (124)..(4626)

20 <400> 1

gtcagcctta aacactgact gcaccctcc cagatttctt ttacattaac taaaaagtct 60

tatcacacaa tctcataaaa tttatgtaat ttcatttaat ttagccaca aatcatcttc 120

25 aaa atg acg agg att ttg aca gct ttc aaa gtg gtg agg aca ctg aag 168
Met Thr Arg Ile Leu Thr Ala Phe Lys Val Val Arg Thr Leu Lys
1 5 10 15

act ggt ttt ggc ttt acc aat gtg act gca cac caa aaa tgg aaa ttt 216
Thr Gly Phe Gly Phe Thr Asn Val Thr Ala His Gln Lys Trp Lys Phe

	20	25	30	
	tca aga cct ggc atc agg ctc ctt tct gtc aag gca cag aca gca cac Ser Arg Pro Gly Ile Arg Leu Leu Ser Val Lys Ala Gln Thr Ala His	264		
	35	40	45	
5	att gtc ctg gaa gat gga act aag atg aaa ggt tac tcc ttt ggc cat Ile Val Leu Gly Asp Gly Thr Lys Met Lys Gly Tyr Ser Phe Gly His	312		
	50	55	60	
10	cca tcc tct gtt gct ggt gaa gtg gtt ttt aat act ggc ctg gga ggg Pro Ser Ser Val Ala Gly Glu Val Val Phe Asn Thr Gly Leu Gly Gly	360		
	65	70	75	
	tac cca gaa gct att act gac cct gcc tac aaa gga cag att ctc aca Tyr Pro Glu Ala Ile Thr Asp Pro Ala Tyr Lys Gly Gln Ile Leu Thr	408		
	80	85	90	95
15	atg gcc aac cct att att ggg aat ggt gga gct cct gat act act gct Met Ala Asn Pro Ile Ile Gly Asn Gly Gly Ala Pro Asp Thr Thr Ala	456		
	100	105	110	
	ctg gat gaa ctg gga ctt agc aaa tat ttg gag tct aat gga atc aag Leu Asp Glu Leu Gly Leu Ser Lys Tyr Leu Glu Ser Asn Gly Ile Lys	504		
	115	120	125	
20	gtt tca ggt ttg ctg gtg ctg gat tat agt aaa gac tac aac cac tgg Val Ser Gly Leu Leu Val Leu Asp Tyr Ser Lys Asp Tyr Asn His Trp	552		
	130	135	140	
25	ctg gct acc aag agt tta ggg caa tgg cta cag gaa gaa aag gtt cct Leu Ala Thr Lys Ser Leu Gly Gln Trp Leu Gln Glu Glu Lys Val Pro	600		
	145	150	155	
	gca att tat gga gtg gac aca aga atg ctg act aaa ata att cgg gat Ala Ile Tyr Gly Val Asp Thr Arg Met Leu Thr Lys Ile Ile Arg Asp	648		
	160	165	170	175
30	aag ggt acc atg ctt ggg aag att gaa ttt gaa ggt cag cct gtg gat Lys Gly Thr Met Leu Gly Lys Ile Glu Phe Glu Gly Gln Pro Val Asp	696		
	180	185	190	
	ttt gtg gat cca aat aaa cag aat ttg att gct gag gtt tca acc aag Phe Val Asp Pro Asn Lys Gln Asn Leu Ile Ala Glu Val Ser Thr Lys	744		
	195	200	205	
35	gat gtc aaa gtg tac ggc aaa gga aac ccc aca aaa gtg gta gct gta Asp Val Lys Val Tyr Gly Lys Gly Asn Pro Thr Lys Val Val Ala Val	792		
	210	215	220	
40	gac tgt ggg att aaa aac aat gta atc cgc ctg cta gta aag cga gga Asp Cys Gly Ile Lys Asn Asn Val Ile Arg Leu Leu Val Lys Arg Gly	840		
	225	230	235	
	gct gaa gtg cac tta gtt ccc tgg aac cat gat ttc acc aag atg gag Ala Glu Val His Leu Val Pro Trp Asn His Asp Phe Thr Lys Met Glu	888		
	240	245	250	255
45	tat gat ggg att ttg atc gcg gga gga ccg ggg aac cca gct ctt gca Tyr Asp Gly Ile Leu Ile Ala Gly Gly Pro Gly Asn Pro Ala Leu Ala	936		
	260	265	270	
	gaa cca cta att cag aat gtc aga aag att ttg gag agt gat cgc aag Glu Pro Leu Ile Gln Asn Val Arg Lys Ile Leu Glu Ser Asp Arg Lys	984		
	275	280	285	
50	gag cca ttg ttt gga atc agt aca gga aac tta ata aca gga ttg gct Glu Pro Leu Phe Gly Ile Ser Thr Gly Asn Leu Ile Thr Gly Leu Ala	1032		
	290	295	300	
55	gct ggt gcc aaa acc tac aag atg tcc atg gcc aac aga ggg cag aat Ala Gly Ala Lys Thr Tyr Lys Met Ser Met Ala Asn Arg Gly Gln Asn	1080		
	305	310	315	

GenBank accession number: F01011.1 (Hemophilus influenzae strain 102) (102)

5	cag Gln 320	cct Pro	gtt Val	ttg Leu	aat Asn	atc Ile 325	aca Thr	aac Asn	aaa Lys	cag Gln	gct Ala 330	ttc Phe	att Ile	act Thr	gct Ala	cag Gln 335	1128
	aat Asn	cat His	ggc Gly	tat Tyr	gcc Ala 340	ttg Leu	gac Asp	aac Asn	acc Thr	ctc Leu 345	cct Pro	gct Ala	ggc Gly	tgg Trp	aaa Lys 350	cca Pro	1176
	ctt Leu	ttt Phe	gtg Val	aat Asn 355	gtc Val	aac Asn	gat Asp	caa Gln	aca Thr 360	aat Asn	gag Glu	ggg Gly	att Ile	atg Met 365	cat His	gag Glu	1224
10	agc Ser	aaa Lys	ccc Pro 370	ttc Phe	ttc Phe	gct Ala	gtg Val	cag Gln 375	ttc Phe	cac His	cca Pro	gag Glu	gtc Val 380	acc Thr	ccg Pro	ggg Gly	1272
15	cca Pro	ata Ile 385	gac Asp	act Thr	gag Glu	tac Tyr	ctg Leu 390	ttt Phe	gat Asp	tcc Ser	ttt Phe 395	ttc Ser	tca Ser	ctg Leu	ata Ile	aag Lys	1320
	aaa Lys 400	gga Gly	aaa Lys	gct Ala	acc Thr	acc Thr	att Ile 405	aca Thr	tca Ser	gtc Val	tta Leu 410	ccg Pro	aag Lys	cca Pro	gca Ala	cta Leu 415	1368
20	gtt Val	gca Ala	tct Ser	cgg Arg	gtt Val	gag Glu	gtt Val	tcc Ser	aaa Lys	gtc Val 425	ctt Leu	att Ile	cta Leu	gga Gly	tca Ser 430	gga Gly	1416
25	ggg Gly	ctg Leu	tcc Ser	att Ile 435	ggg Gly	cag Gln	gct Ala	gga Gly	gaa Glu 440	ttt Phe	gat Asp	tac Tyr	tca Ser	gga Gly 445	tct Ser	caa Gln	1464
	gct Ala	gta Val	aaa Lys 450	gcc Ala	atg Met	aag Lys	gaa Glu	gaa Glu 455	aat Asn	gtc Val	aaa Lys	act Thr	gtt Val 460	ctg Leu	atg Met	aac Asn	1512
30	cca Pro	aac Asn 465	att Ile	gca Ala	tca Ser	gtc Val	cag Gln 470	acc Thr	aat Asn	gag Glu	gtg Val 475	ggc Gly	tta Leu	aag Lys	caa Gln	gcg Ala	1560
	gat Asp 480	act Thr	gtc Val	tac Tyr	ttt Phe	ctt Leu 485	ccc Pro	atc Ile	acc Thr	cct Pro	cag Gln 490	ttt Phe	gtc Val	aca Thr	gag Glu 495	gtc Val	1608
35	atc Ile	aag Lys	gca Ala	gaa Glu	cag Gln 500	cca Pro	gat Asp	ggg Gly	tta Leu	att Ile 505	ctg Leu	ggc Gly	atg Met	ggg Gly 510	ggc Gly	cag Gln	1656
40	aca Thr	gct Ala	ctg Leu	aac Asn 515	tgt Cys	gga Gly	gtg Val	gaa Glu	cta Leu 520	ttc Phe	aag Lys	aga Arg	ggg Gly	gtg Val 525	ctc Leu	aag Lys	1704
	gaa Glu	tat Tyr	ggg Gly 530	gtg Val	aaa Lys	gtc Val	ctg Leu	gga Gly 535	act Thr	tca Ser	gtt Val	gag Glu	tcc Ser 540	att Ile	atg Met	gct Ala	1752
45	acg Thr	gaa Glu	gac Asp	agg Arg	cag Gln	ctg Leu	ttt Phe 550	tca Ser	gat Asp	aaa Lys	cta Leu	aat Asn 555	gag Glu	atc Ile	aat Asn	gaa Glu	1800
	aag Lys 560	att Ile	gct Ala	cca Pro	agt Ser	ttt Phe 565	gca Ala	gtg Val	gaa Glu	tcg Ser 570	att Ile	gag Glu	gat Asp	gca Ala	ctg Leu	aag Lys 575	1848
50	gca Ala	gca Ala	gac Asp	acc Thr	att Ile 580	ggc Gly	tac Tyr	cca Pro	gtg Val	atg Met 585	atc Ile	cgt Arg	tcc Ser	gcc Ala	tat Tyr 590	gca Ala	1896
55	ctg Leu	ggg Gly	ggg Gly	tta Leu 595	ggc Gly	tca Ser	ggc Gly	atc Ile	tgt Cys 600	ccc Pro	aac Asn	aga Arg	gag Glu	act Thr 605	ttg Leu	atg Met	1944
	gac Gln	ctc Pro	agc Val	aca Leu	aag Asn	gcc Thr	ttt Ile	gct Val	atg Ser	acc Lys	aac Gln	caa Ala	att Thr	ctg Val	gtg Leu	gag Gln	1992

	Asp	Leu	Ser	Thr	Lys	Ala	Phe	Ala	Met	Thr	Asn	Gln	Ile	Leu	Val	Glu	
	610							615					620				
5	aag	tca	gtg	aca	ggg	tgg	aaa	gaa	ata	gaa	tat	gaa	gtg	gtt	cga	gat	2040
	Lys	Ser	Val	Thr	Gly	Trp	Lys	Glu	Ile	Glu	Tyr	Glu	Val	Val	Arg	Asp	
	625						630					635					
	gct	gat	gac	aat	tgt	gtc	act	gtc	tgt	aac	atg	gaa	aat	gtt	gat	gcc	2088
	Ala	Asp	Asp	Asn	Cys	Val	Thr	Val	Cys	Asn	Met	Glu	Asn	Val	Asp	Ala	
	640					645					650					655	
10	atg	ggg	gtt	cac	aca	ggg	gac	tca	gtt	gtt	gtg	gct	cct	gcc	cag	aca	2136
	Met	Gly	Val	His	Thr	Gly	Asp	Ser	Val	Val	Val	Ala	Pro	Ala	Gln	Thr	
					660					665					670		
	ctc	tcc	aat	gcc	gag	ttt	cag	atg	ttg	aga	cgt	act	tca	atc	aat	gtt	2184
	Leu	Ser	Asn	Ala	Glu	Phe	Gln	Met	Leu	Arg	Arg	Thr	Ser	Ile	Asn	Val	
				675					680					685			
15	gtt	cgc	cac	ttg	ggc	att	gtg	ggg	gaa	tgc	aac	att	cag	ttt	gcc	ctt	2232
	Val	Arg	His	Leu	Gly	Ile	Val	Gly	Glu	Cys	Asn	Ile	Gln	Phe	Ala	Leu	
				690				695					700				
20	cat	cct	acc	tca	atg	gaa	tac	tgc	atc	att	gaa	gtg	aat	gcc	aga	ctg	2280
	His	Pro	Thr	Ser	Met	Glu	Tyr	Cys	Ile	Ile	Glu	Val	Asn	Ala	Arg	Leu	
		705					710					715					
	tcc	cga	agc	tct	gct	ctg	gcc	tca	aaa	gcc	act	ggc	tac	cca	ttg	gca	2328
	Ser	Arg	Ser	Ser	Ala	Leu	Ala	Ser	Lys	Ala	Thr	Gly	Tyr	Pro	Leu	Ala	
					725						730				735		
25	ttc	att	gct	gca	aag	att	gcc	cta	gga	atc	cca	ctt	cca	gaa	att	aag	2376
	Phe	Ile	Ala	Ala	Lys	Ile	Ala	Leu	Gly	Ile	Pro	Leu	Pro	Glu	Ile	Lys	
					740					745				750			
	aac	gtc	gta	tcc	ggg	aag	aca	tca	gcc	tgt	ttt	gaa	cct	agc	ctg	gat	2424
	Asn	Val	Val	Ser	Gly	Lys	Thr	Ser	Ala	Cys	Phe	Glu	Pro	Ser	Leu	Asp	
				755					760					765			
30	tac	atg	gtc	acc	aag	att	ccc	cgc	tgg	gat	ctt	gac	cgt	ttt	cat	gga	2472
	Tyr	Met	Val	Thr	Lys	Ile	Pro	Arg	Trp	Asp	Leu	Asp	Arg	Phe	His	Gly	
				770				775					780				
35	aca	tct	agc	cga	att	ggg	agc	tct	atg	aaa	agt	gta	gga	gag	gtc	atg	2520
	Thr	Ser	Ser	Arg	Ile	Gly	Ser	Ser	Met	Lys	Ser	Val	Gly	Glu	Val	Met	
		785				790						795					
	gct	att	ggg	cgt	acc	ttt	gag	gag	agt	ttc	cag	aaa	gct	tta	cgg	atg	2568
	Ala	Ile	Gly	Arg	Thr	Phe	Glu	Glu	Ser	Phe	Gln	Lys	Ala	Leu	Arg	Met	
					805					810					815		
40	tgc	cac	cca	tct	ata	gaa	ggg	ttc	act	ccc	cgt	ctc	cca	atg	aac	aaa	2616
	Cys	His	Pro	Ser	Ile	Glu	Gly	Phe	Thr	Pro	Arg	Leu	Pro	Met	Asn	Lys	
					820					825					830		
	gaa	tgg	cca	tct	aat	tta	gat	ctt	aga	aaa	gag	ttg	tct	gaa	cca	agc	2664
	Glu	Trp	Pro	Ser	Asn	Leu	Asp	Leu	Arg	Lys	Glu	Leu	Ser	Glu	Pro	Ser	
				835					840					845			
45	agc	acg	cgt	atc	tat	gcc	att	gcc	aag	gcc	att	gat	gac	aac	atg	tcc	2712
	Ser	Thr	Arg	Ile	Tyr	Ala	Ile	Ala	Lys	Ala	Ile	Asp	Asp	Asn	Met	Ser	
				850				855					860				
50	ctt	gat	gag	att	gag	aag	ctc	aca	tac	att	gac	aag	tgg	ttt	ttg	tat	2760
	Leu	Asp	Glu	Ile	Glu	Lys	Leu	Thr	Tyr	Ile	Asp	Lys	Trp	Phe	Leu	Tyr	
		865				870						875					
	aag	atg	cgt	gat	att	tta	aac	atg	gaa	aag	aca	ctg	aaa	ggg	ctc	aac	2808
	Lys	Met	Arg	Asp	Ile	Leu	Asn	Met	Glu	Lys	Thr	Leu	Lys	Gly	Leu	Asn	
		880				885					890				895		
55	agt	gag	tcc	atg	aca	gaa	gaa	acc	ctg	aaa	agg	gca	aag	gag	att	ggg	2856
	Ser	Glu	Ser	Met	Thr	Glu	Glu	Thr	Leu	Lys	Arg	Ala	Lys	Glu	Ile	Gly	

From: 12/20/2011 10:00 AM To: 12/20/2011 10:00 AM Subject: 12/20/2011 10:00 AM

	900	905	910	
5	ttc tca gat aag cag att tca aaa tgc ctt ggg ctc act gag gcc cag Phe Ser Asp Lys Gln Ile Ser Lys Cys Leu Gly Leu Thr Glu Ala Gln 915 920 925			2904
	aca agg gag ctg agg tta aag aaa aac atc cac cct tgg gtt aaa cag Thr Arg Glu Leu Arg Leu Lys Lys Asn Ile His Pro Trp Val Lys Gln 930 935 940			2952
10	att gat aca ctg gct gca gaa tac cca tca gta aca aac tat ctc tat Ile Asp Thr Leu Ala Ala Glu Tyr Pro Ser Val Thr Asn Tyr Leu Tyr 945 950 955			3000
	gtt acc tac aat ggt cag gag cat gat gtc aat ttt gat gac cat gga Val Thr Tyr Asn Gly Gln Glu His Asp Val Asn Phe Asp Asp His Gly 960 965 970 975			3048
15	atg atg gtg cta ggc tgt ggt cca tat cac att ggc agc agt gtg gaa Met Met Val Leu Gly Cys Gly Pro Tyr His Ile Gly Ser Ser Val Glu 980 985 990			3096
	ttt gat tgg tgt gct gtc tct agt atc cgc aca ctg cgt caa ctt ggc Phe Asp Trp Cys Ala Val Ser Ser Ile Arg Thr Leu Arg Gln Leu Gly 995 1000 1005			3144
20	aag aag acg gtg gtg gtg aat tgc aat cct gag act gtg agc aca gac Lys Lys Thr Val Val Val Asn Cys Asn Pro Glu Thr Val Ser Thr Asp 1010 1015 1020			3192
25	ttt gat gag tgt gac aaa ctg tac ttt gaa gag ttg tcc ttg gag aga Phe Asp Glu Cys Asp Lys Leu Tyr Phe Glu Glu Leu Ser Leu Glu Arg 1025 1030 1035			3240
	atc cta gac atc tac cat cag gag gca tgt ggt ggc tgc atc ata tca Ile Leu Asp Ile Tyr His Gln Glu Ala Cys Gly Gly Cys Ile Ile Ser 1040 1045 1050 1055			3288
30	gtt gga ggc cag att cca aac aac ctg gca gtt cct cta tac aag aat Val Gly Gly Gln Ile Pro Asn Asn Leu Ala Val Pro Leu Tyr Lys Asn 1060 1065 1070			3336
	ggg gtc aag atc atg ggc aca agc ccc ctg cag atc gac agg gct gag Gly Val Lys Ile Met Gly Thr Ser Pro Leu Gln Ile Asp Arg Ala Glu 1075 1080 1085			3384
35	gat cgc tcc atc ttc tca gct gtc ttg gat gag ctg aag gtg gct cag Asp Arg Ser Ile Phe Ser Ala Val Leu Asp Glu Leu Lys Val Ala Gln 1090 1095 1100			3432
40	gca cct tgg aaa gct gtt aat act ttg aat gaa gca ctg gaa ttt gca Ala Pro Trp Lys Ala Val Asn Thr Leu Asn Glu Ala Leu Glu Phe Ala 1105 1110 1115			3480
	aag tct gtg gac tac ccc tgc ttg ttg agg cct tcc tat gtt ttg agt Lys Ser Val Asp Tyr Pro Cys Leu Leu Arg Pro Ser Tyr Val Leu Ser 1120 1125 1130 1135			3528
45	ggg tct gct atg aat gtg gta ttc tct gag gat gag atg aaa aaa ttc Gly Ser Ala Met Asn Val Val Phe Ser Glu Asp Glu Met Lys Lys Phe 1140 1145 1150			3576
	cta gaa gag gcg act aga gtt tct cag gag cac cca gtg gtc ctg aca Leu Glu Glu Ala Thr Arg Val Ser Gln Glu His Pro Val Val Leu Thr 1155 1160 1165			3624
50	aaa ttt gtt gaa ggg gcc cga gaa gta gaa atg gac gct gtt ggc aaa Lys Phe Val Glu Gly Ala Arg Glu Val Glu Met Asp Ala Val Gly Lys 1170 1175 1180			3672
55	gat gga agg gtt atc tct cat gcc atc tct gaa cat gtt gaa gat gca Asp Gly Arg Val Ile Ser His Ala Ile Ser Glu His Val Glu Asp Ala 1185 1190 1195			3720

	ggt gtc cac tcg gga gat gcc act ctg atg ctg ccc aca caa acc atc 3768 Gly Val His Ser Gly Asp Ala Thr Leu Met Leu Pro Thr Gln Thr Ile 1200 1205 1210 1215
5	agc caa ggg gcc att gaa aag gtg aag gat gct acc cgg aag att gca 3816 Ser Gln Gly Ala Ile Glu Lys Val Lys Asp Ala Thr Arg Lys Ile Ala 1220 1225 1230
	aag gct ttt gcc atc tct ggt cca ttc aac gtc caa ttt ctt gtc aaa 3864 Lys Ala Phe Ala Ile Ser Gly Pro Phe Asn Val Gln Phe Leu Val Lys 1235 1240 1245
10	gga aat gat gtc ttg gtg att gag tgt aac ttg aga gct tct cga tcc 3912 Gly Asn Asp Val Leu Val Ile Glu Cys Asn Leu Arg Ala Ser Arg Ser 1250 1255 1260
15	ttc ccc ttt gtt tcc aag act ctt ggg gtt gac ttc att gat gtg gcc 3960 Phe Pro Phe Val Ser Lys Thr Leu Gly Val Asp Phe Ile Asp Val Ala 1265 1270 1275
	acc aag gtg atg att gga gag aat gtt gat gag aaa cat ctt cca aca 4008 Thr Lys Val Met Ile Gly Glu Asn Val Asp Glu Lys His Leu Pro Thr 1280 1285 1290 1295
20	ttg gac cat ccc ata att cct gct gac tat gtt gca att aag gct ccc 4056 Leu Asp His Pro Ile Ile Pro Ala Asp Tyr Val Ala Ile Lys Ala Pro 1300 1305 1310
	atg ttt tcc tgg ccc cgg ttg agg gat gct gac ccc att ctg aga tgt 4104 Met Phe Ser Trp Pro Arg Leu Arg Asp Ala Asp Pro Ile Leu Arg Cys 1315 1320 1325
25	gag atg gct tcc act gga gag gtg gct tgc ttt ggt gaa ggt att cat 4152 Glu Met Ala Ser Thr Gly Glu Val Ala Cys Phe Gly Glu Gly Ile His 1330 1335 1340
30	aca gcc ttc cta aag gca atg ctt tcc aca gga ttt aag ata ccc cag 4200 Thr Ala Phe Leu Lys Ala Met Leu Ser Thr Gly Phe Lys Ile Pro Gln 1345 1350 1355
	aaa ggc atc ctg ata ggc atc cag caa tca ttc cgg cca aga ttc ctt 4248 Lys Gly Ile Leu Ile Gly Ile Gln Gln Ser Phe Arg Pro Arg Phe Leu 1360 1365 1370 1375
35	ggt gtg gct gaa caa tta cac aat gaa ggt ttc aag ctg ttt gcc acg 4296 Gly Val Ala Glu Gln Leu His Asn Glu Gly Phe Lys Leu Phe Ala Thr 1380 1385 1390
	gaa gcc aca tca gac tgg ctc aac gcc aac aat gtc cct gcc aac cca 4344 Glu Ala Thr Ser Asp Trp Leu Asn Ala Asn Asn Val Pro Ala Asn Pro 1395 1400 1405
40	gtg gca tgg ccg tct caa gaa gga cag aat ccc agc ctc tct tcc atc 4392 Val Ala Trp Pro Ser Gln Glu Gly Gln Asn Pro Ser Leu Ser Ser Ile 1410 1415 1420
45	aga aaa ttg att aga gat ggc agc att gac cta gtg att aac ctt ccc 4440 Arg Lys Leu Ile Arg Asp Gly Ser Ile Asp Leu Val Ile Asn Leu Pro 1425 1430 1435
	aac aac aac act aaa ttt gtc cat gat aat tat gtg att cgg agg aca 4488 Asn Asn Asn Thr Lys Phe Val His Asp Asn Tyr Val Ile Arg Arg Thr 1440 1445 1450 1455
50	gct gtt gat agt gga atc cct ctc ctc act aat ttt cag gtg acc aaa 4536 Ala Val Asp Ser Gly Ile Pro Leu Leu Thr Asn Phe Gln Val Thr Lys 1460 1465 1470
	ctt ttt gct gaa gct gtg cag aaa tct cgc aag gtg gac tcc aag agt 4584 Leu Phe Ala Glu Ala Val Gln Lys Ser Arg Lys Val Asp Ser Lys Ser 1475 1480 1485
55	ctt ttc cac tac agg cag tac agt gct gga aaa gca gca tag 4626

1234567891011121314151617181920212223242526272829303132333435363738394041424344454647484950515253545556575859606162636465666768697071727374757677787980818283848586878889909192939495969798991001011021031041051061071081091101111121131141151161171181191201211221231241251261271281291301311321331341351361371381391401411421431441451461471481491501511521531541551561571581591601611621631641651661671681691701711721731741751761771781791801811821831841851861871881891901911921931941951961971981992002012022032042052062072082092102112122132142152162172182192202212222232242252262272282292302312322332342352362372382392402412422432442452462472482492502512522532542552562572582592602612622632642652662672682692702712722732742752762772782792802812822832842852862872882892902912922932942952962972982993003013023033043053063073083093103113123133143153163173183193203213223233243253263273283293303313323333343353363373383393403413423433443453463473483493503513523533543553563573583593603613623633643653663673683693703713723733743753763773783793803813823833843853863873883893903913923933943953963973983994004014024034044054064074084094104114124134144154164174184194204214224234244254264274284294304314324334344354364374384394404414424434444454464474484494504514524534544554564574584594604614624634644654664674684694704714724734744754764774784794804814824834844854864874884894904914924934944954964974984995005015025035045055065075085095105115125135145155165175185195205215225235245255265275285295305315325335345355365375385395405415425435445455465475485495505515525535545555565575585595605615625635645655665675685695705715725735745755765775785795805815825835845855865875885895905915925935945955965975985996006016026036046056066076086096106116126136146156166176186196206216226236246256266276286296306316326336346356366376386396406416426436446456466476486496506516526536546556566576586596606616626636646656666676686696706716726736746756766776786796806816826836846856866876886896906916926936946956966976986997007017027037047057067077087097107117127137147157167177187197207217227237247257267277287297307317327337347357367377387397407417427437447457467477487497507517527537547557567577587597607617627637647657667677687697707717727737747757767777787797807817827837847857867877887897907917927937947957967977987998008018028038048058068078088098108118128138148158168178188198208218228238248258268278288298308318328338348358368378388398408418428438448458468478488498508518528538548558568578588598608618628638648658668678688698708718728738748758768778788798808818828838848858868878888898908918928938948958968978988999009019029039049059069079089099109119129139149159169179189199209219229239249259269279289299309319329339349359369379389399409419429439449459469479489499509519529539549559569579589599609619629639649659669679689699709719729739749759769779789799809819829839849859869879889899909919929939949959969979989991000100110021003100410051006100710081009101010111012101310141015101610171018101910201021102210231024102510261027102810291030103110321033103410351036103710381039104010411042104310441045104610471048104910501051105210531054105510561057105810591060106110621063106410651066106710681069107010711072107310741075107610771078107910801081108210831084108510861087108810891090109110921093109410951096109710981099110011011102110311041105110611071108110911101111111211131114111511161117111811191120112111221123112411251126112711281129113011311132113311341135113611371138113911401141114211431144114511461147114811491150115111521153115411551156115711581159116011611162116311641165116611671168116911701171117211731174117511761177117811791180118111821183118411851186118711881189119011911192119311941195119611971198119912001201120212031204120512061207120812091210121112121213121412151216121712181219122012211222122312241225122612271228122912301231123212331234123512361237123812391240124112421243124412451246124712481249125012511252125312541255125612571258125912601261126212631264126512661267126812691270127112721273127412751276127712781279128012811282128312841285128612871288128912901291129212931294129512961297129812991300130113021303130413051306130713081309131013111312131313141315131613171318131913201321132213231324132513261327132813291330133113321333133413351336133713381339134013411342134313441345134613471348134913501351135213531354135513561357135813591360136113621363136413651366136713681369137013711372137313741375137613771378137913801381138213831384138513861387138813891390139113921393139413951396139713981399140014011402140314041405140614071408140914101411141214131414141514161417141814191420142114221423142414251426142714281429143014311432143314341435143614371438143914401441144214431444144514461447144814491450145114521453145414551456145714581459146014611462146314641465146614671468146914701471147214731474147514761477147814791480148114821483148414851486148714881489149014911492149314941495149614971498149915001501150215031504150515061507150815091510151115121513151415151516151715181519152015211522152315241525152615271528152915301531153215331534153515361537153815391540154115421543154415451546154715481549155015511552155315541555155615571558155915601561156215631564156515661567156815691570157115721573157415751576157715781579158015811582158315841585158615871588158915901591159215931594159515961597159815991600160116021603160416051606160716081609161016111612161316141615161616171618161916201621162216231624162516261627162816291630163116321633163416351636163716381639164016411642164316441645164616471648164916501651165216531654165516561657165816591660166116621663166416651666166716681669167016711672167316741675167616771678167916801681168216831684168516861687168816891690169116921693169416951696169716981699170017011702170317041705170617071708170917101711171217131714171517161717171817191720172117221723172417251726172717281729173017311732173317341735173617371738173917401741174217431744174517461747174817491750175117521753175417551756175717581759176017611762176317641765176617671768176917701771177217731774177517761777177817791780178117821783178417851786178717881789179017911792179317941795179617971798179918001801180218031804180518061807180818091810181118121813181418151816181718181819182018211822182318241825182618271828182918301831183218331834183518361837183818391840184118421843184418451846184718481849185018511852185318541855185618571858185918601861186218631864186518661867186818691870187118721873187418751876187718781879188018811882188318841885188618871888188918901891189218931894189518961897189818991900190119021903190419051906190719081909191019111912191319141915191619171918191919201921192219231924192519261927192819291930193119321933193419351936193719381939194019411942194319441945194619471948194919501951195219531954195519561957195819591960196119621963196419651966196719681969197019711972197319741975197619771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029203020312032203320342035203620372038203920402041204220432044204520462047204820492050205120522053205420552056205720582059206020612062206320642065206620672068206920702071207220732074207520762077207820792080208120822083208420852086208720882089209020912092209320942095209620972098209921002101210221032104210521062107210821092110211121122113211421152116211721182119212021212122212321242125212621272128212921302131213221332134213521362137213821392140214121422143214421452146214721482149215021512152215321542155215621572158215921602161216221632164216521662167216821692170217121722173217421752176217721782179218021812182218321842185218621872188218921902191219221932194219521962197219821992200220122022203220422052206220722082209221022112212221322142215221622172218221922202221222222232224222522262227222822292230223122322233223422352236223722382239224022412242224322442245224622472248224922502251225222532254225522562257225822592260226122622263226422652266226722682269227022712272227322742275227622772278227922802281228222832284228522862287228822892290229122922293229422952296229722982299230023012302230323042305230623072308230923102311231223132314231523162317231823192320232123222323232423252326232723282329233023312332233323342335233623372338233923402341234223432344234523462347234823492350235123522353235423552356235723582359236023612362236323642365236623672368236923702371237223732374237523762377237823792380238123822383238423852386238723882389239023912392239323942395239623972398239924002401240224032404240524062407240824092410241124122413241424152416241724182419242024212422242324242425242624272428242924302431243224332434243524362437243824392440244124422443244424452446244724482449245024512452245324542455245624572458245924602461246224632464246524662467246824692470247124722473247424752476247724782479248024812482248324842485248624872488248924902491249224932494249524962497249824992500250125022503250425052506250725082509251025112512251325142515251625172518251925202521252225232524252525262527252825292530253125322533253425352536253725382539254025412542254325442545254625472548254925502551255225532554255525562557255825592560256125622563256425652566256725682569257025712572257325742575257625772578257925802581258225832584258525862587258825892590259125922593259425952596259725982599260026012602260326042605260626072608260926102611261226132614261526162617261826192620262126222623262426252626262726282629263026312632263326342635263626372638263926402641264226432644264526462647264826492650265126522653265426552656265726582659266026612662266326642665266626672668266926702671267226732674267526762677267826792680268126822683268426852686268726882689269026912692269326942695269626972698269927002701270227032704270527062707270827092710271127122713271427152716271727182719272027212722272327242725272627272728272927302731273227332734273527362737273827392740274127422743274427452746274727482749275027512752275327542755275627572758275927602761276227632764276527662767276827692770277127722773277427752776277727782779278027812782278327842785278627872788278927902791279227932794279527962797279827992800280128022803280428052806280728082809281028112812281328142815281628172818281928202821282228232824282528262827282828292830283128322833283428352836283728382839284028412842284328442845284628472848284928502851285228532854285528562857285828592860286128622863286428652866286728682869287028712872287328742875287628772878287928802881288228832884288528862887288828892890289128922893289428952896289728982899290029012902290329042905290629072908290929102911291229132914291529162917291829192920292129222923292429252926292729

Leu Phe His Tyr Arg Gln Tyr Ser Ala Gly Lys Ala Ala
1490 1495 1500

agatgcagac accccagccc cattattaaa tcaacctgag ccacatgtta tctaaaggaa 4686
ctgattcaca actttctcag agatgaatat tgataactaa acttcatttc agtttacttt 4746
5 gttatgcctt aatattctgt gtcttttgca attaaattgt cagtcacttc ttcaaaacct 4806
tacagtccct cctaagttac tcttcatgag atttcatcca ttactaata ctgtattttt 4866
ggtaggactag gcttgcctat gtgcttatgt gtagcttttt actttttatg gtgctgatta 4926
atggtgatca aggtaggaaa agttgctgtt ctattttctg aactctttct atactttaag 4986
atactctatt tttaaaacac tatctgcaaa ctcaggacac tttaacaggg cagaatactc 5046
10 taaaaacttg ataaaatgaa atatagattt aatttatgaa ccttccatca tgatgtttgt 5106
gtattgcttc tttttggatc ctcatctca cccatttggc taatccagga atattgttat 5166
cccttcccat tatattgaag ttgagaaatg tgacagaggc atttagagta tggacttttc 5226
ttttcttttt cttttctttt ttttctttt gagatggagt cacactctcc aggctggagt 5286
gcagtggcac aatctcggt cactgcaatt tgcgtctccc aagttcaagc gattctcctg 5346
15 ctttagacta tggatttctt taaggaatac tggtttgag tttgttttc tggactatat 5406
cagcagatgg tagacagtgt ttatgtagat gtgtgttgt tttatcatt ggattttaac 5466
ttggcccagag tgaaataatc agattttgt cattcacact ctccccagt tttggaataa 5526
cttgaagta aggttcattc ccttaagacg atggattctg ttgaactatg ggggtcccaca 5586
ctgcactatt aattccaccc actgaaggg caaggacacc attccttcta catataagaa 5646
20 aaaagtctct cccaagggc agcctttgtt acttttaaat attttctgtt attacaagtg 5706
ctctaattgt gaacttttaa ataaaatact attaagaggt aaaaaaaaaa aaaaa 5761

<210> 2

<211> 1500

<212> PRT

25 <213> Homo sapiens

<400> 2

Met Thr Arg Ile Leu Thr Ala Phe Lys Val Val Arg Thr Leu Lys Thr
1 5 10 15
30 Gly Phe Gly Phe Thr Asn Val Thr Ala His Gln Lys Trp Lys Phe Ser
20 25 30
Arg Pro Gly Ile Arg Leu Leu Ser Val Lys Ala Gln Thr Ala His Ile
35 40 45
Val Leu Glu Asp Gly Thr Lys Met Lys Gly Tyr Ser Phe Gly His Pro
50 55 60
35 Ser Ser Val Ala Gly Glu Val Val Phe Asn Thr Gly Leu Gly Gly Tyr
65 70 75 80
Pro Glu Ala Ile Thr Asp Pro Ala Tyr Lys Gly Gln Ile Leu Thr Met
85 90 95

Ala Asn Pro Ile Ile Gly Asn Gly Gly Ala Pro Asp Thr Thr Ala Leu
100 105 110
Asp Glu Leu Gly Leu Ser Lys Tyr Leu Glu Ser Asn Gly Ile Lys Val
115 120 125

5 Ser Gly Leu Leu Val Leu Asp Tyr Ser Lys Asp Tyr Asn His Trp Leu
130 135 140

Ala Thr Lys Ser Leu Gly Gln Trp Leu Gln Glu Glu Lys Val Pro Ala
145 150 155 160

10 Ile Tyr Gly Val Asp Thr Arg Met Leu Thr Lys Ile Ile Arg Asp Lys
165 170 175

Gly Thr Met Leu Gly Lys Ile Glu Phe Glu Gly Gln Pro Val Asp Phe
180 185 190

Val Asp Pro Asn Lys Gln Asn Leu Ile Ala Glu Val Ser Thr Lys Asp
195 200 205

15 Val Lys Val Tyr Gly Lys Gly Asn Pro Thr Lys Val Val Ala Val Asp
210 215 220

Cys Gly Ile Lys Asn Asn Val Ile Arg Leu Leu Val Lys Arg Gly Ala
225 230 235 240

20 Glu Val His Leu Val Pro Trp Asn His Asp Phe Thr Lys Met Glu Tyr
245 250 255

Asp Gly Ile Leu Ile Ala Gly Gly Pro Gly Asn Pro Ala Leu Ala Glu
260 265 270

Pro Leu Ile Gln Asn Val Arg Lys Ile Leu Glu Ser Asp Arg Lys Glu
275 280 285

25 Pro Leu Phe Gly Ile Ser Thr Gly Asn Leu Ile Thr Gly Leu Ala Ala
290 295 300

Gly Ala Lys Thr Tyr Lys Met Ser Met Ala Asn Arg Gly Gln Asn Gln
305 310 315 320

30 Pro Val Leu Asn Ile Thr Asn Lys Gln Ala Phe Ile Thr Ala Gln Asn
325 330 335

His Gly Tyr Ala Leu Asp Asn Thr Leu Pro Ala Gly Trp Lys Pro Leu
340 345 350

Phe Val Asn Val Asn Asp Gln Thr Asn Glu Gly Ile Met His Glu Ser
355 360 365

35 Lys Pro Phe Phe Ala Val Gln Phe His Pro Glu Val Thr Pro Gly Pro
370 375 380

Ile Asp Thr Glu Tyr Leu Phe Asp Ser Phe Phe Ser Leu Ile Lys Lys
385 390 395 400

40 Gly Lys Ala Thr Thr Ile Thr Ser Val Leu Pro Lys Pro Ala Leu Val
405 410 415

Ala Ser Arg Val Glu Val Ser Lys Val Leu Ile Leu Gly Ser Gly Gly
420 425 430

Leu Ser Ile Gly Gln Ala Gly Glu Phe Asp Tyr Ser Gly Ser Gln Ala
435 440 445

45 Val Lys Ala Met Lys Glu Glu Asn Val Lys Thr Val Leu Met Asn Pro
450 455 460

Asn Ile Ala Ser Val Gln Thr Asn Glu Val Gly Leu Lys Gln Ala Asp
465 470 475 480

50 Thr Val Tyr Phe Leu Pro Ile Thr Pro Gln Phe Val Thr Glu Val Ile
485 490 495

Lys Ala Glu Gln Pro Asp Gly Leu Ile Leu Gly Met Gly Gly Gln Thr
500 505 510

Ala Leu Asn Cys Gly Val Glu Leu Phe Lys Arg Gly Val Leu Lys Glu
515 520 525

5 Tyr Gly Val Lys Val Leu Gly Thr Ser Val Glu Ser Ile Met Ala Thr
530 535 540

Glu Asp Arg Gln Leu Phe Ser Asp Lys Leu Asn Glu Ile Asn Glu Lys
545 550 555 560

10 Ile Ala Pro Ser Phe Ala Val Glu Ser Ile Glu Asp Ala Leu Lys Ala
565 570 575

Ala Asp Thr Ile Gly Tyr Pro Val Met Ile Arg Ser Ala Tyr Ala Leu
580 585 590

Gly Gly Leu Gly Ser Gly Ile Cys Pro Asn Arg Glu Thr Leu Met Asp
595 600 605

15 Leu Ser Thr Lys Ala Phe Ala Met Thr Asn Gln Ile Leu Val Glu Lys
610 615 620

Ser Val Thr Gly Trp Lys Glu Ile Glu Tyr Glu Val Val Arg Asp Ala
625 630 635 640

20 Asp Asp Asn Cys Val Thr Val Cys Asn Met Glu Asn Val Asp Ala Met
645 650 655

Gly Val His Thr Gly Asp Ser Val Val Val Ala Pro Ala Gln Thr Leu
660 665 670

Ser Asn Ala Glu Phe Gln Met Leu Arg Arg Thr Ser Ile Asn Val Val
675 680 685

25 Arg His Leu Gly Ile Val Gly Glu Cys Asn Ile Gln Phe Ala Leu His
690 695 700

Pro Thr Ser Met Glu Tyr Cys Ile Ile Glu Val Asn Ala Arg Leu Ser
705 710 715 720

30 Arg Ser Ser Ala Leu Ala Ser Lys Ala Thr Gly Tyr Pro Leu Ala Phe
725 730 735

Ile Ala Ala Lys Ile Ala Leu Gly Ile Pro Leu Pro Glu Ile Lys Asn
740 745 750

Val Val Ser Gly Lys Thr Ser Ala Cys Phe Glu Pro Ser Leu Asp Tyr
755 760 765

35 Met Val Thr Lys Ile Pro Arg Trp Asp Leu Asp Arg Phe His Gly Thr
770 775 780

Ser Ser Arg Ile Gly Ser Ser Met Lys Ser Val Gly Glu Val Met Ala
785 790 795 800

40 Ile Gly Arg Thr Phe Glu Glu Ser Phe Gln Lys Ala Leu Arg Met Cys
805 810 815

His Pro Ser Ile Glu Gly Phe Thr Pro Arg Leu Pro Met Asn Lys Glu
820 825 830

Trp Pro Ser Asn Leu Asp Leu Arg Lys Glu Leu Ser Glu Pro Ser Ser
835 840 845

45 Thr Arg Ile Tyr Ala Ile Ala Lys Ala Ile Asp Asp Asn Met Ser Leu
850 855 860

Asp Glu Ile Glu Lys Leu Thr Tyr Ile Asp Lys Trp Phe Leu Tyr Lys
865 870 875 880

Met Arg Asp Ile Leu Asn Met Glu Lys Thr Leu Lys Gly Leu Asn Ser

					885					890					895	
					Glu Ser Met Thr	Glu Glu Thr	Leu Lys Arg	Ala Lys	Glu Ile	Gly Phe						
					900		905		910							
5					Ser Asp Lys Gln	Ile Ser Lys	Cys Leu Gly	Leu Thr	Glu Ala	Gln Thr						
					915		920		925							
					Arg Glu Leu Arg	Leu Lys Lys	Asn Ile His	Pro Trp	Val Lys	Gln Ile						
					930		935		940							
					Asp Thr Leu Ala	Ala Glu Tyr	Pro Ser Val	Thr Asn	Tyr Leu	Tyr Val						
					945		950		955							
10					Thr Tyr Asn Gly	Gln Glu His	Asp Val Asn	Phe Asp	Asp His	Gly Met						
					965		970		975							
					Met Val Leu Gly	Cys Gly Pro	Tyr His Ile	Gly Ser	Ser Val	Glu Phe						
					980		985		990							
15					Asp Trp Cys Ala	Val Ser Ser	Ile Arg Thr	Leu Arg	Gln Leu	Gly Lys						
					995		1000		1005							
					Lys Thr Val Val	Val Asn Cys	Asn Pro Glu	Thr Val	Ser Thr	Asp Phe						
					1010		1015		1020							
					Asp Glu Cys Asp	Lys Leu Tyr	Phe Glu Glu	Leu Ser	Leu Glu	Arg Ile						
					025		1030		1035							
20					Leu Asp Ile Tyr	His Gln Glu	Ala Cys Gly	Gly Cys	Ile Ile	Ser Val						
					1045		1050		1055							
					Gly Gly Gln Ile	Pro Asn Asn	Leu Ala Val	Pro Leu	Tyr Lys	Asn Gly						
					1060		1065		1070							
25					Val Lys Ile Met	Gly Thr Ser	Pro Leu Gln	Ile Asp	Arg Ala	Glu Asp						
					1075		1080		1085							
					Arg Ser Ile Phe	Ser Ala Val	Leu Asp Glu	Leu Lys	Val Ala	Gln Ala						
					1090		1095		1100							
					Pro Trp Lys Ala	Val Asn Thr	Leu Asn Glu	Ala Leu	Glu Phe	Ala Lys						
					105		1110		1115							
30					Ser Val Asp Tyr	Pro Cys Leu	Leu Arg Pro	Ser Tyr	Val Leu	Ser Gly						
					1125		1130		1135							
					Ser Ala Met Asn	Val Val Phe	Ser Glu Asp	Glu Met	Lys Lys	Phe Leu						
					1140		1145		1150							
35					Glu Glu Ala Thr	Arg Val Ser	Gln Glu His	Pro Val	Val Leu	Thr Lys						
					1155		1160		1165							
					Phe Val Glu Gly	Ala Arg Glu	Val Glu Met	Asp Ala	Val Gly	Lys Asp						
					1170		1175		1180							
					Gly Arg Val Ile	Ser His Ala	Ile Ser Glu	His Val	Glu Asp	Ala Gly						
					185		1190		1195							
40					Val His Ser Gly	Asp Ala Thr	Leu Met Leu	Pro Thr	Gln Thr	Ile Ser						
					1205		1210		1215							
					Gln Gly Ala Ile	Glu Lys Val	Lys Asp Ala	Thr Arg	Lys Ile	Ala Lys						
					1220		1225		1230							
45					Ala Phe Ala Ile	Ser Gly Pro	Phe Asn Val	Gln Phe	Leu Val	Lys Gly						
					1235		1240		1245							
					Asn Asp Val Leu	Val Ile Glu	Cys Asn Leu	Arg Ala	Ser Arg	Ser Phe						
					1250		1255		1260							
					Pro Phe Val Ser	Lys Thr Leu	Gly Val Asp	Phe Ile	Asp Val	Ala Thr						
					265		1270		1275							

Lys Val Met Ile Gly Glu Asn Val Asp Glu Lys His Leu Pro Thr Leu
1285 1290 1295

Asp His Pro Ile Ile Pro Ala Asp Tyr Val Ala Ile Lys Ala Pro Met
1300 1305 1310

5 Phe Ser Trp Pro Arg Leu Arg Asp Ala Asp Pro Ile Leu Arg Cys Glu
1315 1320 1325

Met Ala Ser Thr Gly Glu Val Ala Cys Phe Gly Glu Gly Ile His Thr
1330 1335 1340

10 Ala Phe Leu Lys Ala Met Leu Ser Thr Gly Phe Lys Ile Pro Gln Lys
345 1350 1355 1360

Gly Ile Leu Ile Gly Ile Gln Gln Ser Phe Arg Pro Arg Phe Leu Gly
1365 1370 1375

Val Ala Glu Gln Leu His Asn Glu Gly Phe Lys Leu Phe Ala Thr Glu
1380 1385 1390

15 Ala Thr Ser Asp Trp Leu Asn Ala Asn Asn Val Pro Ala Asn Pro Val
1395 1400 1405

Ala Trp Pro Ser Gln Glu Gly Gln Asn Pro Ser Leu Ser Ser Ile Arg
1410 1415 1420

20 Lys Leu Ile Arg Asp Gly Ser Ile Asp Leu Val Ile Asn Leu Pro Asn
425 1430 1435 1440

Asn Asn Thr Lys Phe Val His Asp Asn Tyr Val Ile Arg Arg Thr Ala
1445 1450 1455

Val Asp Ser Gly Ile Pro Leu Leu Thr Asn Phe Gln Val Thr Lys Leu
1460 1465 1470

25 Phe Ala Glu Ala Val Gln Lys Ser Arg Lys Val Asp Ser Lys Ser Leu
1475 1480 1485

Phe His Tyr Arg Gln Tyr Ser Ala Gly Lys Ala Ala
1490 1495 1500

<210> 3

30 <211> 5761

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

35 <222> (124)..(4626)

<400> 3

gtcagcctta aacctgact gcacccctcc cagatttctt ttacattaac taaaaagtct 60

tatcacacaa tctcataaaa tttatgtaat ttcatttaat tttagccaca aatcatcttc 120

40 aaa atg acg agg att ttg aca gct ttc aaa gtg gtg agg aca ctg aag 168
Met Thr Arg Ile Leu Thr Ala Phe Lys Val Val Arg Thr Leu Lys

	1	5	10	15	
	act ggt ttt ggc ttt acc aat gtg act gca cac caa aaa tgg aaa ttt				216
	Thr Gly Phe Gly Phe Thr Asn Val Thr Ala His Gln Lys Trp Lys Phe				
	20	25	30		
5	tca aga cct ggc atc agg ctc ctt tct gtc aag gca cag aca gca cac				264
	Ser Arg Pro Gly Ile Arg Leu Leu Ser Val Lys Ala Gln Thr Ala His				
	35	40	45		
10	att gtc ctg gaa gat gga act aag atg aaa ggt tac tcc ttt ggc cat				312
	Ile Val Leu Glu Asp Gly Thr Lys Met Lys Gly Tyr Ser Phe Gly His				
	50	55	60		
	cca tcc tct gtt gct ggt gaa gtg gtt ttt aat act ggc ctg gga ggg				360
	Pro Ser Ser Val Ala Gly Glu Val Val Phe Asn Thr Gly Leu Gly Gly				
	65	70	75		
15	tac cca gaa gct att act gac cct gcc tac aaa gga cag att ctc aca				408
	Tyr Pro Glu Ala Ile Thr Asp Pro Ala Tyr Lys Gly Gln Ile Leu Thr				
	80	85	90		
	atg gcc aac cct att att ggg aat ggt gga gct cct gat act act gct				456
	Met Ala Asn Pro Ile Ile Gly Asn Gly Gly Ala Pro Asp Thr Thr Ala				
	100	105	110		
20	ctg gat gaa ctg gga ctt agc aaa tat ttg gag tct aat gga atc aag				504
	Leu Asp Glu Leu Gly Leu Ser Lys Tyr Leu Glu Ser Asn Gly Ile Lys				
	115	120	125		
25	gtt tca ggt ttg ctg gtg ctg gat tat agt aaa gac tac aac cac tgg				552
	Val Ser Gly Leu Leu Val Leu Asp Tyr Ser Lys Asp Tyr Asn His Trp				
	130	135	140		
	ctg gct acc aag agt tta ggg caa tgg cta cag gaa gaa aag gtt cct				600
	Leu Ala Thr Lys Ser Leu Gly Gln Trp Leu Gln Glu Glu Lys Val Pro				
	145	150	155		
30	gca att tat gga gtg gac aca aga atg ctg act aaa ata att cgg gat				648
	Ala Ile Tyr Gly Val Asp Thr Arg Met Leu Thr Lys Ile Ile Arg Asp				
	160	165	170		
	aag ggt acc atg ctt ggg aag att gaa ttt gaa ggt cag cct gtg gat				696
	Lys Gly Thr Met Leu Gly Lys Ile Glu Phe Glu Gly Gln Pro Val Asp				
	180	185	190		
35	ttt gtg gat cca aat aaa cag aat ttg att gct gag gtt tca acc aag				744
	Phe Val Asp Pro Asn Lys Gln Asn Leu Ile Ala Glu Val Ser Thr Lys				
	195	200	205		
40	gat gtc aaa gtg tac ggc aaa gga aac ccc aca aaa gtg gta gct gta				792
	Asp Val Lys Val Tyr Gly Lys Gly Asn Pro Thr Lys Val Val Ala Val				
	210	215	220		
	gac tgt ggg att aaa aac aat gta atc cgc ctg cta gta aag cga gga				840
	Asp Cys Gly Ile Lys Asn Asn Val Ile Arg Leu Leu Val Lys Arg Gly				
	225	230	235		
45	gct gaa gtg cac tta gtt ccc tgg aac cat gat ttc acc aag atg gag				888
	Ala Glu Val His Leu Val Pro Trp Asn His Asp Phe Thr Lys Met Glu				
	240	245	250		
	tat gat ggg att ttg atc gcg gga gga ccg ggg aac cca gct ctt gca				936
	Tyr Asp Gly Ile Leu Ile Ala Gly Gly Pro Gly Asn Pro Ala Leu Ala				
	260	265	270		
50	gaa cca cta att cag aat gtc aga aag att ttg gag agt gat cgc aag				984
	Glu Pro Leu Ile Gln Asn Val Arg Lys Ile Leu Glu Ser Asp Arg Lys				
	275	280	285		
55	gag cca ttg ttt gga atc agt aca gga aac tta ata aca gga ttg gct				1032
	Glu Pro Leu Phe Gly Ile Ser Thr Gly Asn Leu Ile Thr Gly Leu Ala				
	290	295	300		

		gct ggt gcc aaa acc tac aag atg tcc atg gcc aac aga ggg cag aat	1080
		Ala Gly Ala Lys Thr Tyr Lys Met Ser Met Ala Asn Arg Gly Gln Asn	
		305 310 315	
5		cag cct gtt ttg aat atc aca aac aaa cag gct ttc att act gct cag	1128
		Gln Pro Val Leu Asn Ile Thr Asn Lys Gln Ala Phe Ile Thr Ala Gln	
		320 325 330 335	
		aat cat ggc tat gcc ttg gac aac acc ctc cct gct ggc tgg aaa cca	1176
		Asn His Gly Tyr Ala Leu Asp Asn Thr Leu Pro Ala Gly Trp Lys Pro	
		340 345 350	
10		ctt ttt gtg aat gtc aac gat caa aca aat gag ggg att atg cat gag	1224
		Leu Phe Val Asn Val Asn Asp Gln Thr Asn Glu Gly Ile Met His Glu	
		355 360 365	
15		agc aaa ccc ttc ttc gct gtg cag ttc cac cca gag gtc acc ccg ggg	1272
		Ser Lys Pro Phe Phe Ala Val Gln Phe His Pro Glu Val Thr Pro Gly	
		370 375 380	
		cca ata gac act gag tac ctg ttt gat tcc ttt ttc tca ctg ata aag	1320
		Pro Ile Asp Thr Glu Tyr Leu Phe Asp Ser Phe Phe Ser Leu Ile Lys	
		385 390 395	
20		aaa gga aaa gct acc acc att aca tca gtc tta ccg aag cca gca cta	1368
		Lys Gly Lys Ala Thr Thr Ile Thr Ser Val Leu Pro Lys Pro Ala Leu	
		400 405 410 415	
		ggt gca tct cgg gtt gag gtt tcc aaa gtc ctt att cta gga tca gga	1416
		Val Ala Ser Arg Val Glu Val Ser Lys Val Leu Ile Leu Gly Ser Gly	
		420 425 430	
25		ggt ctg tcc att ggt cag gct gga gaa ttt gat tac tca gga tct caa	1464
		Gly Leu Ser Ile Gly Gln Ala Gly Glu Phe Asp Tyr Ser Gly Ser Gln	
		435 440 445	
30		gct gta aaa gcc atg aag gaa gaa aat gtc aaa act gtt ctg atg aac	1512
		Ala Val Lys Ala Met Lys Glu Glu Asn Val Lys Thr Val Leu Met Asn	
		450 455 460	
		cca aac att gca tca gtc cag acc aat gag gtg ggc tta aag caa gcg	1560
		Pro Asn Ile Ala Ser Val Gln Thr Asn Glu Val Gly Leu Lys Gln Ala	
		465 470 475	
35		gat act gtc tac ttt ctt ccc atc acc cct cag ttt gtc aca gag gtc	1608
		Asp Thr Val Tyr Phe Leu Pro Ile Thr Pro Gln Phe Val Thr Glu Val	
		480 485 490 495	
		atc aag gca gaa cag cca gat ggg tta att ctg ggc atg ggt ggc cag	1656
		Ile Lys Ala Glu Gln Pro Asp Gly Leu Ile Leu Gly Met Gly Gly Gln	
		500 505 510	
40		aca gct ctg aac tgt gga gtg gaa cta ttc aag aga ggt gtg ctc aag	1704
		Thr Ala Leu Asn Cys Gly Val Glu Leu Phe Lys Arg Gly Val Leu Lys	
		515 520 525	
45		gaa tat ggt gtg aaa gtc ctg gga act tca gtt gag tcc att atg gct	1752
		Glu Tyr Gly Val Lys Val Leu Gly Thr Ser Val Glu Ser Ile Met Ala	
		530 535 540	
		acg gaa gac agg cag ctg ttt tca gat aaa cta aat gag atc aat gaa	1800
		Thr Glu Asp Arg Gln Leu Phe Ser Asp Lys Leu Asn Glu Ile Asn Glu	
		545 550 555	
50		aag att gct cca agt ttt gca gtg gaa tcg att gag gat gca ctg aag	1848
		Lys Ile Ala Pro Ser Phe Ala Val Glu Ser Ile Glu Asp Ala Leu Lys	
		560 565 570 575	
		gca gca gac acc att ggc tac cca gtg atg atc cgt tcc gcc tat gca	1896
		Ala Ala Asp Thr Ile Gly Tyr Pro Val Met Ile Arg Ser Ala Tyr Ala	
		580 585 590	
55		ctg ggt ggg tta ggc tca ggc atc tgt ccc aac aga gag act ttg atg	1944
		Leu Gly Gly Leu Gly Ser Gly Ile Cys Pro Asn Arg Glu Thr Leu Met	

bioRxiv preprint doi: <https://doi.org/10.1101/111111>; this version posted May 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

	595	600	605	
	gac ctc agc aca aag gcc ttt gct atg acc aac caa att ctg gtg gag Asp Leu Ser Thr Lys Ala Phe Ala Met Thr Asn Gln Ile Leu Val Glu 610 615 620	1992		
5	aag tca gtg aca ggt tgg aaa gaa ata gaa tat gaa gtg gtt cga gat Lys Ser Val Thr Gly Trp Lys Glu Ile Glu Tyr Glu Val Val Arg Asp 625 630 635	2040		
10	gct gat gac aat tgt gtc act gtc tgt aac atg gaa aat gtt gat gcc Ala Asp Asp Asn Cys Val Thr Val Cys Asn Met Glu Asn Val Asp Ala 640 645 650 655	2088		
	atg ggt gtt cac aca ggt gac tca gtt gtt gtg gct cct gcc cag aca Met Gly Val His Thr Gly Asp Ser Val Val Val Ala Pro Ala Gln Thr 660 665 670	2136		
15	ctc tcc aat gcc gag ttt cag atg ttg aga cgt act tca atc aat gtt Leu Ser Asn Ala Glu Phe Gln Met Leu Arg Arg Thr Ser Ile Asn Val 675 680 685	2184		
	gtt cgc cac ttg ggc att gtg ggt gaa tgc aac att cag ttt gcc ctt Val Arg His Leu Gly Ile Val Gly Glu Cys Asn Ile Gln Phe Ala Leu 690 695 700	2232		
20	cat cct acc tca atg gaa tac tgc atc att gaa gtg aat gcc aga ctg His Pro Thr Ser Met Glu Tyr Cys Ile Ile Glu Val Asn Ala Arg Leu 705 710 715	2280		
25	tcc cga agc tct gct ctg gcc tca aaa gcc act ggc tac cca ttg gca Ser Arg Ser Ser Ala Leu Ala Ser Lys Ala Thr Gly Tyr Pro Leu Ala 720 725 730 735	2328		
	ttc att gct gca aag att gcc cta gga atc cca ctt cca gaa att aag Phe Ile Ala Ala Lys Ile Ala Leu Gly Ile Pro Leu Pro Glu Ile Lys 740 745 750	2376		
30	aac gtc gta tcc ggg aag aca tca gcc tgt ttt gaa cct agc ctg gat Asn Val Val Ser Gly Lys Thr Ser Ala Cys Phe Glu Pro Ser Leu Asp 755 760 765	2424		
	tac atg gtc acc aag att ccc cgc tgg gat ctt gac cgt ttt cat gga Tyr Met Val Thr Lys Ile Pro Arg Trp Asp Leu Asp Arg Phe His Gly 770 775 780	2472		
35	aca tct agc cga att ggt agc tct atg aaa agt gta gga gag gtc atg Thr Ser Ser Arg Ile Gly Ser Ser Met Lys Ser Val Gly Glu Val Met 785 790 795	2520		
40	gct att ggt cgt acc ttt gag gag agt ttc cag aaa gct tta cgg atg Ala Ile Gly Arg Thr Phe Glu Glu Ser Phe Gln Lys Ala Leu Arg Met 800 805 810 815	2568		
	tgc cac cca tct ata gaa ggt ttc act ccc cgt ctc cca atg aac aaa Cys His Pro Ser Ile Glu Gly Phe Thr Pro Arg Leu Pro Met Asn Lys 820 825 830	2616		
45	gaa tgg cca tct aat tta gat ctt aga aaa gag ttg tct gaa cca agc Glu Trp Pro Ser Asn Leu Asp Leu Arg Lys Glu Leu Ser Glu Pro Ser 835 840 845	2664		
	agc acg cgt atc tat gcc att gcc aag gcc att gat gac aac atg tcc Ser Thr Arg Ile Tyr Ala Ile Ala Lys Ala Ile Asp Asp Asn Met Ser 850 855 860	2712		
50	ctt gat gag att gag aag ctc aca tac att gac aag tgg ttt ttg tat Leu Asp Glu Ile Glu Lys Leu Thr Tyr Ile Asp Lys Trp Phe Leu Tyr 865 870 875	2760		
55	aag atg cgt gat att tta aac atg gaa aag aca ctg aaa ggg ctc aac Lys Met Arg Asp Ile Leu Asn Met Glu Lys Thr Leu Lys Gly Leu Asn 880 885 890 895	2808		

	agt gag tcc atg aca gaa gaa acc ctg aaa agg gca aag gag att ggg	2856
	Ser Glu Ser Met Thr Glu Glu Thr Leu Lys Arg Ala Lys Glu Ile Gly	
	900 905 910	
5	ttc tca gat aag cag att tca aaa tgc ctt ggg ctc act gag gcc cag	2904
	Phe Ser Asp Lys Gln Ile Ser Lys Cys Leu Gly Leu Thr Glu Ala Gln	
	915 920 925	
	aca agg gag ctg agg tta aag aaa aac atc cac cct tgg gtt aaa cag	2952
	Thr Arg Glu Leu Arg Leu Lys Lys Asn Ile His Pro Trp Val Lys Gln	
	930 935 940	
10	att gat aca ctg gct gca gaa tac cca tca gta aca aac tat ctc tat	3000
	Ile Asp Thr Leu Ala Ala Glu Tyr Pro Ser Val Thr Asn Tyr Leu Tyr	
	945 950 955	
	gtt acc tac aat ggt cag gag cat gat gtc aat ttt gat gac cat gga	3048
15	Val Thr Tyr Asn Gly Gln Glu His Asp Val Asn Phe Asp Asp His Gly	
	960 965 970 975	
	atg atg gtg cta ggc tgt ggt cca tat cac att ggc agc agt gtg gaa	3096
	Met Met Val Leu Gly Cys Gly Pro Tyr His Ile Gly Ser Ser Val Glu	
	980 985 990	
20	ttt gat tgg tgt gct gtc tct agt atc cgc aca ctg cgt caa ctt ggc	3144
	Phe Asp Trp Cys Ala Val Ser Ser Ile Arg Thr Leu Arg Gln Leu Gly	
	995 1000 1005	
	aag aag acg gtg gtg gtg aat tgc aat cct gag act gtg agc aca gac	3192
	Lys Lys Thr Val Val Val Asn Cys Asn Pro Glu Thr Val Ser Thr Asp	
	1010 1015 1020	
25	ttt gat gag tgt gac aaa ctg tac ttt gaa gag ttg tcc ttg gag aga	3240
	Phe Asp Glu Cys Asp Lys Leu Tyr Phe Glu Glu Leu Ser Leu Glu Arg	
	1025 1030 1035	
	atc cta gac atc tac cat cag gag gca tgt ggt ggc tgc atc ata tca	3288
30	Ile Leu Asp Ile Tyr His Gln Glu Ala Cys Gly Gly Cys Ile Ile Ser	
	1040 1045 1050 1055	
	gtt gga ggc cag att cca aac aac ctg gca gtt cct cta tac aag aat	3336
	Val Gly Gly Gln Ile Pro Asn Asn Leu Ala Val Pro Leu Tyr Lys Asn	
	1060 1065 1070	
35	ggt gtc aag atc atg ggc aca agc ccc ctg cag atc gac agg gct gag	3384
	Gly Val Lys Ile Met Gly Thr Ser Pro Leu Gln Ile Asp Arg Ala Glu	
	1075 1080 1085	
	gat cgc tcc atc ttc tca gct gtc ttg gat gag ctg aag gtg gct cag	3432
	Asp Arg Ser Ile Phe Ser Ala Val Leu Asp Glu Leu Lys Val Ala Gln	
	1090 1095 1100	
40	gca cct tgg aaa gct gtt aat act ttg aat gaa gca ctg gaa ttt gca	3480
	Ala Pro Trp Lys Ala Val Asn Thr Leu Asn Glu Ala Leu Glu Phe Ala	
	1105 1110 1115	
	aag tct gtg gac tac ccc tgc ttg ttg agg cct tcc tat gtt ttg agt	3528
45	Lys Ser Val Asp Tyr Pro Cys Leu Leu Arg Pro Ser Tyr Val Leu Ser	
	1120 1125 1130 1135	
	ggg tct gct atg aat gtg gta ttc tct gag gat gag atg aaa aaa ttc	3576
	Gly Ser Ala Met Asn Val Val Phe Ser Glu Asp Glu Met Lys Lys Phe	
	1140 1145 1150	
50	cta gaa gag gcg act aga gtt tct cag gag cac cca gtg gtc ctg aca	3624
	Leu Glu Glu Ala Thr Arg Val Ser Gln Glu His Pro Val Val Leu Thr	
	1155 1160 1165	
	aaa ttt gtt gaa ggg gcc cga gaa gta gaa atg gac gct gtt ggc aaa	3672
	Lys Phe Val Glu Gly Ala Arg Glu Val Glu Met Asp Ala Val Gly Lys	
	1170 1175 1180	
55	gat gga agg gtt atc tct cat gcc atc tct gaa cat gtt gaa gat gca	3720

	Asp Gly Arg Val Ile Ser His Ala Ile Ser Glu His Val Glu Asp Ala	
	1185 1190 1195	
5	ggt gtc cac tcg gga gat gcc act ctg atg ctg ccc aca caa acc atc 3768 Gly Val His Ser Gly Asp Ala Thr Leu Met Leu Pro Thr Gln Thr Ile 1200 1205 1210 1215	
	agc caa ggg gcc att gaa aag gtg aag gat gct acc cgg aag att gca 3816 Ser Gln Gly Ala Ile Glu Lys Val Lys Asp Ala Thr Arg Lys Ile Ala 1220 1225 1230	
10	aag gct ttt gcc atc tct ggt cca ttc aac gtc caa ttt ctt gtc aaa 3864 Lys Ala Phe Ala Ile Ser Gly Pro Phe Asn Val Gln Phe Leu Val Lys 1235 1240 1245	
	gga aat gat gtc ttg gtg att gag tgt aac ttg aga gct tct cga tcc 3912 Gly Asn Asp Val Leu Val Ile Glu Cys Asn Leu Arg Ala Ser Arg Ser 1250 1255 1260	
15	ttc ccc ttt gtt tcc aag act ctt ggg gtt gac ttc att gat gtg gcc 3960 Phe Pro Phe Val Ser Lys Thr Leu Gly Val Asp Phe Ile Asp Val Ala 1265 1270 1275	
20	acc aag gtg atg att gga gag aat gtt gat gag aaa cat ctt cca aca 4008 Thr Lys Val Met Ile Gly Glu Asn Val Asp Glu Lys His Leu Pro Thr 1280 1285 1290 1295	
	ttg gac cat ccc ata att cct gct gac tat gtt gca att aag gct ccc 4056 Leu Asp His Pro Ile Ile Pro Ala Asp Tyr Val Ala Ile Lys Ala Pro 1300 1305 1310	
25	atg ttt tcc tgg ccc cgg ttg agg gat gct gac ccc att ctg aga tgt 4104 Met Phe Ser Trp Pro Arg Leu Arg Asp Ala Asp Pro Ile Leu Arg Cys 1315 1320 1325	
	gag atg gct tcc act gga gag gtg gct tgc ttt ggt gaa ggt att cat 4152 Glu Met Ala Ser Thr Gly Glu Val Ala Cys Phe Gly Glu Gly Ile His 1330 1335 1340	
30	aca gcc ttc cta aag gca atg ctt tcc aca gga ttt aag ata ccc cag 4200 Thr Ala Phe Leu Lys Ala Met Leu Ser Thr Gly Phe Lys Ile Pro Gln 1345 1350 1355	
35	aaa ggc atc ctg ata ggc atc cag caa tca ttc cgg cca aga ttc ctt 4248 Lys Gly Ile Leu Ile Gly Ile Gln Gln Ser Phe Arg Pro Arg Phe Leu 1360 1365 1370 1375	
	ggt gtg gct gaa caa tta cac aat gaa ggt ttc aag ctg ttt gcc acg 4296 Gly Val Ala Glu Gln Leu His Asn Glu Gly Phe Lys Leu Phe Ala Thr 1380 1385 1390	
40	gaa gcc aca tca gac tgg ctc aac gcc aac aat gtc cct gcc acc cca 4344 Glu Ala Thr Ser Asp Trp Leu Asn Ala Asn Asn Val Pro Ala Thr Pro 1395 1400 1405	
	gtg gca tgg ccg tct caa gaa gga cag aat ccc agc ctc tct tcc atc 4392 Val Ala Trp Pro Ser Gln Glu Gly Gln Asn Pro Ser Leu Ser Ser Ile 1410 1415 1420	
45	aga aaa ttg att aga gat ggc agc att gac cta gtg att aac ctt ccc 4440 Arg Lys Leu Ile Arg Asp Gly Ser Ile Asp Leu Val Ile Asn Leu Pro 1425 1430 1435	
50	aac aac aac act aaa ttt gtc cat gat aat tat gtg att cgg agg aca 4488 Asn Asn Asn Thr Lys Phe Val His Asp Asn Tyr Val Ile Arg Arg Thr 1440 1445 1450 1455	
	gct gtt gat agt gga atc cct ctc ctc act aat ttt cag gtg acc aaa 4536 Ala Val Asp Ser Gly Ile Pro Leu Leu Thr Asn Phe Gln Val Thr Lys 1460 1465 1470	
55	ctt ttt gct gaa gct gtg cag aaa tct cgc aag gtg gac tcc aag agt 4584 Leu Phe Ala Glu Ala Val Gln Lys Ser Arg Lys Val Asp Ser Lys Ser 1475 1480 1485	

1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485

ctt ttc cac tac agg cag tac agt gct gga aaa gca gca tag 4626
 Leu Phe His Tyr Arg Gln Tyr Ser Ala Gly Lys Ala Ala
 1490 1495 1500

5 agatgcagac accccagccc cattattaaa tcaacctgag ccacatgtta tctaaaggaa 4686
 ctgattcaca actttctcag agatgaatat tgataactaa acttcatttc agtttacttt 4746
 gttatgcctt aatattctgt gtcttttgca attaaattgt cagtcacttc ttcaaaacct 4806
 tacagtcctt cctaagttac tcttcagtag atttcatcca ttactaata ctgtattttt 4866
 ggtggactag gcttgccat gtgcttatgt gtagcttttt actttttatg gtgttgatta 4926
 atggtgatca aggtaggaaa agttgctgtt ctattttctg aactctttct atactttaag 4986
 10 atactctatt tttaaaacac tatctgcaaa ctcaggacac tttacagggg cagaatactc 5046
 taaaaacttg ataaaatgaa atatagattt aatttatgaa ccttccatca tgatgtttgt 5106
 gtattgcttc ttttggatc ctcattctca cccatttggc taatccagga atattgttat 5166
 cccttcccat tatattgaag ttgagaaatg tgacagaggg atttagagta tggacttttc 5226
 tttctttttt cttttctttt ttttctttt gagatggagt cacactctcc aggctggagt 5286
 15 gcagtggcac aatctcggt cactgcaatt tgcgtctccc aagttcaagc gattctcctg 5346
 ctttagacta tggatttctt taaggaatac tggtttgag tttgttttc tggactatat 5406
 cagcagatgg tagacagtgt ttatgtagat gtgttggtgt tttatcatt ggattttaac 5466
 ttggcccag tgaaataatc agatttttgt cattcacact ctccccagt tttggaataa 5526
 cttggaagta aggttcattc ccttaagacg atggattctg ttgaactatg ggtgccaca 5586
 20 ctgcactatt aattccaccc actgtaaggg caaggacacc attccttcta catataagaa 5646
 aaaagtctct cccaagggc agcctttgtt acttttaaat atttctgtt attacaagtg 5706
 ctctaattgt gaacttttaa ataaaatact attaaagggt aaaaaaaaa aaaaa 5761

<210> 4

<211> 1500

25 <212> PRT

<213> Homo sapiens

<400> 4

30 Met Thr Arg Ile Leu Thr Ala Phe Lys Val Val Arg Thr Leu Lys Thr
 1 5 10 15
 Gly Phe Gly Phe Thr Asn Val Thr Ala His Gln Lys Trp Lys Phe Ser
 20 25 30
 Arg Pro Gly Ile Arg Leu Leu Ser Val Lys Ala Gln Thr Ala His Ile
 35 40 45
 35 Val Leu Glu Asp Gly Thr Lys Met Lys Gly Tyr Ser Phe Gly His Pro
 50 55 60
 Ser Ser Val Ala Gly Glu Val Val Phe Asn Thr Gly Leu Gly Gly Tyr
 65 70 75 80

Ala Asn Pro Ile Ile Gly Asn Gly Gly Ala Pro Asp Thr Thr Ala Leu
100 105 110

5

10

Ile Tyr Gly Val Asp Thr Arg Met Leu Thr Lys Ile Ile Arg Asp Lys
165 170 175

15

Val Lys Val Tyr Gly Lys Gly Asn Pro Thr Lys Val Val Ala Val Asp
210 215 220

20

Asp Gly Ile Leu Ile Ala Gly Gly Pro Gly Asn Pro Ala Leu Ala Glu
260 265 270

25

30

Pro Val Leu Asn Ile Thr Asn Lys Gln Ala Phe Ile Thr Ala Gln Asn
325 330 335

35

Lys Pro Phe Phe Ala Val Gln Phe His Pro Glu Val Thr Pro Gly Pro
370 375 380

40

Ala Ser Arg Val Glu Val Ser Lys Val Leu Ile Leu Gly Ser Gly Gly
420 425 430

45

Asn Ile Ala Ser Val Gln Thr Asn Glu Val Gly Leu Lys Gln Ala Asp

	465	470	475	480
	Thr Val Tyr Phe	Leu Pro Ile Thr Pro Gln Phe Val Thr Glu Val Ile		
		485	490	495
5	Lys Ala Glu Gln Pro Asp Gly Leu Ile Leu Gly Met Gly Gly Gln Thr			
		500	505	510
	Ala Leu Asn Cys Gly Val Glu Leu Phe Lys Arg Gly Val Leu Lys Glu			
		515	520	525
	Tyr Gly Val Lys Val Leu Gly Thr Ser Val Glu Ser Ile Met Ala Thr			
		530	535	540
10	Glu Asp Arg Gln Leu Phe Ser Asp Lys Leu Asn Glu Ile Asn Glu Lys			
		545	550	555
	Ile Ala Pro Ser Phe Ala Val Glu Ser Ile Glu Asp Ala Leu Lys Ala			
		565	570	575
15	Ala Asp Thr Ile Gly Tyr Pro Val Met Ile Arg Ser Ala Tyr Ala Leu			
		580	585	590
	Gly Gly Leu Gly Ser Gly Ile Cys Pro Asn Arg Glu Thr Leu Met Asp			
		595	600	605
	Leu Ser Thr Lys Ala Phe Ala Met Thr Asn Gln Ile Leu Val Glu Lys			
		610	615	620
20	Ser Val Thr Gly Trp Lys Glu Ile Glu Tyr Glu Val Val Arg Asp Ala			
		625	630	635
	Asp Asp Asn Cys Val Thr Val Cys Asn Met Glu Asn Val Asp Ala Met			
		645	650	655
25	Gly Val His Thr Gly Asp Ser Val Val Val Ala Pro Ala Gln Thr Leu			
		660	665	670
	Ser Asn Ala Glu Phe Gln Met Leu Arg Arg Thr Ser Ile Asn Val Val			
		675	680	685
	Arg His Leu Gly Ile Val Gly Glu Cys Asn Ile Gln Phe Ala Leu His			
		690	695	700
30	Pro Thr Ser Met Glu Tyr Cys Ile Ile Glu Val Asn Ala Arg Leu Ser			
		705	710	715
	Arg Ser Ser Ala Leu Ala Ser Lys Ala Thr Gly Tyr Pro Leu Ala Phe			
		725	730	735
35	Ile Ala Ala Lys Ile Ala Leu Gly Ile Pro Leu Pro Glu Ile Lys Asn			
		740	745	750
	Val Val Ser Gly Lys Thr Ser Ala Cys Phe Glu Pro Ser Leu Asp Tyr			
		755	760	765
	Met Val Thr Lys Ile Pro Arg Trp Asp Leu Asp Arg Phe His Gly Thr			
		770	775	780
40	Ser Ser Arg Ile Gly Ser Ser Met Lys Ser Val Gly Glu Val Met Ala			
		785	790	795
	Ile Gly Arg Thr Phe Glu Glu Ser Phe Gln Lys Ala Leu Arg Met Cys			
		805	810	815
45	His Pro Ser Ile Glu Gly Phe Thr Pro Arg Leu Pro Met Asn Lys Glu			
		820	825	830
	Trp Pro Ser Asn Leu Asp Leu Arg Lys Glu Leu Ser Glu Pro Ser Ser			
		835	840	845
	Thr Arg Ile Tyr Ala Ile Ala Lys Ala Ile Asp Asp Asn Met Ser Leu			
		850	855	860

5	Asp 865	Glu	Ile	Glu	Lys	Leu	Thr	Tyr	Ile	Asp 870	Lys	Trp	Phe	Leu	Tyr	Lys 880
	Met	Arg	Asp	Ile	Leu	Asn	Met	Glu	Lys	Thr	Leu	Lys	Gly	Leu	Asn	Ser 895
	Glu	Ser	Met	Thr	Glu	Glu	Thr	Leu	Lys	Arg	Ala	Lys	Glu	Ile	Gly	Phe 910
10	Ser	Asp	Lys	Gln	Ile	Ser	Lys	Cys	Leu	Gly	Leu	Thr	Glu	Ala	Gln	Thr 925
	Arg	Glu	Leu	Arg	Leu	Lys	Lys	Asn	Ile	His	Pro	Trp	Val	Lys	Gln	Ile 940
	Asp	Thr	Leu	Ala	Ala	Glu	Tyr	Pro	Ser	Val	Thr	Asn	Tyr	Leu	Tyr	Val 960
15	Thr	Tyr	Asn	Gly	Gln	Glu	His	Asp	Val	Asn	Phe	Asp	Asp	His	Gly	Met 975
	Met	Val	Leu	Gly	Cys	Gly	Pro	Tyr	His	Ile	Gly	Ser	Ser	Val	Glu	Phe 990
	Asp	Trp	Cys	Ala	Val	Ser	Ser	Ile	Arg	Thr	Leu	Arg	Gln	Leu	Gly	Lys 1005
20	Lys	Thr	Val	Val	Val	Asn	Cys	Asn	Pro	Glu	Thr	Val	Ser	Thr	Asp	Phe 1020
	Asp	Glu	Cys	Asp	Lys	Leu	Tyr	Phe	Glu	Glu	Leu	Ser	Leu	Glu	Arg	Ile 1040
	Leu	Asp	Ile	Tyr	His	Gln	Glu	Ala	Cys	Gly	Gly	Cys	Ile	Ile	Ser	Val 1055
25	Gly	Gly	Gln	Ile	Pro	Asn	Asn	Leu	Ala	Val	Pro	Leu	Tyr	Lys	Asn	Gly 1070
	Val	Lys	Ile	Met	Gly	Thr	Ser	Pro	Leu	Gln	Ile	Asp	Arg	Ala	Glu	Asp 1085
	Arg	Ser	Ile	Phe	Ser	Ala	Val	Leu	Asp	Glu	Leu	Lys	Val	Ala	Gln	Ala 1100
30	Pro	Trp	Lys	Ala	Val	Asn	Thr	Leu	Asn	Glu	Ala	Leu	Glu	Phe	Ala	Lys 1120
	Ser	Val	Asp	Tyr	Pro	Cys	Leu	Leu	Arg	Pro	Ser	Tyr	Val	Leu	Ser	Gly 1135
	Ser	Ala	Met	Asn	Val	Val	Phe	Ser	Glu	Asp	Glu	Met	Lys	Lys	Phe	Leu 1150
35	Glu	Glu	Ala	Thr	Arg	Val	Ser	Gln	Glu	His	Pro	Val	Val	Leu	Thr	Lys 1165
	Phe	Val	Glu	Gly	Ala	Arg	Glu	Val	Glu	Met	Asp	Ala	Val	Gly	Lys	Asp 1180
	Gly	Arg	Val	Ile	Ser	His	Ala	Ile	Ser	Glu	His	Val	Glu	Asp	Ala	Gly 1200
40	Val	His	Ser	Gly	Asp	Ala	Thr	Leu	Met	Leu	Pro	Thr	Gln	Thr	Ile	Ser 1215
	Gln	Gly	Ala	Ile	Glu	Lys	Val	Lys	Asp	Ala	Thr	Arg	Lys	Ile	Ala	Lys 1230
	Ala	Phe	Ala	Ile	Ser	Gly	Pro	Phe	Asn	Val	Gln	Phe	Leu	Val	Lys	Gly 1245
45	Asn	Asp	Val	Leu	Val	Ile	Glu	Cys	Asn	Leu	Arg	Ala	Ser	Arg	Ser	Phe 1260

	1250	1255	1260
	Pro Phe Val Ser Lys Thr Leu Gly Val Asp Phe Ile Asp Val Ala Thr		
	265	1270	1275 1280
5	Lys Val Met Ile Gly Glu Asn Val Asp Glu Lys His Leu Pro Thr Leu		
		1285	1290 1295
	Asp His Pro Ile Ile Pro Ala Asp Tyr Val Ala Ile Lys Ala Pro Met		
		1300	1305 1310
	Phe Ser Trp Pro Arg Leu Arg Asp Ala Asp Pro Ile Leu Arg Cys Glu		
		1315	1320 1325
10	Met Ala Ser Thr Gly Glu Val Ala Cys Phe Gly Glu Gly Ile His Thr		
		1330	1335 1340
	Ala Phe Leu Lys Ala Met Leu Ser Thr Gly Phe Lys Ile Pro Gln Lys		
		1345	1350 1355 1360
15	Gly Ile Leu Ile Gly Ile Gln Gln Ser Phe Arg Pro Arg Phe Leu Gly		
		1365	1370 1375
	Val Ala Glu Gln Leu His Asn Glu Gly Phe Lys Leu Phe Ala Thr Glu		
		1380	1385 1390
	Ala Thr Ser Asp Trp Leu Asn Ala Asn Asn Val Pro Ala Thr Pro Val		
		1395	1400 1405
20	Ala Trp Pro Ser Gln Glu Gly Gln Asn Pro Ser Leu Ser Ser Ile Arg		
		1410	1415 1420
	Lys Leu Ile Arg Asp Gly Ser Ile Asp Leu Val Ile Asn Leu Pro Asn		
		1425	1430 1435 1440
25	Asn Asn Thr Lys Phe Val His Asp Asn Tyr Val Ile Arg Arg Thr Ala		
		1445	1450 1455
	Val Asp Ser Gly Ile Pro Leu Leu Thr Asn Phe Gln Val Thr Lys Leu		
		1460	1465 1470
	Phe Ala Glu Ala Val Gln Lys Ser Arg Lys Val Asp Ser Lys Ser Leu		
		1475	1480 1485
30	Phe His Tyr Arg Gln Tyr Ser Ala Gly Lys Ala Ala		
		1490	1495 1500

<210> 5

<211> 495

<212> DNA

35 <213> Homo sapiens

<220>

<221> exon

<222> (111)..(224)

<220>

40 <221> misc_feature

<222> (70)

<223> (a or c or g or t/u)

<400> 5

ctacttctca tgttcagcaa tttcttcttc tttatgtttt aaattacatg ttccataaaa 60
5 ataagaaatn cactgtgata cggtaattga ttttttcatt ttaaatagcag ctg ttt 116
gcc acg gaa gcc aca tca gac tgg ctc aac gcc aac aat gtc cct gcc 164
acc cca gtg gca tgg ccg tct caa gaa gga cag aat ccc agc ctc tct 212
tcc atc aga aag taagaactag gcatactggt tctgaaata atttagagga 264
ttaactttga gaaccagtat atgaatatc accttgcttg attgcaagtc ttttaaaca 324
10 aatttaaaaa tgaatacatt tgtggatgat tgtcaagttt cactctccat cactatggaa 384
tacataacgt catgtgtaca tggatgatg aaacgtgttt caaatactt cttagtaagg 444
atactttcct tgacggaaac aagtgagagt atgaagaatg taatgcagca c 495

<210> 6

<211> 20

<212> DNA

<213> Homo sapiens

<400> 6

agctgtttgc cacggaagcc 20

<210> 7

<211> 28

<212> DNA

<213> Homo sapiens

<400> 7

cccagcctct cttccatcag aaagtaag 28

<210> 8

<211> 20

<212> DNA

<213> Homo sapiens

<400> 8

cacggaagcc acatcagact

20

5

<210> 9

<211> 21

<212> DNA

<213> Homo sapiens

<400> 9

10

ttctgatgga agagaggctt g

21

<210> 10

<211> 24

<212> DNA

<213> Homo sapiens

15

<400> 10

agagtgaac ttgacaatca tcca

24

<210> 11

<211> 5761

<212> DNA

20

<213> Homo sapiens

<220>

<221> CDS

<222> (124)..(4626)

<400> 11

	gtcagcctta aacactgact gcacccctcc cagatttctt ttacattaac taaaaagtct	60
	tatcacacaa tctcataaaa tttatgtaat ttcatttaat tttagccaca aatcatcttc	120
5	aaa atg acg agg tta ttg aca gct ttc aaa gtg gtg agg aca ctg aag	168
	Met Thr Arg Leu Leu Thr Ala Phe Lys Val Val Arg Thr Leu Lys	
	1 5 10 15	
10	act ggt ttt ggc ttt acc aat gtg act gca cac caa aaa tgg aaa ttt	216
	Thr Gly Phe Gly Phe Thr Asn Val Thr Ala His Gln Lys Trp Lys Phe	
	20 25 30	
	tca aga cct ggc atc agg ctc ctt tct gtc aag gca cag aca gca cac	264
	Ser Arg Pro Gly Ile Arg Leu Leu Ser Val Lys Ala Gln Thr Ala His	
	35 40 45	
15	att gtc ctg gaa gat gga act aag atg aaa ggt tac tcc ttt ggc cat	312
	Ile Val Leu Glu Asp Gly Thr Lys Met Lys Gly Tyr Ser Phe Gly His	
	50 55 60	
	cca tcc tct gtt gct ggt gaa gtg gtt ttt aat act ggc ctg gga ggg	360
	Pro Ser Ser Val Ala Gly Glu Val Val Phe Asn Thr Gly Leu Gly Gly	
	65 70 75	
20	tac cca gaa gct att act gac cct gcc tac aaa gga cag att ctc aca	408
	Tyr Pro Glu Ala Ile Thr Asp Pro Ala Tyr Lys Gly Gln Ile Leu Thr	
	80 85 90 95	
	atg gcc aac cct att att ggg aat ggt gga gct cct gat act act gct	456
	Met Ala Asn Pro Ile Ile Gly Asn Gly Gly Ala Pro Asp Thr Thr Ala	
	100 105 110	
25	ctg gat gaa ctg gga ctt agc aaa tat ttg gag tct aat gga atc aag	504
	Leu Asp Glu Leu Gly Leu Ser Lys Tyr Leu Glu Ser Asn Gly Ile Lys	
	115 120 125	
30	gtt tca ggt ttg ctg gtg ctg gat tat agt aaa gac tac aac cac tgg	552
	Val Ser Gly Leu Leu Val Leu Asp Tyr Ser Lys Asp Tyr Asn His Trp	
	130 135 140	
	ctg gct acc aag agt tta ggg caa tgg cta cag gaa gaa aag gtt cct	600
	Leu Ala Thr Lys Ser Leu Gly Gln Trp Leu Gln Glu Glu Lys Val Pro	
	145 150 155	
35	gca att tat gga gtg gac aca aga atg ctg act aaa ata att cgg gat	648
	Ala Ile Tyr Gly Val Asp Thr Arg Met Leu Thr Lys Ile Ile Arg Asp	
	160 165 170 175	
40	aag ggt acc atg ctt ggg aag att gaa ttt gaa ggt cag cct gtg gat	696
	Lys Gly Thr Met Leu Gly Lys Ile Glu Phe Glu Gly Gln Pro Val Asp	
	180 185 190	
	ttt gtg gat cca aat aaa cag aat ttg att gct gag gtt tca acc aag	744
	Phe Val Asp Pro Asn Lys Gln Asn Leu Ile Ala Glu Val Ser Thr Lys	
	195 200 205	
45	gat gtc aaa gtg tac ggc aaa gga aac ccc aca aaa gtg gta gct gta	792
	Asp Val Lys Val Tyr Gly Lys Gly Asn Pro Thr Lys Val Val Ala Val	
	210 215 220	
	gac tgt ggg att aaa aac aat gta atc cgc ctg cta gta aag cga gga	840
	Asp Cys Gly Ile Lys Asn Asn Val Ile Arg Leu Leu Val Lys Arg Gly	
	225 230 235	
50	gct gaa gtg cac tta gtt ccc tgg aac cat gat ttc acc aag atg gag	888
	Ala Glu Val His Leu Val Pro Trp Asn His Asp Phe Thr Lys Met Glu	
	240 245 250 255	

	tat gat ggg att ttg atc gcg gga gga ccg ggg aac cca gct ctt gca	936
	Tyr Asp Gly Ile Leu Ile Ala Gly Gly Pro Gly Asn Pro Ala Leu Ala	
	260 265 270	
5	gaa cca cta att cag aat gtc aga aag att ttg gag agt gat cgc aag	984
	Glu Pro Leu Ile Gln Asn Val Arg Lys Ile Leu Glu Ser Asp Arg Lys	
	275 280 285	
	gag cca ttg ttt gga atc agt aca gga aac tta ata aca gga ttg gct	1032
	Glu Pro Leu Phe Gly Ile Ser Thr Gly Asn Leu Ile Thr Gly Leu Ala	
	290 295 300	
10	gct ggt gcc aaa acc tac aag atg tcc atg gcc aac aga ggg cag aat	1080
	Ala Gly Ala Lys Thr Tyr Lys Met Ser Met Ala Asn Arg Gly Gln Asn	
	305 310 315	
	cag cct gtt ttg aat atc aca aac aaa cag gct ttc att act gct cag	1128
	Gln Pro Val Leu Asn Ile Thr Asn Lys Gln Ala Phe Ile Thr Ala Gln	
	320 325 330 335	
15	aat cat ggc tat gcc ttg gac aac acc ctc cct gct ggc tgg aaa cca	1176
	Asn His Gly Tyr Ala Leu Asp Asn Thr Leu Pro Ala Gly Trp Lys Pro	
	340 345 350	
20	ctt ttt gtg aat gtc aac gat caa aca aat gag ggg att atg cat gag	1224
	Leu Phe Val Asn Val Asn Asp Gln Thr Asn Glu Gly Ile Met His Glu	
	355 360 365	
	agc aaa ccc ttc ttc gct gtg cag ttc cac cca gag gtc acc ccg ggg	1272
	Ser Lys Pro Phe Phe Ala Val Gln Phe His Pro Glu Val Thr Pro Gly	
	370 375 380	
25	cca ata gac act gag tac ctg ttt gat tcc ttt ttc tca ctg ata aag	1320
	Pro Ile Asp Thr Glu Tyr Leu Phe Asp Ser Phe Phe Ser Leu Ile Lys	
	385 390 395	
	aaa gga aaa gct acc acc att aca tca gtc tta ccg aag cca gca cta	1368
	Lys Gly Lys Ala Thr Thr Ile Thr Ser Val Leu Pro Lys Pro Ala Leu	
	400 405 410 415	
30	gtt gca tct cgg gtt gag gtt tcc aaa gtc ctt att cta gga tca gga	1416
	Val Ala Ser Arg Val Glu Val Ser Lys Val Leu Ile Leu Gly Ser Gly	
	420 425 430	
35	ggg ctg tcc att ggt cag gct gga gaa ttt gat tac tca gga tct caa	1464
	Gly Leu Ser Ile Gly Gln Ala Gly Glu Phe Asp Tyr Ser Gly Ser Gln	
	435 440 445	
	gct gta aaa gcc atg aag gaa gaa aat gtc aaa act gtt ctg atg aac	1512
	Ala Val Lys Ala Met Lys Glu Glu Asn Val Lys Thr Val Leu Met Asn	
	450 455 460	
40	cca aac att gca tca gtc cag acc aat gag gtg ggc tta aag caa gcg	1560
	Pro Asn Ile Ala Ser Val Gln Thr Asn Glu Val Gly Leu Lys Gln Ala	
	465 470 475	
	gat act gtc tac ttt ctt ccc atc acc cct cag ttt gtc aca gag gtc	1608
	Asp Thr Val Tyr Phe Leu Pro Ile Thr Pro Gln Phe Val Thr Glu Val	
	480 485 490 495	
45	atc aag gca gaa cag cca gat ggg tta att ctg ggc atg ggt ggc cag	1656
	Ile Lys Ala Glu Gln Pro Asp Gly Leu Ile Leu Gly Met Gly Gly Gln	
	500 505 510	
50	aca gct ctg aac tgt gga gtg gaa cta ttc aag aga ggt gtg ctc aag	1704
	Thr Ala Leu Asn Cys Gly Val Glu Leu Phe Lys Arg Gly Val Leu Lys	
	515 520 525	
	gaa tat ggt gtg aaa gtc ctg gga act tca gtt gag tcc att atg gct	1752
	Glu Tyr Gly Val Lys Val Leu Gly Thr Ser Val Glu Ser Ile Met Ala	
	530 535 540	
55	acg gaa gac agg cag ctg ttt tca gat aaa cta aat gag atc aat gaa	1800

aag att gct cca agt ttt gca gtg gaa tcg att gag gat gca ctg aag 1848
Lys Ile Ala Pro Ser Phe Ala Val Glu Ser Ile Glu Asp Ala Leu Lys
560 565 570 575

gca gca gac acc att ggc tac cca gtg atg atc cgt tcc gcc tat gca 1896
Ala Ala Asp Thr Ile Gly Tyr Pro Val Met Ile Arg Ser Ala Tyr Ala
580 585 590

ctg ggt ggg tta ggc tca ggc atc tgt ccc aac aga gag act ttg atg 1944
Leu Gly Gly Leu Gly Ser Gly Ile Cys Pro Asn Arg Glu Thr Leu Met
595 600 605

gac ctc agc aca aag gcc ttt gct atg acc aac caa att ctg gtg gag 1992
Asp Leu Ser Thr Lys Ala Phe Ala Met Thr Asn Gln Ile Leu Val Glu
610 615 620

aag tca gtg aca ggt tgg aaa gaa ata gaa tat gaa gtg gtt cga gat 2040
Lys Ser Val Thr Gly Trp Lys Glu Ile Glu Tyr Glu Val Val Arg Asp
625 630 635

gct gat gac aat tgt gtc act gtc tgt aac atg gaa aat gtt gat gcc 2088
Ala Asp Asp Asn Cys Val Thr Val Cys Asn Met Glu Asn Val Asp Ala
640 645 650 655

atg ggt gtt cac aca ggt gac tca gtt gtt gtg gct cct gcc cag aca 2136
Met Gly Val His Thr Gly Asp Ser Val Val Val Ala Pro Ala Gln Thr
660 665 670

ctc tcc aat gcc gag ttt cag atg ttg aga cgt act tca atc aat gtt 2184
Leu Ser Asn Ala Glu Phe Gln Met Leu Arg Arg Thr Ser Ile Asn Val
675 680 685

gtt ggc cac ttg ggc att gtg ggt gaa tgc aac att cag ttt gcc ctt 2232
Val Arg His Leu Gly Ile Val Gly Glu Cys Asn Ile Gln Phe Ala Leu
690 695 700

cat cct acc tca atg gaa tac tgc atc att gaa gtg aat gcc aga ctg 2280
His Pro Thr Ser Met Glu Tyr Cys Ile Ile Glu Val Asn Ala Arg Leu
705 710 715

tcc cga agc tct gct ctg gcc tca aaa gcc act ggc tac cca ttg gca 2328
Ser Arg Ser Ser Ala Leu Ala Ser Lys Ala Thr Gly Tyr Pro Leu Ala
720 725 730 735

ttc att gct gca aag att gcc cta gga atc cca ctt cca gaa att aag 2376
Phe Ile Ala Ala Lys Ile Ala Leu Gly Ile Pro Leu Pro Glu Ile Lys
740 745 750

aac gtc gta tcc ggg aag aca tca gcc tgt ttt gaa cct agc ctg gat 2424
Asn Val Val Ser Gly Lys Thr Ser Ala Cys Phe Glu Pro Ser Leu Asp
755 760 765

tac atg gtc acc aag att ccc cgc tgg gat ctt gac cgt ttt cat gga 2472
 Tyr Met Val Thr Lys Ile Pro Arg Trp Asp Leu Asp Arg Phe His Gly
 770 775 780

aca tct agc cga att ggt agc tct atg aaa agt gta gga gag gtc atg 2520
Thr Ser Ser Arg Ile Gly Ser Ser Met Lys Ser Val Gly Glu Val Met
785 790 795

gct att ggt cgt acc ttt gag gag agt ttc cag aaa gct tta cgg atg 2568
Ala Ile Gly Arg Thr Phe Glu Glu Ser Phe Gln Lys Ala Leu Arg Met
800 805 810 815

tgc cac cca tct ata gaa ggt ttc act ccc cgt ctc cca atg aac aaa 2616
Cys His Pro Ser Ile Glu Gly Phe Thr Pro Arg Leu Pro Met Asn Lys
820 825 830

gaa tgg cca tct aat tta gat ctt aga aaa gag ttg tct gaa cca agc 2664
Glu Trp Pro Ser Asn Leu Asp Leu Arg Lys Glu Leu Ser Glu Pro Ser

	835	840	845	
	agc acg cgt atc tat gcc att gcc aag gcc att gat gac aac atg tcc Ser Thr Arg Ile Tyr Ala Ile Ala Lys Ala Ile Asp Asp Asn Met Ser 850 855 860	2712		
5	ctt gat gag att gag aag ctc aca tac att gac aag tgg ttt ttg tat Leu Asp Glu Ile Glu Lys Leu Thr Tyr Ile Asp Lys Trp Phe Leu Tyr 865 870 875	2760		
10	aag atg cgt gat att tta aac atg gaa aag aca ctg aaa ggg ctc aac Lys Met Arg Asp Ile Leu Asn Met Glu Lys Thr Leu Lys Gly Leu Asn 880 885 890 895	2808		
	agt gag tcc atg aca gaa gaa acc ctg aaa agg gca aag gag att ggg Ser Glu Ser Met Thr Glu Glu Thr Leu Lys Arg Ala Lys Glu Ile Gly 900 905 910	2856		
15	ttc tca gat aag cag att tca aaa tgc ctt ggg ctc act gag gcc cag Phe Ser Asp Lys Gln Ile Ser Lys Cys Leu Gly Leu Thr Glu Ala Gln 915 920 925	2904		
	aca agg gag ctg agg tta aag aaa aac atc cac cct tgg gtt aaa cag Thr Arg Glu Leu Arg Leu Lys Lys Asn Ile His Pro Trp Val Lys Gln 930 935 940	2952		
20	att gat aca ctg gct gca gaa tac cca tca gta aca aac tat ctc tat Ile Asp Thr Leu Ala Ala Glu Tyr Pro Ser Val Thr Asn Tyr Leu Tyr 945 950 955	3000		
25	gtt acc tac aat ggt cag gag cat gat gtc aat ttt gat gac cat gga Val Thr Tyr Asn Gly Gln Glu His Asp Val Asn Phe Asp Asp His Gly 960 965 970 975	3048		
	atg atg gtg cta ggc tgt ggt cca tat cac att ggc agc agt gtg gaa Met Met Val Leu Gly Cys Gly Pro Tyr His Ile Gly Ser Ser Val Glu 980 985 990	3096		
30	ttt gat tgg tgt gct gtc tct agt atc cgc aca ctg cgt caa ctt ggc Phe Asp Trp Cys Ala Val Ser Ser Ile Arg Thr Leu Arg Gln Leu Gly 995 1000 1005	3144		
	aag aag acg gtg gtg gtg aat tgc aat cct gag act gtg agc aca gac Lys Lys Thr Val Val Val Asn Cys Asn Pro Glu Thr Val Ser Thr Asp 1010 1015 1020	3192		
35	ttt gat gag tgt gac aaa ctg tac ttt gaa gag ttg tcc ttg gag aga Phe Asp Glu Cys Asp Lys Leu Tyr Phe Glu Glu Leu Ser Leu Glu Arg 1025 1030 1035	3240		
40	atc cta gac atc tac cat cag gag gca tgt ggt ggc tgc atc ata tca Ile Leu Asp Ile Tyr His Gln Glu Ala Cys Gly Gly Cys Ile Ile Ser 1040 1045 1050 1055	3288		
	gtt gga ggc cag att cca aac aac ctg gca gtt cct cta tac aag aat Val Gly Gly Gln Ile Pro Asn Asn Leu Ala Val Pro Leu Tyr Lys Asn 1060 1065 1070	3336		
45	ggc gtc aag atc atg ggc aca agc ccc ctg cag atc gac agg gct gag Gly Val Lys Ile Met Gly Thr Ser Pro Leu Gln Ile Asp Arg Ala Glu 1075 1080 1085	3384		
	gat cgc tcc atc ttc tca gct gtc ttg gat gag ctg aag gtg gct cag Asp Arg Ser Ile Phe Ser Ala Val Leu Asp Glu Leu Lys Val Ala Gln 1090 1095 1100	3432		
50	gca cct tgg aaa gct gtt aat act ttg aat gaa gca ctg gaa ttt gca Ala Pro Trp Lys Ala Val Asn Thr Leu Asn Glu Ala Leu Glu Phe Ala 1105 1110 1115	3480		
55	aag tct gtg gac tac ccc tgc ttg ttg agg cct tcc tat gtt ttg agt Lys Ser Val Asp Tyr Pro Cys Leu Leu Arg Pro Ser Tyr Val Leu Ser 1120 1125 1130 1135	3528		

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted March 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

	ggg tct gct atg aat gtg gta ttc tct gag gat gag atg aaa aaa ttc	3576
	Gly Ser Ala Met Asn Val Val Phe Ser Glu Asp Glu Met Lys Lys Phe	
	1140 1145 1150	
5	cta gaa gag gcg act aga gtt tct cag gag cac cca gtg gtc ctg aca	3624
	Leu Glu Glu Ala Thr Arg Val Ser Gln Glu His Pro Val Val Leu Thr	
	1155 1160 1165	
	aaa ttt gtt gaa ggg gcc cga gaa gta gaa atg gac gct gtt ggc aaa	3672
	Lys Phe Val Glu Gly Ala Arg Glu Val Glu Met Asp Ala Val Gly Lys	
	1170 1175 1180	
10	gat gga agg gtt atc tct cat gcc atc tct gaa cat gtt gaa gat gca	3720
	Asp Gly Arg Val Ile Ser His Ala Ile Ser Glu His Val Glu Asp Ala	
	1185 1190 1195	
	ggg gtc cac tcg gga gat gcc act ctg atg ctg ccc aca caa acc atc	3768
15	Gly Val His Ser Gly Asp Ala Thr Leu Met Leu Pro Thr Gln Thr Ile	
	1200 1205 1210 1215	
	agc caa ggg gcc att gaa aag gtg aag gat gct acc cgg aag att gca	3816
	Ser Gln Gly Ala Ile Glu Lys Val Lys Asp Ala Thr Arg Lys Ile Ala	
	1220 1225 1230	
20	aag gct ttt gcc atc tct ggt cca ttc aac gtc caa ttt ctt gtc aaa	3864
	Lys Ala Phe Ala Ile Ser Gly Pro Phe Asn Val Gln Phe Leu Val Lys	
	1235 1240 1245	
	gga aat gat gtc ttg gtg att gag tgt aac ttg aga gct tct cga tcc	3912
	Gly Asn Asp Val Leu Val Ile Glu Cys Asn Leu Arg Ala Ser Arg Ser	
	1250 1255 1260	
25	ttc ccc ttt gtt tcc aag act ctt ggg gtt gac ttc att gat gtg gcc	3960
	Phe Pro Phe Val Ser Lys Thr Leu Gly Val Asp Phe Ile Asp Val Ala	
	1265 1270 1275	
	acc aag gtg atg att gga gag aat gtt gat gag aaa cat ctt cca aca	4008
30	Thr Lys Val Met Ile Gly Glu Asn Val Asp Glu Lys His Leu Pro Thr	
	1280 1285 1290 1295	
	ttg gac cat ccc ata att cct gct gac tat gtt gca att aag gct ccc	4056
	Leu Asp His Pro Ile Ile Pro Ala Asp Tyr Val Ala Ile Lys Ala Pro	
	1300 1305 1310	
35	atg ttt tcc tgg ccc cgg ttg agg gat gct gac ccc att ctg aga tgt	4104
	Met Phe Ser Trp Pro Arg Leu Arg Asp Ala Asp Pro Ile Leu Arg Cys	
	1315 1320 1325	
	gag atg gct tcc act gga gag gtg gct tgc ttt ggt gaa ggt att cat	4152
	Glu Met Ala Ser Thr Gly Glu Val Ala Cys Phe Gly Glu Gly Ile His	
	1330 1335 1340	
40	aca gcc ttc cta aag gca atg ctt tcc aca gga ttt aag ata ccc cag	4200
	Thr Ala Phe Leu Lys Ala Met Leu Ser Thr Gly Phe Lys Ile Pro Gln	
	1345 1350 1355	
45	aaa ggc atc ctg ata ggc atc cag caa tca ttc cgg cca aga ttc ctt	4248
	Lys Gly Ile Leu Ile Gly Ile Gln Gln Ser Phe Arg Pro Arg Phe Leu	
	1360 1365 1370 1375	
	ggg gtg gct gaa caa tta cac aat gaa ggt ttc aag ctg ttt gcc acg	4296
	Gly Val Ala Glu Gln Leu His Asn Glu Gly Phe Lys Leu Phe Ala Thr	
	1380 1385 1390	
50	gaa gcc aca tca gac tgg ctc aac gcc aac aat gtc cct gcc aac cca	4344
	Glu Ala Thr Ser Asp Trp Leu Asn Ala Asn Asn Val Pro Ala Asn Pro	
	1395 1400 1405	
	gtg gca tgg ccg tct caa gaa gga cag aat ccc agc ctc tct tcc atc	4392
	Val Ala Trp Pro Ser Gln Glu Gly Gln Asn Pro Ser Leu Ser Ser Ile	
	1410 1415 1420	
55	aga aaa ttg att aga gat ggc agc att gac cta gtg att aac ctt ccc	4440

Arg Lys Leu Ile Arg Asp Gly Ser Ile Asp Leu Val Ile Asn Leu Pro
1425 1430 1435

5 aac aac aac act aaa ttt gtc cat gat aat tat gtg att cgg agg aca 4488
Asn Asn Asn Thr Lys Phe Val His Asp Asn Tyr Val Ile Arg Arg Thr
1440 1445 1450 1455

gct gtt gat agt gga atc cct ctc ctc act aat ttt cag gtg acc aaa 4536
Ala Val Asp Ser Gly Ile Pro Leu Leu Thr Asn Phe Gln Val Thr Lys
1460 1465 1470

10 ctt ttt gct gaa gct gtg cag aaa tct cgc aag gtg gac tcc aag agt 4584
Leu Phe Ala Glu Ala Val Gln Lys Ser Arg Lys Val Asp Ser Lys Ser
1475 1480 1485

ctt ttc cac tac agg cag tac agt gct gga aaa gca gca tag 4626
Leu Phe His Tyr Arg Gln Tyr Ser Ala Gly Lys Ala Ala
1490 1495 1500

15 agatgcagac accccagccc cattattaaa tcaacctgag ccacatgtta tctaaaggaa 4686

ctgattcaca actttctcag agatgaatat tgataactaa acttcatttc agtttacttt 4746

gttatgcctt aatattctgt gtcttttgca attaaattgt cagtcacttc ttcaaaacct 4806

tacagtccct cctaagttac tcttcatgag atttcatcca ttactaata ctgtattttt 4866

ggtaggactag gcttgccat gtgcttatgt gtagcttttt actttttatg gtgctgatta 4926

20 atgggtgatca aggtaggaaa agttgctgtt ctattttctg aactctttct atactttaag 4986

atactctatt tttaaaacac tatctgcaaa ctccaggacac tttacaggag cagaatactc 5046

taaaaacttg ataaaatgaa atatatgattt aatttatgaa ctttccatca tgatgtttgt 5106

gtattgcttc tttttggatc ctcatcttca cccatttggc taatccagga atattgttat 5166

cccttcccat tatattgaag ttgagaaatg tgacagaggc atttagagta tggacttttc 5226

25 ttttcttttt cttttctttt ttttctttt gagatggagt cacactctcc aggctggagt 5286

gcagtggcac aatctcggct cactgcaatt tgcgtctccc aagtccaagc gattctcctg 5346

ctttagacta tggatttctt taaggaatac tggtttgag ttttgtttcc tggactatat 5406

cagcagatgg tagacagtgt ttatgtagat gtgtgtttgt ttttatcatt ggattttaac 5466

ttggcccagag tgaaataatc agatttttgt cattcacact ctccccagc tttggaataa 5526

30 cttggaagta aggttcattc ccttaagacg atggattctg ttgaactatg ggggtcccaca 5586

ctgcactatt aattccaccc actgtaaggc caaggacacc attccttcta catataagaa 5646

aaaagtctct ccccaagggc agcctttgtt acttttaaat attttctgtt attacaagtg 5706

ctctaattgt gaacttttaa ataaaatact attaagaggt aaaaaaaaaa aaaaa 5761

<210> 12

35 <211> 1500

<212> PRT

<213> Homo sapiens

<400> 12

Met Thr Arg Lue Leu Thr Ala Phe Lys Val Val Arg Thr Leu Lys Thr
1 5 10 15

Gly Phe Gly Phe Thr Asn Val Thr Ala His Gln Lys Trp Lys Phe Ser
20 25 30

5 Arg Pro Gly Ile Arg Leu Leu Ser Val Lys Ala Gln Thr Ala His Ile
35 40 45

Val Leu Glu Asp Gly Thr Lys Met Lys Gly Tyr Ser Phe Gly His Pro
50 55 60

10 Ser Ser Val Ala Gly Glu Val Val Phe Asn Thr Gly Leu Gly Gly Tyr
65 70 75 80

Pro Glu Ala Ile Thr Asp Pro Ala Tyr Lys Gly Gln Ile Leu Thr Met
85 90 95

Ala Asn Pro Ile Ile Gly Asn Gly Gly Ala Pro Asp Thr Thr Ala Leu
100 105 110

15 Asp Glu Leu Gly Leu Ser Lys Tyr Leu Glu Ser Asn Gly Ile Lys Val
115 120 125

Ser Gly Leu Leu Val Leu Asp Tyr Ser Lys Asp Tyr Asn His Trp Leu
130 135 140

20 Ala Thr Lys Ser Leu Gly Gln Trp Leu Gln Glu Lys Val Pro Ala
145 150 155 160

Ile Tyr Gly Val Asp Thr Arg Met Leu Thr Lys Ile Ile Arg Asp Lys
165 170 175

Gly Thr Met Leu Gly Lys Ile Glu Phe Glu Gly Gln Pro Val Asp Phe
180 185 190

25 Val Asp Pro Asn Lys Gln Asn Leu Ile Ala Glu Val Ser Thr Lys Asp
195 200 205

Val Lys Val Tyr Gly Lys Gly Asn Pro Thr Lys Val Val Ala Val Asp
210 215 220

30 Cys Gly Ile Lys Asn Asn Val Ile Arg Leu Leu Val Lys Arg Gly Ala
225 230 235 240

Glu Val His Leu Val Pro Trp Asn His Asp Phe Thr Lys Met Glu Tyr
245 250 255

Asp Gly Ile Leu Ile Ala Gly Gly Pro Gly Asn Pro Ala Leu Ala Glu
260 265 270

35 Pro Leu Ile Gln Asn Val Arg Lys Ile Leu Glu Ser Asp Arg Lys Glu
275 280 285

Pro Leu Phe Gly Ile Ser Thr Gly Asn Leu Ile Thr Gly Leu Ala Ala
290 295 300

40 Gly Ala Lys Thr Tyr Lys Met Ser Met Ala Asn Arg Gly Gln Asn Gln
305 310 315 320

Pro Val Leu Asn Ile Thr Asn Lys Gln Ala Phe Ile Thr Ala Gln Asn
325 330 335

His Gly Tyr Ala Leu Asp Asn Thr Leu Pro Ala Gly Trp Lys Pro Leu
340 345 350

45 Phe Val Asn Val Asn Asp Gln Thr Asn Glu Gly Ile Met His Glu Ser
355 360 365

Lys Pro Phe Phe Ala Val Gln Phe His Pro Glu Val Thr Pro Gly Pro
370 375 380

Ile Asp Thr Glu Tyr Leu Phe Asp Ser Phe Phe Ser Leu Ile Lys Lys

[illegible]

Ile Gly Arg Thr Phe Glu Glu Ser Phe Gln Lys Ala Leu Arg Met Cys
805 810 815

Trp Pro Ser Asn Leu Asp Leu Arg Lys Glu Leu Ser Glu Pro Ser Ser
835 840 845

Asp Glu Ile Glu Lys Leu Thr Tyr Ile Asp Lys Trp Phe Leu Tyr Lys
865 870 875 880

Met Arg Asp Ile Leu Asn Met Glu Lys Thr Leu Lys Gly Leu Asn Ser
885 890 895

Ser Asp Lys Gln Ile Ser Lys Cys Leu Gly Leu Thr Glu Ala Gln Thr
915 920 925

Asp Thr Leu Ala Ala Glu Tyr Pro Ser Val Thr Asn Tyr Leu Tyr Val
945 950 955 960

Thr Tyr Asn Gly Gln Glu His Asp Val Asn Phe Asp Asp His Gly Met
965 970 975

Asp Trp Cys Ala Val Ser Ser Ile Arg Thr Leu Arg Gln Leu Gly Lys
995 1000 1005

Asp Glu Cys Asp Lys Leu Tyr Phe Glu Glu Leu Ser Leu Glu Arg Ile
025 1030 1035 1040

Leu Asp Ile Tyr His Gln Glu Ala Cys Gly Gly Cys Ile Ile Ser Val
1045 1050 1055

Val Lys Ile Met Gly Thr Ser Pro Leu Gln Ile Asp Arg Ala Glu Asp
1075 1080 1085

Pro Trp Lys Ala Val Asn Thr Leu Asn Glu Ala Leu Glu Phe Ala Lys
105 1110 1115 1120

Ser Val Asp Tyr Pro Cys Leu Leu Arg Pro Ser Tyr Val Leu Ser Gly
1125 1130 1135

Glu Glu Ala Thr Arg Val Ser Gln Glu His Pro Val Val Leu Thr Lys
1155 1160 1165

Phe Val Glu Gly Ala Arg Glu Val Glu Met Asp Ala Val Gly Lys Asp

	1170	1175	1180
	Gly Arg Val Ile Ser His Ala Ile Ser Glu His Val Glu Asp Ala Gly		
	185	1190	1195 1200
5	Val His Ser Gly Asp Ala Thr Leu Met Leu Pro Thr Gln Thr Ile Ser		
		1205	1210 1215
	Gln Gly Ala Ile Glu Lys Val Lys Asp Ala Thr Arg Lys Ile Ala Lys		
		1220	1225 1230
	Ala Phe Ala Ile Ser Gly Pro Phe Asn Val Gln Phe Leu Val Lys Gly		
		1235	1240 1245
10	Asn Asp Val Leu Val Ile Glu Cys Asn Leu Arg Ala Ser Arg Ser Phe		
		1250	1255 1260
	Pro Phe Val Ser Lys Thr Leu Gly Val Asp Phe Ile Asp Val Ala Thr		
		1265	1270 1275 1280
15	Lys Val Met Ile Gly Glu Asn Val Asp Glu Lys His Leu Pro Thr Leu		
		1285	1290 1295
	Asp His Pro Ile Ile Pro Ala Asp Tyr Val Ala Ile Lys Ala Pro Met		
		1300	1305 1310
	Phe Ser Trp Pro Arg Leu Arg Asp Ala Asp Pro Ile Leu Arg Cys Glu		
		1315	1320 1325
20	Met Ala Ser Thr Gly Glu Val Ala Cys Phe Gly Glu Gly Ile His Thr		
		1330	1335 1340
	Ala Phe Leu Lys Ala Met Leu Ser Thr Gly Phe Lys Ile Pro Gln Lys		
		1345	1350 1355 1360
25	Gly Ile Leu Ile Gly Ile Gln Gln Ser Phe Arg Pro Arg Phe Leu Gly		
		1365	1370 1375
	Val Ala Glu Gln Leu His Asn Glu Gly Phe Lys Leu Phe Ala Thr Glu		
		1380	1385 1390
	Ala Thr Ser Asp Trp Leu Asn Ala Asn Asn Val Pro Ala Asn Pro Val		
		1395	1400 1405
30	Ala Trp Pro Ser Gln Glu Gly Gln Asn Pro Ser Leu Ser Ser Ile Arg		
		1410	1415 1420
	Lys Leu Ile Arg Asp Gly Ser Ile Asp Leu Val Ile Asn Leu Pro Asn		
		1425	1430 1435 1440
35	Asn Asn Thr Lys Phe Val His Asp Asn Tyr Val Ile Arg Arg Thr Ala		
		1445	1450 1455
	Val Asp Ser Gly Ile Pro Leu Leu Thr Asn Phe Gln Val Thr Lys Leu		
		1460	1465 1470
	Phe Ala Glu Ala Val Gln Lys Ser Arg Lys Val Asp Ser Lys Ser Leu		
		1475	1480 1485
40	Phe His Tyr Arg Gln Tyr Ser Ala Gly Lys Ala Ala		
		1490	1495 1500

<210> 13

<211> 5761

<212> DNA

45 <213> Homo sapiens

<220>

<221> CDS

<222> (124)..(4626)

<400> 13

5 gtcagcctta aacactgact gcacccctcc cagatttctt ttacattaac taaaaagtct 60
tatcacacaa tctcataaaa tttatgtaat ttcatttaat tttagccaca aatcatcttc 120
aaa atg acg agg att att aca gct ttc aaa gtg gtg agg aca ctg aag 168
Met Thr Arg Ile Ile Thr Ala Phe Lys Val Val Arg Thr Leu Lys
1 5 10 15
10 act ggt ttt ggc ttt acc aat gtg act gca cac caa aaa tgg aaa ttt 216
Thr Gly Phe Gly Thr Asn Val Thr Ala His Gln Lys Trp Lys Phe
20 25 30
15 tca aga cct ggc atc agg ctc ctt tct gtc aag gca cag aca gca cac 264
Ser Arg Pro Gly Ile Arg Leu Leu Ser Val Lys Ala Gln Thr Ala His
35 40 45
att gtc ctg gaa gat gga act aag atg aaa ggt tac tcc ttt ggc cat 312
Ile Val Leu Glu Asp Gly Thr Lys Met Lys Gly Tyr Ser Phe Gly His
50 55 60
20 cca tcc tct gtt gct ggt gaa gtg gtt ttt aat act ggc ctg gga ggg 360
Pro Ser Ser Val Ala Gly Glu Val Val Phe Asn Thr Gly Leu Gly Gly
65 70 75
tac cca gaa gct att act gac cct gcc tac aaa gga cag att ctc aca 408
Tyr Pro Glu Ala Ile Thr Asp Pro Ala Tyr Lys Gly Gln Ile Leu Thr
80 85 90 95
25 atg gcc aac cct att att ggg aat ggt gga gct cct gat act act gct 456
Met Ala Asn Pro Ile Ile Gly Asn Gly Gly Ala Pro Asp Thr Thr Ala
100 105 110
30 ctg gat gaa ctg gga ctt agc aaa tat ttg gag tct aat gga atc aag 504
Leu Asp Glu Leu Gly Leu Ser Lys Tyr Leu Glu Ser Asn Gly Ile Lys
115 120 125
gtt tca ggt ttg ctg gtg ctg gat tat agt aaa gac tac aac cac tgg 552
Val Ser Gly Leu Leu Val Leu Asp Tyr Ser Lys Asp Tyr Asn His Trp
130 135 140
35 ctg gct acc aag agt tta ggg caa tgg cta cag gaa gaa aag gtt cct 600
Leu Ala Thr Lys Ser Leu Gly Gln Trp Leu Gln Glu Glu Lys Val Pro
145 150 155
gca att tat gga gtg gac aca aga atg ctg act aaa ata att cgg gat 648
Ala Ile Tyr Gly Val Asp Thr Arg Met Leu Thr Lys Ile Ile Arg Asp
160 165 170 175
40 aag ggt acc atg ctt ggg aag att gaa ttt gaa ggt cag cct gtg gat 696
Lys Gly Thr Met Leu Gly Lys Ile Glu Phe Glu Gly Gln Pro Val Asp
180 185 190
45 ttt gtg gat cca aat aaa cag aat ttg att gct gag gtt tca acc aag 744
Phe Val Asp Pro Asn Lys Gln Asn Leu Ile Ala Glu Val Ser Thr Lys
195 200 205
gat gtc aaa gtg tac ggc aaa gga aac ccc aca aaa gtg gta gct gta 792
Asp Val Lys Val Tyr Gly Lys Gly Asn Pro Thr Lys Val Val Ala Val
210 215 220
gac tgt ggg att aaa aac aat gta atc cgc ctg cta gta aag cga gga 840

bioRxiv preprint doi: <https://doi.org/10.1101/111111>; this version posted May 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

	Asp Cys Gly Ile Lys Asn Asn Val Ile Arg Leu Leu Val Lys Arg Gly	
	225 230 235	
5	gct gaa gtg cac tta gtt ccc tgg aac cat gat ttc acc aag atg gag Ala Glu Val His Leu Val Pro Trp Asn His Asp Phe Thr Lys Met Glu	888
	240 245 250 255	
	tat gat ggg att ttg atc gcg gga gga ccg ggg aac cca gct ctt gca Tyr Asp Gly Ile Leu Ile Ala Gly Gly Pro Gly Asn Pro Ala Leu Ala	936
	260 265 270	
10	gaa cca cta att cag aat gtc aga aag att ttg gag agt gat cgc aag Glu Pro Leu Ile Gln Asn Val Arg Lys Ile Leu Glu Ser Asp Arg Lys	984
	275 280 285	
	gag cca ttg ttt gga atc agt aca gga aac tta ata aca gga ttg gct Glu Pro Leu Phe Gly Ile Ser Thr Gly Asn Leu Ile Thr Gly Leu Ala	1032
	290 295 300	
15	gct ggt gcc aaa acc tac aag atg tcc atg gcc aac aga ggg cag aat Ala Gly Ala Lys Thr Tyr Lys Met Ser Met Ala Asn Arg Gly Gln Asn	1080
	305 310 315	
20	cag cct gtt ttg aat atc aca aac aaa cag gct ttc att act gct cag Gln Pro Val Leu Asn Ile Thr Asn Lys Gln Ala Phe Ile Thr Ala Gln	1128
	320 325 330 335	
	aat cat ggc tat gcc ttg gac aac acc ctc cct gct ggc tgg aaa cca Asn His Gly Tyr Ala Leu Asp Asn Thr Leu Pro Ala Gly Trp Lys Pro	1176
	340 345 350	
25	ctt ttt gtg aat gtc aac gat caa aca aat gag ggg att atg cat gag Leu Phe Val Asn Val Asn Asp Gln Thr Asn Glu Gly Ile Met His Glu	1224
	355 360 365	
	agc aaa ccc ttc ttc gct gtg cag ttc cac cca gag gtc acc ccg ggg Ser Lys Pro Phe Phe Ala Val Gln Phe His Pro Glu Val Thr Pro Gly	1272
	370 375 380	
30	cca ata gac act gag tac ctg ttt gat tcc ttt ttc tca ctg ata aag Pro Ile Asp Thr Glu Tyr Leu Phe Asp Ser Phe Phe Ser Leu Ile Lys	1320
	385 390 395	
35	aaa gga aaa gct acc acc att aca tca gtc tta ccg aag cca gca cta Lys Gly Lys Ala Thr Thr Ile Thr Ser Val Leu Pro Lys Pro Ala Leu	1368
	400 405 410 415	
	gtt gca tct cgg gtt gag gtt tcc aaa gtc ctt att cta gga tca gga Val Ala Ser Arg Val Glu Val Ser Lys Val Leu Ile Leu Gly Ser Gly	1416
	420 425 430	
40	ggc ctg tcc att ggt cag gct gga gaa ttt gat tac tca gga tct caa Gly Leu Ser Ile Gly Gln Ala Gly Glu Phe Asp Tyr Ser Gly Ser Gln	1464
	435 440 445	
	gct gta aaa gcc atg aag gaa gaa aat gtc aaa act gtt ctg atg aac Ala Val Lys Ala Met Lys Glu Glu Asn Val Lys Thr Val Leu Met Asn	1512
	450 455 460	
45	cca aac att gca tca gtc cag acc aat gag gtg ggc tta aag caa gcg Pro Asn Ile Ala Ser Val Gln Thr Asn Glu Val Gly Leu Lys Gln Ala	1560
	465 470 475	
	gat act gtc tac ttt ctt ccc atc acc cct cag ttt gtc aca gag gtc Asp Thr Val Tyr Phe Leu Pro Ile Thr Pro Gln Phe Val Thr Glu Val	1608
	480 485 490 495	
50	atc aag gca gaa cag cca gat ggg tta att ctg ggc atg ggt ggc cag Ile Lys Ala Glu Gln Pro Asp Gly Leu Ile Leu Gly Met Gly Gly Gln	1656
	500 505 510	
55	aca gct ctg aac tgt gga gtg gaa cta ttc aag aga ggt gtg ctc aag Thr Ala Leu Asn Cys Gly Val Glu Leu Phe Lys Arg Gly Val Leu Lys	1704
	515 520 525	

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted March 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

		gaa tat ggt gtg aaa gtc ctg gga act tca gtt gag tcc att atg gct Glu Tyr Gly Val Lys Val Leu Gly Thr Ser Val Glu Ser Ile Met Ala 530 535 540	1752
5		acg gaa gac agg cag ctg ttt tca gat aaa cta aat gag atc aat gaa Thr Glu Asp Arg Gln Leu Phe Ser Asp Lys Leu Asn Glu Ile Asn Glu 545 550 555	1800
		aag att gct cca agt ttt gca gtg gaa tcg att gag gat gca ctg aag Lys Ile Ala Pro Ser Phe Ala Val Glu Ser Ile Glu Asp Ala Leu Lys 560 565 570 575	1848
10		gca gca gac acc att ggc tac cca gtg atg atc cgt tcc gcc tat gca Ala Ala Asp Thr Ile Gly Tyr Pro Val Met Ile Arg Ser Ala Tyr Ala 580 585 590	1896
15		ctg ggt ggg tta ggc tca ggc atc tgt ccc aac aga gag act ttg atg Leu Gly Gly Leu Gly Ser Gly Ile Cys Pro Asn Arg Glu Thr Leu Met 595 600 605	1944
		gac ctc agc aca aag gcc ttt gct atg acc aac caa att ctg gtg gag Asp Leu Ser Thr Lys Ala Phe Ala Met Thr Asn Gln Ile Leu Val Glu 610 615 620	1992
20		aag tca gtg aca ggt tgg aaa gaa ata gaa tat gaa gtg gtt cga gat Lys Ser Val Thr Gly Trp Lys Glu Ile Glu Tyr Glu Val Val Arg Asp 625 630 635	2040
		gct gat gac aat tgt gtc act gtc tgt aac atg gaa aat gtt gat gcc Ala Asp Asp Asn Cys Val Thr Val Cys Asn Met Glu Asn Val Asp Ala 640 645 650 655	2088
25		atg ggt gtt cac aca ggt gac tca gtt gtt gtg gct cct gcc cag aca Met Gly Val His Thr Gly Asp Ser Val Val Val Ala Pro Ala Gln Thr 660 665 670	2136
30		ctc tcc aat gcc gag ttt cag atg ttg aga cgt act tca atc aat gtt Leu Ser Asn Ala Glu Phe Gln Met Leu Arg Arg Thr Ser Ile Asn Val 675 680 685	2184
		gtt cgc cac ttg ggc att gtg ggt gaa tgc aac att cag ttt gcc ctt Val Arg His Leu Gly Ile Val Gly Glu Cys Asn Ile Gln Phe Ala Leu 690 695 700	2232
35		cat cct acc tca atg gaa tac tgc atc att gaa gtg aat gcc aga ctg His Pro Thr Ser Met Glu Tyr Cys Ile Ile Glu Val Asn Ala Arg Leu 705 710 715	2280
		tcc cga agc tct gct ctg gcc tca aaa gcc act ggc tac cca ttg gca Ser Arg Ser Ser Ala Leu Ala Ser Lys Ala Thr Gly Tyr Pro Leu Ala 720 725 730 735	2328
40		ttc att gct gca aag att gcc cta gga atc cca ctt cca gaa att aag Phe Ile Ala Ala Lys Ile Ala Leu Gly Ile Pro Leu Pro Glu Ile Lys 740 745 750	2376
45		aac gtc gta tcc ggg aag aca tca gcc tgt ttt gaa cct agc ctg gat Asn Val Val Ser Gly Lys Thr Ser Ala Cys Phe Glu Pro Ser Leu Asp 755 760 765	2424
		tac atg gtc acc aag att ccc cgc tgg gat ctt gac cgt ttt cat gga Tyr Met Val Thr Lys Ile Pro Arg Trp Asp Leu Asp Arg Phe His Gly 770 775 780	2472
50		aca tct agc cga att ggt agc tct atg aaa agt gta gga gag gtc atg Thr Ser Ser Arg Ile Gly Ser Ser Met Lys Ser Val Gly Glu Val Met 785 790 795	2520
		gct att ggt cgt acc ttt gag gag agt ttc cag aaa gct tta cgg atg Ala Ile Gly Arg Thr Phe Glu Glu Ser Phe Gln Lys Ala Leu Arg Met 800 805 810 815	2568
55		tgc cac cca tct ata gaa ggt ttc act ccc cgt ctc cca atg aac aaa	2616

	Cys His Pro Ser Ile Glu Gly Phe Thr Pro Arg Leu Pro Met Asn Lys	
	820 825 830	
5	gaa tgg cca tct aat tta gat ctt aga aaa gag ttg tct gaa cca agc Glu Trp Pro Ser Asn Leu Asp Leu Arg Lys Glu Leu Ser Glu Pro Ser	2664
	835 840 845	
	agc acg cgt atc tat gcc att gcc aag gcc att gat gac aac atg tcc Ser Thr Arg Ile Tyr Ala Ile Ala Lys Ala Ile Asp Asp Asn Met Ser	2712
	850 855 860	
10	ctt gat gag att gag aag ctc aca tac att gac aag tgg ttt ttg tat Leu Asp Glu Ile Glu Lys Leu Thr Tyr Ile Asp Lys Trp Phe Leu Tyr	2760
	865 870 875	
	aag atg cgt gat att tta aac atg gaa aag aca ctg aaa ggg ctc aac Lys Met Arg Asp Ile Leu Asn Met Glu Lys Thr Leu Lys Gly Leu Asn	2808
	880 885 890 895	
15	agt gag tcc atg aca gaa gaa acc ctg aaa agg gca aag gag att ggg Ser Glu Ser Met Thr Glu Glu Thr Leu Lys Arg Ala Lys Glu Ile Gly	2856
	900 905 910	
20	ttc tca gat aag cag att tca aaa tgc ctt ggg ctc act gag gcc cag Phe Ser Asp Lys Gln Ile Ser Lys Cys Leu Gly Leu Thr Glu Ala Gln	2904
	915 920 925	
	aca agg gag ctg agg tta aag aaa aac atc cac cct tgg gtt aaa cag Thr Arg Glu Leu Arg Leu Lys Lys Asn Ile His Pro Trp Val Lys Gln	2952
	930 935 940	
25	att gat aca ctg gct gca gaa tac cca tca gta aca aac tat ctc tat Ile Asp Thr Leu Ala Ala Glu Tyr Pro Ser Val Thr Asn Tyr Leu Tyr	3000
	945 950 955	
	gtt acc tac aat ggt cag gag cat gat gtc aat ttt gat gac cat gga Val Thr Tyr Asn Gly Gln Glu His Asp Val Asn Phe Asp Asp His Gly	3048
	960 965 970 975	
30	atg atg gtg cta ggc tgt ggt cca tat cac att ggc agc agt gtg gaa Met Met Val Leu Gly Cys Gly Pro Tyr His Ile Gly Ser Ser Val Glu	3096
	980 985 990	
35	ttt gat tgg tgt gct gtc tct agt atc cgc aca ctg cgt caa ctt ggc Phe Asp Trp Cys Ala Val Ser Ser Ile Arg Thr Leu Arg Gln Leu Gly	3144
	995 1000 1005	
	aag aag acg gtg gtg gtg aat tgc aat cct gag act gtg agc aca gac Lys Lys Thr Val Val Val Asn Cys Asn Pro Glu Thr Val Ser Thr Asp	3192
	1010 1015 1020	
40	ttt gat gag tgt gac aaa ctg tac ttt gaa gag ttg tcc ttg gag aga Phe Asp Glu Cys Asp Lys Leu Tyr Phe Glu Glu Leu Ser Leu Glu Arg	3240
	1025 1030 1035	
	atc cta gac atc tac cat cag gag gca tgt ggt ggc tgc atc ata tca Ile Leu Asp Ile Tyr His Gln Glu Ala Cys Gly Gly Cys Ile Ile Ser	3288
	1040 1045 1050 1055	
45	gtt gga ggc cag att cca aac aac ctg gca gtt cct cta tac aag aat Val Gly Gly Gln Ile Pro Asn Asn Leu Ala Val Pro Leu Tyr Lys Asn	3336
	1060 1065 1070	
50	ggt gtc aag atc atg ggc aca agc ccc ctg cag atc gac agg gct gag Gly Val Lys Ile Met Gly Thr Ser Pro Leu Gln Ile Asp Arg Ala Glu	3384
	1075 1080 1085	
	gat cgc tcc atc ttc tca gct gtc ttg gat gag ctg aag gtg gct cag Asp Arg Ser Ile Phe Ser Ala Val Leu Asp Glu Leu Lys Val Ala Gln	3432
	1090 1095 1100	
55	gca cct tgg aaa gct gtt aat act ttg aat gaa gca ctg gaa ttt gca Ala Pro Trp Lys Ala Val Asn Thr Leu Asn Glu Ala Leu Glu Phe Ala	3480

From: https://www.ncbi.nlm.nih.gov/nucl/1000000000/

	1105	1110	1115	
	aag tct gtg gac tac ccc tgc ttg ttg agg cct tcc tat gtt ttg agt Lys Ser Val Asp Tyr Pro Cys Leu Leu Arg Pro Ser Tyr Val Leu Ser 1120 1125 1130 1135	3528		
5	ggg tct gct atg aat gtg gta ttc tct gag gat gag atg aaa aaa ttc Gly Ser Ala Met Asn Val Val Phe Ser Glu Asp Glu Met Lys Lys Phe 1140 1145 1150	3576		
10	cta gaa gag gcg act aga gtt tct cag gag cac cca gtg gtc ctg aca Leu Glu Glu Ala Thr Arg Val Ser Gln Glu His Pro Val Val Leu Thr 1155 1160 1165	3624		
	aaa ttt gtt gaa ggg gcc cga gaa gta gaa atg gac gct gtt ggc aaa Lys Phe Val Glu Gly Ala Arg Glu Val Glu Met Asp Ala Val Gly Lys 1170 1175 1180	3672		
15	gat gga agg gtt atc tct cat gcc atc tct gaa cat gtt gaa gat gca Asp Gly Arg Val Ile Ser His Ala Ile Ser Glu His Val Glu Asp Ala 1185 1190 1195	3720		
	ggg gtc cac tgc gga gat gcc act ctg atg ctg ccc aca caa acc atc Gly Val His Ser Gly Asp Ala Thr Leu Met Leu Pro Thr Gln Thr Ile 1200 1205 1210 1215	3768		
20	agc caa ggg gcc att gaa aag gtg aag gat gct acc cgg aag att gca Ser Gln Gly Ala Ile Glu Lys Val Lys Asp Ala Thr Arg Lys Ile Ala 1220 1225 1230	3816		
25	aag gct ttt gcc atc tct ggt cca ttc aac gtc caa ttt ctt gtc aaa Lys Ala Phe Ala Ile Ser Gly Pro Phe Asn Val Gln Phe Leu Val Lys 1235 1240 1245	3864		
	gga aat gat gtc ttg gtg att gag tgt aac ttg aga gct tct cga tcc Gly Asn Asp Val Leu Val Ile Glu Cys Asn Leu Arg Ala Ser Arg Ser 1250 1255 1260	3912		
30	ttc ccc ttt gtt tcc aag act ctt ggg gtt gac ttc att gat gtg gcc Phe Pro Phe Val Ser Lys Thr Leu Gly Val Asp Phe Ile Asp Val Ala 1265 1270 1275	3960		
	acc aag gtg atg att gga gag aat gtt gat gag aaa cat ctt cca aca Thr Lys Val Met Ile Gly Glu Asn Val Asp Glu Lys His Leu Pro Thr 1280 1285 1290 1295	4008		
35	ttg gac cat ccc ata att cct gct gac tat gtt gca att aag gct ccc Leu Asp His Pro Ile Ile Pro Ala Asp Tyr Val Ala Ile Lys Ala Pro 1300 1305 1310	4056		
40	atg ttt tcc tgg ccc cgg ttg agg gat gct gac ccc att ctg aga tgt Met Phe Ser Trp Pro Arg Leu Arg Asp Ala Asp Pro Ile Leu Arg Cys 1315 1320 1325	4104		
	gag atg gct tcc act gga gag gtg gct tgc ttt ggt gaa ggt att cat Glu Met Ala Ser Thr Gly Glu Val Ala Cys Phe Gly Glu Gly Ile His 1330 1335 1340	4152		
45	aca gcc ttc cta aag gca atg ctt tcc aca gga ttt aag ata ccc cag Thr Ala Phe Leu Lys Ala Met Leu Ser Thr Gly Phe Lys Ile Pro Gln 1345 1350 1355	4200		
	aaa ggc atc ctg ata ggc atc cag caa tca ttc cgg cca aga ttc ctt Lys Gly Ile Leu Ile Gly Ile Gln Gln Ser Phe Arg Pro Arg Phe Leu 1360 1365 1370 1375	4248		
50	ggg gtg gct gaa caa tta cac aat gaa ggt ttc aag ctg ttt gcc acg Gly Val Ala Glu Gln Leu His Asn Glu Gly Phe Lys Leu Phe Ala Thr 1380 1385 1390	4296		
55	gaa gcc aca tca gac tgg ctc aac gcc aac aat gtc cct gcc aac cca Glu Ala Thr Ser Asp Trp Leu Asn Ala Asn Asn Val Pro Ala Asn Pro 1395 1400 1405	4344		

CC-BY-NC-ND 4.0 International license

gtg gca tgg ccg tct caa gaa gga cag aat ccc agc ctc tct tcc atc 4392
Val Ala Trp Pro Ser Gln Glu Gly Gln Asn Pro Ser Leu Ser Ser Ile
1410 1415 1420

5 aga aaa ttg att aga gat ggc agc att gac cta gtg att aac ctt ccc 4440
Arg Lys Leu Ile Arg Asp Gly Ser Ile Asp Leu Val Ile Asn Leu Pro
1425 1430 1435

aac aac aac act aaa ttt gtc cat gat aat tat gtg att cgg agg aca 4488
Asn Asn Asn Thr Lys Phe Val His Asp Asn Tyr Val Ile Arg Arg Thr
1440 1445 1450 1455

10 gct gtt gat agt gga atc cct ctc ctc act aat ttt cag gtg acc aaa 4536
Ala Val Asp Ser Gly Ile Pro Leu Leu Thr Asn Phe Gln Val Thr Lys
1460 1465 1470

15 ctt ttt gct gaa gct gtg cag aaa tct cgc aag gtg gac tcc aag agt 4584
Leu Phe Ala Glu Ala Val Gln Lys Ser Arg Lys Val Asp Ser Lys Ser
1475 1480 1485

ctt ttc cac tac agg cag tac agt gct gga aaa gca gca tag 4626
Leu Phe His Tyr Arg Gln Tyr Ser Ala Gly Lys Ala Ala
1490 1495 1500

20 agatgcagac accccagccc cattattaaa tcaacctgag ccacatgtta tctaaaggaa 4686
ctgattcaca actttctcag agatgaatat tgataactaa acttcatttc agtttacttt 4746
gttatgcctt aatattctgt gtcttttgca attaaattgt cagtcacttc ttcaaaacct 4806
tacagtccct cctaagttac tcttcatgag atttcatcca ttactaata ctgtattttt 4866
gggtggactag gcttgccat gtgcttatgt gtagcttttt actttttatg gtgctgatta 4926
atgggtgatca aggtaggaaa agttgctgtt ctattttctg aactctttct atactttaag 4986

25 atactctatt tttaaaacac tatctgcaaa ctccaggacac tttacaggag cagaatactc 5046
taaaaacttg ataaaatgaa atatatgattt aatttatgaa ccttccatca tgatgtttgt 5106
gtattgcttc tttttggatc ctcatctcca cccatttgcc taatccagga atattgttat 5166
cccttcccat tatattgaag ttgagaaatg tgacagaggc atttagagta tggacttttc 5226
ttttcttttt cttttctttt ttttcttttt gagatggagt cacactctcc aggctggagt 5286

30 gcagtggcac aatctcggct cactgcaatt tgcgtctccc aagtccaagc gattctcctg 5346
ctttagacta tggatttctt taaggaatac tggtttgag ttttgtttc tggactatat 5406
cagcagatgg tagacagtgt ttatgtagat gtgttggtgt ttttatcatt ggattttaac 5466
ttggcccag tgaaataatc agatttttgt cattcacact ctccccagt tttggaataa 5526
cttggaaagta aggttcattc ccttaagacg atggattctg ttgaactatg ggggtcccaca 5586

35 ctgcactatt aattccaccc actgtaaggc caaggacacc attccttcta catataagaa 5646
aaaagtcctt ccccaagggc agcctttgtt acttttaaat attttctgtt attacaagtg 5706
ctctaattgt gaacttttaa ataaaatact attaaagagt aaaaaaaaa aaaaa 5761

<210> 14

<211> 1500

40 <212> PRT

<213> Homo sapiens

<400> 14

Met Thr Arg Ile Ile Thr Ala Phe Lys Val Val Arg Thr Leu Lys Thr
1 5 10 15

5 Gly Phe Gly Phe Thr Asn Val Thr Ala His Gln Lys Trp Lys Phe Ser
20 25 30

Arg Pro Gly Ile Arg Leu Leu Ser Val Lys Ala Gln Thr Ala His Ile
35 40 45

Val Leu Glu Asp Gly Thr Lys Met Lys Gly Tyr Ser Phe Gly His Pro
50 55 60

10 Ser Ser Val Ala Gly Glu Val Val Phe Asn Thr Gly Leu Gly Gly Tyr
65 70 75 80

Pro Glu Ala Ile Thr Asp Pro Ala Tyr Lys Gly Gln Ile Leu Thr Met
85 90 95

15 Ala Asn Pro Ile Ile Gly Asn Gly Gly Ala Pro Asp Thr Thr Ala Leu
100 105 110

Asp Glu Leu Gly Leu Ser Lys Tyr Leu Glu Ser Asn Gly Ile Lys Val
115 120 125

Ser Gly Leu Leu Val Leu Asp Tyr Ser Lys Asp Tyr Asn His Trp Leu
130 135 140

20 Ala Thr Lys Ser Leu Gly Gln Trp Leu Gln Glu Lys Val Pro Ala
145 150 155 160

Ile Tyr Gly Val Asp Thr Arg Met Leu Thr Lys Ile Ile Arg Asp Lys
165 170 175

25 Gly Thr Met Leu Gly Lys Ile Glu Phe Glu Gly Gln Pro Val Asp Phe
180 185 190

Val Asp Pro Asn Lys Gln Asn Leu Ile Ala Glu Val Ser Thr Lys Asp
195 200 205

Val Lys Val Tyr Gly Lys Gly Asn Pro Thr Lys Val Val Ala Val Asp
210 215 220

30 Cys Gly Ile Lys Asn Asn Val Ile Arg Leu Leu Val Lys Arg Gly Ala
225 230 235 240

Glu Val His Leu Val Pro Trp Asn His Asp Phe Thr Lys Met Glu Tyr
245 250 255

35 Asp Gly Ile Leu Ile Ala Gly Gly Pro Gly Asn Pro Ala Leu Ala Glu
260 265 270

Pro Leu Ile Gln Asn Val Arg Lys Ile Leu Glu Ser Asp Arg Lys Glu
275 280 285

Pro Leu Phe Gly Ile Ser Thr Gly Asn Leu Ile Thr Gly Leu Ala Ala
290 295 300

40 Gly Ala Lys Thr Tyr Lys Met Ser Met Ala Asn Arg Gly Gln Asn Gln
305 310 315 320

Pro Val Leu Asn Ile Thr Asn Lys Gln Ala Phe Ile Thr Ala Gln Asn
325 330 335

45 His Gly Tyr Ala Leu Asp Asn Thr Leu Pro Ala Gly Trp Lys Pro Leu
340 345 350

Phe Val Asn Val Asn Asp Gln Thr Asn Glu Gly Ile Met His Glu Ser
355 360 365

Lys Pro Phe Phe Ala Val Gln Phe His Pro Glu Val Thr Pro Gly Pro

[illegible]

Met Val Thr Lys Ile Pro Arg Trp Asp Leu Asp Arg Phe His Gly Thr
770 775 780

Ser Ser Arg Ile Gly Ser Ser Met Lys Ser Val Gly Glu Val Met Ala
785 790 795 800

5 Ile Gly Arg Thr Phe Glu Glu Ser Phe Gln Lys Ala Leu Arg Met Cys
805 810 815

His Pro Ser Ile Glu Gly Phe Thr Pro Arg Leu Pro Met Asn Lys Glu
820 825 830

10 Trp Pro Ser Asn Leu Asp Leu Arg Lys Glu Leu Ser Glu Pro Ser Ser
835 840 845

Thr Arg Ile Tyr Ala Ile Ala Lys Ala Ile Asp Asp Asn Met Ser Leu
850 855 860

Asp Glu Ile Glu Lys Leu Thr Tyr Ile Asp Lys Trp Phe Leu Tyr Lys
865 870 875 880

15 Met Arg Asp Ile Leu Asn Met Glu Lys Thr Leu Lys Gly Leu Asn Ser
885 890 895

Glu Ser Met Thr Glu Glu Thr Leu Lys Arg Ala Lys Glu Ile Gly Phe
900 905 910

20 Ser Asp Lys Gln Ile Ser Lys Cys Leu Gly Leu Thr Glu Ala Gln Thr
915 920 925

Arg Glu Leu Arg Leu Lys Lys Asn Ile His Pro Trp Val Lys Gln Ile
930 935 940

Asp Thr Leu Ala Ala Glu Tyr Pro Ser Val Thr Asn Tyr Leu Tyr Val
945 950 955 960

25 Thr Tyr Asn Gly Gln Glu His Asp Val Asn Phe Asp Asp His Gly Met
965 970 975

Met Val Leu Gly Cys Gly Pro Tyr His Ile Gly Ser Ser Val Glu Phe
980 985 990

30 Asp Trp Cys Ala Val Ser Ser Ile Arg Thr Leu Arg Gln Leu Gly Lys
995 1000 1005

Lys Thr Val Val Val Asn Cys Asn Pro Glu Thr Val Ser Thr Asp Phe
1010 1015 1020

Asp Glu Cys Asp Lys Leu Tyr Phe Glu Glu Leu Ser Leu Glu Arg Ile
1025 1030 1035 1040

35 Leu Asp Ile Tyr His Gln Glu Ala Cys Gly Gly Cys Ile Ile Ser Val
1045 1050 1055

Gly Gly Gln Ile Pro Asn Asn Leu Ala Val Pro Leu Tyr Lys Asn Gly
1060 1065 1070

40 Val Lys Ile Met Gly Thr Ser Pro Leu Gln Ile Asp Arg Ala Glu Asp
1075 1080 1085

Arg Ser Ile Phe Ser Ala Val Leu Asp Glu Leu Lys Val Ala Gln Ala
1090 1095 1100

Pro Trp Lys Ala Val Asn Thr Leu Asn Glu Ala Leu Glu Phe Ala Lys
1105 1110 1115 1120

45 Ser Val Asp Tyr Pro Cys Leu Leu Arg Pro Ser Tyr Val Leu Ser Gly
1125 1130 1135

Ser Ala Met Asn Val Val Phe Ser Glu Asp Glu Met Lys Lys Phe Leu
1140 1145 1150

Glu Glu Ala Thr Arg Val Ser Gln Glu His Pro Val Val Leu Thr Lys

1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 10000

	1155	1160	1165
	Phe Val Glu Gly Ala Arg Glu Val Glu Met Asp Ala Val Gly Lys Asp 1170 1175 1180		
5	Gly Arg Val Ile Ser His Ala Ile Ser Glu His Val Glu Asp Ala Gly 185 1190 1195 1200		
	Val His Ser Gly Asp Ala Thr Leu Met Leu Pro Thr Gln Thr Ile Ser 1205 1210 1215		
	Gln Gly Ala Ile Glu Lys Val Lys Asp Ala Thr Arg Lys Ile Ala Lys 1220 1225 1230		
10	Ala Phe Ala Ile Ser Gly Pro Phe Asn Val Gln Phe Leu Val Lys Gly 1235 1240 1245		
	Asn Asp Val Leu Val Ile Glu Cys Asn Leu Arg Ala Ser Arg Ser Phe 1250 1255 1260		
15	Pro Phe Val Ser Lys Thr Leu Gly Val Asp Phe Ile Asp Val Ala Thr 265 1270 1275 1280		
	Lys Val Met Ile Gly Glu Asn Val Asp Glu Lys His Leu Pro Thr Leu 1285 1290 1295		
	Asp His Pro Ile Ile Pro Ala Asp Tyr Val Ala Ile Lys Ala Pro Met 1300 1305 1310		
20	Phe Ser Trp Pro Arg Leu Arg Asp Ala Asp Pro Ile Leu Arg Cys Glu 1315 1320 1325		
	Met Ala Ser Thr Gly Glu Val Ala Cys Phe Gly Glu Gly Ile His Thr 1330 1335 1340		
25	Ala Phe Leu Lys Ala Met Leu Ser Thr Gly Phe Lys Ile Pro Gln Lys 345 1350 1355 1360		
	Gly Ile Leu Ile Gly Ile Gln Gln Ser Phe Arg Pro Arg Phe Leu Gly 1365 1370 1375		
	Val Ala Glu Gln Leu His Asn Glu Gly Phe Lys Leu Phe Ala Thr Glu 1380 1385 1390		
30	Ala Thr Ser Asp Trp Leu Asn Ala Asn Asn Val Pro Ala Asn Pro Val 1395 1400 1405		
	Ala Trp Pro Ser Gln Glu Gly Gln Asn Pro Ser Leu Ser Ser Ile Arg 1410 1415 1420		
35	Lys Leu Ile Arg Asp Gly Ser Ile Asp Leu Val Ile Asn Leu Pro Asn 425 1430 1435 1440		
	Asn Asn Thr Lys Phe Val His Asp Asn Tyr Val Ile Arg Arg Thr Ala 1445 1450 1455		
	Val Asp Ser Gly Ile Pro Leu Leu Thr Asn Phe Gln Val Thr Lys Leu 1460 1465 1470		
40	Phe Ala Glu Ala Val Gln Lys Ser Arg Lys Val Asp Ser Lys Ser Leu 1475 1480 1485		
	Phe His Tyr Arg Gln Tyr Ser Ala Gly Lys Ala Ala 1490 1495 1500		

<210> 15

45 <211> 20

20

24

19

<400> 18

tcatcaccaa ctgaacagg

19

<210> 19

<211> 21

<212> DNA

5 <213> *Homo sapiens*

<400> 19

ggttaagaga aggaggagct g

21

<210> 20

<211> 21

10 <212> DNA

<213> *Homo sapiens*

<400> 20

aaccagtctt cagtgtcctc a

21

15 It will be understood that various details of the invention may be changed without departing from the scope of the invention. Furthermore, the foregoing description is for the purpose of illustration only, and not for the purpose of limitation--the invention being defined by the claims.

CLAIMS

What is claimed is:

1. A method of treating or preventing sub-optimal urea cycle function in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a nitric oxide precursor, whereby treatment or prevention of sub-optimal urea cycle function is accomplished.

2. The method of claim 1, wherein the sub-optimal urea cycle function further comprises hyperammonemia or decreased arginine production.

3. The method of claim 1, wherein the subject is suffering from a disorder associated with impaired liver function or wherein the subject is exposed or about to be exposed to an environmental stimulus associated with impaired liver function.

4. The method of claim 3, wherein the disorder is selected from the group consisting of hepatitis, sclerosis, pulmonary hypertension, bone marrow transplant toxicity in a subject undergoing bone marrow transplant and combinations thereof.

5. The method of claim 3, wherein the environmental stimulus is selected from the group consisting of chemotherapy, cardiac surgery, increased oxidative stress, bone marrow transplant, and combinations thereof.

6. The method of claim 1, wherein the nitric oxide precursor is selected from the group consisting of citrulline, arginine and combinations thereof.

7. The method of claim 1, wherein the nitric oxide precursor is administered in a dose ranging from about 0.01 mg to about 1,000 mg.

8. The method of claim 7, wherein the nitric oxide precursor is administered in a dose ranging from about 0.5 mg to about 500 mg.

9. The method of claim 8, wherein the nitric oxide precursor is administered in a dose ranging from about 1.0 mg to about 250 mg.

5 10. The method of claim 1, wherein the subject is a human.

11. The method of claim 1, further comprising the step of initially detecting a polymorphism of a carbamyl phosphate synthase I (CPSI) gene in the subject.

10 12. The method of claim 11, wherein the polymorphism of the carbamyl phosphate synthetase polypeptide comprises a C to A transversion within CPSI exon 36.

13. The method of claim 12, wherein the polymorphism of the carbamyl phosphate synthetase polypeptide comprises a C to A transversion at nucleotide 4340 of a cDNA that corresponds to the CPSI gene.

15 14. The method of claim 13, wherein the C to A transversion at nucleotide 4340 of the cDNA that corresponds to the CPSI gene further comprises a change in the triplet code from AAC to ACC, which encodes a CPSI polypeptide having an threonine moiety at amino acid 1405.

20 15. A method of treating or preventing bone marrow transplant toxicity in a subject undergoing bone marrow transplant, the method comprising administering to the subject a therapeutically effective amount of a nitric oxide precursor, whereby bone marrow transplant toxicity is treated or prevented in the subject.

16. The method of claim 15, wherein the nitric oxide precursor is

selected from the group consisting of citrulline, arginine and combinations thereof.

17. The method of claim 15, wherein the nitric oxide precursor is administered in a dose ranging from about 0.01 mg to about 1,000 mg.

5 18. The method of claim 17, wherein the nitric oxide precursor is administered in a dose ranging from about 0.5 mg to about 500 mg.

19. The method of claim 18, wherein the nitric oxide precursor is administered in a dose ranging from about 1.0 mg to about 250 mg.

10 20. The method of claim 15, wherein the bone marrow transplant toxicity comprises hepatic veno-occlusive disease.

21. The method of claim 15, wherein the subject is a human.

22. The method of claim 15, further comprising the step of initially detecting a polymorphism of a carbamyl phosphate synthase I (CPSI) gene in the subject.

15 23. The method of claim 22, wherein the polymorphism of the carbamyl phosphate synthetase polypeptide comprises a C to A transversion within CPSI exon 36.

20 24. The method of claim 23, wherein the polymorphism of the carbamyl phosphate synthetase polypeptide comprises a C to A transversion at nucleotide 4340 of a cDNA that corresponds to the CPSI gene.

25. The method of claim 24, wherein the C to A transversion at nucleotide 4340 of the cDNA that corresponds to the CPSI gene further comprises a change in the triplet code from AAC to ACC, which encodes a CPSI polypeptide having an threonine moiety at amino acid 1405.

Abstract of the Disclosure

Isolated polynucleotide molecules and peptides encoded by these molecules are used in the analysis of human carbamyl phosphate synthetase I phenotypes, as well as in diagnostic and therapeutic applications, relating to a human carbamyl phosphate synthetase I polymorphism. By analyzing genomic DNA or amplified genomic DNA, or amplified cDNA derived from mRNA, it is possible to type a human carbamyl phosphate synthetase I with regard to the human carbamyl phosphate synthetase I polymorphism, for example, in the context of diagnosing and treating hepatic veno-occlusive disease (HVOD) associated with bone marrow transplants.

5
10




FIGURE 1

FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7

Building a Full-length CPSI cDNA




FIGURE 8




FIGURE 9




FIGURE 10

```

1
ctacttctca tgttcagcaa tttcttcttc tttatgtttt aaattacatg ttccataaaa ataagaaat
71
cactgtgata cggtaattga ttttttcatt ttaaagcag/(intron exon boundary)
111 (U4295)
CTGTTTGCCA CGGAAGCCAC ATCAGACTGG CTCAACGCCA ACAATGTCCC TGCCACCCCA GTGGCATGGC
181
CGTCTCAAGA AGGACAGAAT CCCAGCCTCT CTTCCATCAG AAA/ (intron exon boundary)
224 GTCGGAGA GAAGGTAGTC TT L(135a)
gtaagaacta ggcatactgt tttctgaaat aatttagagg attaactttg agaaccagta tatgaatatt
294
caccttgctt gattgcaagt cttttaaac aaatttaaaa atgaatacat ttgtggatga ttgtcaagtt
364 (L135b)
tcactctcca tcactatgga atacataacg tcattgtgtac atggtgatat gaaacgtgtt tcaaaatact
434
tcttagtaag gatactttcc ttgacggaaa caagtgagag tatgaagaat gtaatgcagc ac

```

Primer	Begins	Size	SEQ ID NO:
U4295	119	20	8
L135a	220	21	9
L135b	370	24	10
Spanner 1	agctgtttgccacggaagcc		6
Spanner 2	cccagcctctcttccatcagaaagtaag		7

Pairs

U4295 - L135a 101 base fragment

U4295 - L135b 251 base fragment

Spanner1 - Spanner2 119 base fragment

FIGURE 11

CPSI T1405 SEQUENCE (SEQ ID NO:4)

MTRILTAFKV VRTLKTGFGF TNVTAHQKWK FSRPGIRLLS VKAQTAHIVL EDGTMKMGYS
FGHPSSVAGE VVFNTGLGGY PEAITDPAYK GQILTMANPI IGNGGAPDTT ALDELGLSKY
LESNGIKVSG LLVLDYSKDY NHWLATKSLG QWLQEEKVPA IYGVDRMLT KIIRDKGTML
GKIEFEGQPV DFVDPNKQNL IAEVSTKDVK VYGKGNPTKV VAVDCGIKNN VIRLLVKRGA
EVHLVPWNHD FTKMEYDGIL IAGGPGNPAL AEPLIQNVRK ILESDRKEPL FGISTGNLIT
GLAAGAKTYK MSMANRGQNN PVLNITNKQA FITAQNHGYA LDNTLPAGWK PLFVNVNDQT
NEGIMHESKP FFAVQFHPEV TPGPIDTEYL FDSFFSLIKK GKATTITSVL PKPALVASRV
EVSKVLILGS GGLSIGQAGE FDYSGSQAVK AMKEENVKTV LMNPNIASVQ TNEVGLKQAD
TVYFLPITPQ FVTEVIKAEQ PDGLILGMGG QTALNCGVEL FKRGLVKEYG VKVLGTSVES
IMATEDRQLF SDKLNEINEK IAPSFIVESI EDALKAADTI GYPVMIRSAY ALGGLGSGIC
PNRETLMDLS TKAFAMTNQI LVEKSVTGWK EIEYEVVRDA DDNCVTVCNM ENVDAMGVHT
GDSVVVAPAQ TLSNAEFQML RRTSINVVRH LGIVGECNIQ FALHPTSMEY CIIEVNARLS
RSSALASKAT GYPLAFIAAK IALGIPLPEI KNVVSGKTS ACFEPLDYMV TKIPRWDLDR
FHGTSSRIGS SMKSVGEVMA IGRTFEESFQ KALRMCHPSI EGFTPRLPMN KEWPSNLDLR
KELSEPSSTR IYAIKAIDD NMSLDEIEKL TYIDKWFLYK MRDILNMEKT LKGLNSESMT
EETLKRAKEI GFSDKQISKC LGLTEAQTRE LRLKKNIHPW VKQIDTLAAE YPSVTNYLYV
TYNGQEHDVN FDDHGMMVLG CGPYHIGSSV EFDWCAVSSI RTLRQLGKKT VVNCNPETV
STDFDECCKL YFEELSLERI LDIYHQEACG GCIISVGGQI PNNLAVPLYK NGVKIMGTSP
LQIDRAEDRS IFSAVLDELK VAQAPWKAVN TLNEALEFAK SVDYPCLLRP SYVLSGSAMN
VVFSEDEMCK FLEEATRVSQ EHPVVLTKFV EGAREVEMDA VGKDRVISH AISEHVEDAG
VHSGDATLML PTQTISQGA EKVKDATRKI AKAFASGPF NVQFLVKGND VLVIECNLRA
SRSFPFVSKT LGVDFIDVAT KVMIGENVDE KHLPTLDHPI IPADYVAIKA PMFSWPRLRD
ADPILRCEMA STGEVACFGE GIHTAFLKAM LSTGFKIPQK GILIGIQQS RPRFLGVAEQ
LHNEGFKLFA TEATSDWLNA NNVPATPVAW PSQEGQNPSL SSIRKLIRDG SIDLVINLPN
NNTKFVHDNY VIRRTAVDSG IPLLTNFQVT KLFAEAVQKS RKVDSKSLFH YRQYSAGKAA
X

FIGURE 12

CPSI N1405 SEQUENCE (SEQ ID NO:2)

MTRILTAFKV VRTLKTGFGF TNVTAHQKWK FSRPGIRLLS VKAQTAHIVL EDGTMKMGYS
FGHPSSVAGE VVFNTGLGGY PEAITDPAYK GQILTMANPI IGNGGAPD TT ALDELGLSKY
LENGIKVSG LLVLDYSKDY NHWLATKSLG QWLQEEKVPA IYGVDT RMLT KIIRDKGTML
GKIEFEGQPV DFVDPNKQNL IAEVSTKDVK VYGKGNPTKV VAVDCGIKNN VIRLLVKRGA
EVHLVPWNHD FTKMEYDGIL IAGGPGNPAL AEPLIQNVRK ILESDRKEPL FGISTGNLIT
GLAAGAKTYK MSMANRGQNNQ PVLNITNKQA FITAQNHGYA LDNTLPAGWK PLFVNVNDQT
NEGIMHESKP FFAVQFHPEV TPGPIDTEYL FDSFFSLIKK GKATTITSVL PKPALVASRV
EVSKVLILGS GGLSIGQAGE FDYSGSQAVK AMKEENVKTV LMNPNIASVQ TNEVGLKQAD
TVYFLPITPQ FVTEVIKAEQ PDGLILGMGG QTALNCGVEL FKRGV LKEYG VKVLGTSVES
IMATEDRQLF SDKLNEINEK IAPSF AVESI EDALKAADTI GYPVMIRSAY ALGG LGSGIC
PNRETLMDLS TKAFAMTNQI LVEKSVTGWK EIEYEVVRDA DDNCV/TVCNM ENVDAMGVHT
GDSVVVAPAQ TLSNAEFQML RRTSINVVRH LGIVGECNIQ FALHPTSMEY CIEVNARLS
RSSALASKAT GYPLAFIAAK IALGIPLPEI KNVVSGK TSA CFEP SLDYMV TKIPRWDLDR
FHGTSSRIGS SMKSVGEVMA IGRTFEESFQ KALRMCHPSI EGFTPRLPMN KEWPSNLDLR
KELSEPSSTR IYAIKAIDD NMSLDEIEKL TYIDKWFLYK MRDILNMEKT LKGLNSESMT
EETLKRAKEI GFSDKQISKC LGLTEAQ TRE LRLKKNIHPW VKQIDTLAAE YPSVTNYLYV
TYNGQEHDVN FDDHGMMVLG CGPYHIGSSV EFDWCAVSSI RTLRQLGKKT VVNCNPETV
STDFDEC DKL YFEELSLERI LDIYHQEACG GCII SVGGQI PNNLAVPLYK NGVKIMGTSP
LQIDRAEDRS IFSAVLDELK VAQAPWKAVN TLNEALEFAK SVDYPCLLRP SYVLSGSAMN
VVFSEDEM KK FLEEATRV SQ EHPVVLTKFV EGAREVEMDA VGKDGRVISH AISEHVEDAG
VHSGDATLML PTQTISQ GAI EKVKDATRKI AKAF AISGPF NVQFLVKGND VLVIECNLRA
SRSFPFVSKT LGVDFIDVAT KVMIGENVDE KHLPTLDHPI IPADYVAIKA PMFSWPRLRD
ADPILRCEMA STGEVACFGE GIHTAFLKAM LSTGFKIPQK GILIGIQQSF RPRFLGVAEQ
LHNEGKLF A TEATSDWLNA NNVPANPVAW PSQEGQNPSL SSIRKLIRDG SIDLVINLPN
NNTKFVHDNY VIRRTAVDSG IPLL TNFQVT KLFAEAVQKS RKVDSKSLFH YRQYSAGKAA
X

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)	Attorney Docket Number	1242/19/2
	First Named Inventor	Summar et al.
	COMPLETE IF KNOWN	
	Application Number	
	Filing Date	Herewith
	Group Art Unit	
<input checked="" type="checkbox"/> Declaration Submitted with Initial Filing	OR	<input type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)
Examiner Name		

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

THERAPEUTIC METHODS RELATING TO CARBAMYL PHOSPHATE SYNTHETASE I POLYMORPHISM

the specification of which (Title of the Invention)

☒ is attached hereto

OR

☐ was filed on (MM/DD/YYYY) [] as United States Application Number or PCT International

Application Number [] and was amended on (MM/DD/YYYY) [] (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 356(b) of any foreign application(s) for patent or inventor's certificate, or 356(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	<input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)

☐ Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)
Approved for use through 9/30/00. OMB 0651-0032
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
09/323,472	June 1, 1999	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02C attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number OR
☒ Registered practitioner(s) name/registration number listed below

Place Customer
Number Bar Code
Label here

Name	Registration Number	Name	Registration Number
Richard E. Jenkins	28,428	Jennifer L. Skord	30,687
Jeffrey L. Wilson	36,058	David P. Glockler	41,037
Arles A. Taylor, Jr.	39,395	Gregory A. Hunt	41,085

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number OR ☒ Correspondence address below

Name	Arles A. Taylor, Jr.				
Address	JENKINS & WILSON, P.A.				
Address	Suite 1400 University Tower, 3100 Tower Boulevard				
City	Durham	State	NC	ZIP	27707
Country	USA	Telephone	(919) 493-8000	Fax	(919) 419-0383

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])	Family Name or Surname
Marshall L.	Summar

Inventor's Signature				Date	
Residence: City	Brentwood	State	TN	Country	USA
Post Office Address	513 Bel Air Place				
Post Office Address					
City	Brentwood	State	TN	ZIP	37207
				Country	USA

☒ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto

Please type a plus sign (+) inside this box → +

PTO/SB/02A (3-97)
Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION

ADDITIONAL INVENTOR(S)
Supplemental Sheet
Page 1 of 1

Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor				
Given Name (first and middle [if any])				Family Name or Surname				
Brian W.				Christman				
Inventor's Signature					Date			
Residence: City		Nashville	State	TN	Country	USA	Citizenship	USA
Post Office Address		1713 Temple Avenue						
Post Office Address								
City		Nashville	State	TN	ZIP	37215	Country	USA
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor				
Given Name (first and middle [if any])				Family Name or Surname				
Inventor's Signature					Date			
Residence: City			State		Country		Citizenship	
Post Office Address								
Post Office Address								
City			State		ZIP		Country	
Name of Additional Joint Inventor, if any:				<input type="checkbox"/> A petition has been filed for this unsigned inventor				
Given Name (first and middle [if any])				Family Name or Surname				
Inventor's Signature					Date			
Residence: City			State		Country		Citizenship	
Post Office Address								
Post Office Address								
City			State		ZIP		Country	

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.